1:0:0:0:100:217:393:710:12:g_d0_f1:12:g_d0_f1:NBER WORKING PAPER SERIES
1:1:25:100:14:189:423:610:12:g_d0_f1:12:g_d0_f1:PHYSICIAN AGENCY AND COMPETITION:
1:2:58:14:28:34:578:596:12:g_d0_f1:12:g_d0_f1:EVIDENCE FROM A MAJOR CHANGE TO MEDICARE CHEMOTHERAPY REIMBURSEMENT POLICY
1:3:132:28:14:263:349:568:12:g_d0_f1:12:g_d0_f1:Mireille Jacobson
1:4:149:14:14:270:342:554:12:g_d0_f1:12:g_d0_f1:Tom Y. Chang
1:5:161:14:14:256:355:540:12:g_d0_f1:12:g_d0_f1:Joseph P. Newhouse
1:6:179:14:28:255:355:526:12:g_d0_f1:12:g_d0_f1:Craig C. Earle, M.D.
1:7:199:28:14:253:359:498:12:g_d0_f1:12:g_d0_f1:Working Paper 19247
1:8:218:14:42:218:393:484:12:g_d0_f1:12:g_d0_f1:http://www.nber.org/papers/w19247
1:9:251:42:14:173:438:442:12:g_d0_f1:12:g_d0_f1:NATIONAL BUREAU OF ECONOMIC RESEARCH
1:10:287:14:14:237:374:428:12:g_d0_f1:12:g_d0_f1:1050 Massachusetts Avenue
1:11:312:14:14:250:362:414:12:g_d0_f1:12:g_d0_f1:Cambridge, MA 02138
1:12:331:14:74:282:329:400:12:g_d0_f1:12:g_d0_f1:July 2013
1:13:340:74:14:72:540:326:12:g_d0_f1:12:g_d0_f1:Mary Price provided excellent programming to create the original cohort used in this work. We thank
1:14:439:14:14:72:540:312:12:g_d0_f1:12:g_d0_f1:Ernie Berndt, Srikanth Kadiyala, Emmett Keeler, David I. Levine, Tom McGuire, Giuseppe Ragusa,
1:15:533:14:14:72:540:298:12:g_d0_f1:12:g_d0_f1:Heather Royer, James P. Smith, Tim Vogelsang and seminar participants at USC’s Sol Price School
1:16:628:14:14:72:540:284:12:g_d0_f1:12:g_d0_f1:of Public Policy and the NBER Spring Health Care Program meetings for many helpful comments.
1:17:720:14:14:72:540:270:12:g_d0_f1:12:g_d0_f1:Support for this analysis was made possible by grants from the Robert Wood Johnson Foundation’s
1:18:815:14:14:72:540:256:12:g_d0_f1:12:g_d0_f1:Changes in Health Care Financing and Organization (HCFO) program and the National Cancer Institute,
1:19:914:14:14:72:540:242:12:g_d0_f1:12:g_d0_f1:1R01CA152043-01. All remaining errors are our own. The views expressed herein are those of the
1:20:1008:14:28:72:527:228:12:g_d0_f1:12:g_d0_f1:authors and do not necessarily reflect the views of the National Bureau of Economic Research.
1:21:1101:28:14:72:540:200:12:g_d0_f1:12:g_d0_f1:At least one co-author has disclosed a financial relationship of potential relevance for this research.
1:22:1204:14:28:72:466:186:12:g_d0_f1:12:g_d0_f1:Further information is available online at http://www.nber.org/papers/w19247.ack
1:23:1284:28:14:72:540:158:12:g_d0_f1:12:g_d0_f1:NBER working papers are circulated for discussion and comment purposes. They have not been peer-
1:24:1380:14:14:72:540:144:12:g_d0_f1:12:g_d0_f1:reviewed or been subject to the review by the NBER Board of Directors that accompanies official
1:25:1475:14:28:72:169:130:12:g_d0_f1:12:g_d0_f1:NBER publications.
1:26:1493:28:14:72:540:102:12:g_d0_f1:12:g_d0_f1:© 2013 by Mireille Jacobson, Tom Y. Chang, Joseph P. Newhouse, and Craig C. Earle, M.D.. All
1:27:1585:14:14:72:540:88:12:g_d0_f1:12:g_d0_f1:rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit
1:28:1686:14:0:72:448:74:12:g_d0_f1:12:g_d0_f1:permission provided that full credit, including © notice, is given to the source.
2:29:1767:0:14:72:534:700:12:g_d0_f2:12:g_d0_f2:Physician Agency and Competition: Evidence from a Major Change to Medicare Chemotherapy
2:30:1854:14:14:72:182:686:12:g_d0_f2:12:g_d0_f2:Reimbursement Policy
2:31:1874:14:14:72:467:672:12:g_d0_f2:12:g_d0_f2:Mireille Jacobson, Tom Y. Chang, Joseph P. Newhouse, and Craig C. Earle, M.D.
2:32:1951:14:14:72:234:658:12:g_d0_f2:12:g_d0_f2:NBER Working Paper No. 19247
2:33:1979:14:14:72:119:644:12:g_d0_f2:12:g_d0_f2:July 2013
2:34:1988:14:28:72:144:630:12:g_d0_f2:12:g_d0_f2:JEL No. I1,I11
2:35:2002:28:28:273:338:602:12:Times:12:Times:ABSTRACT
2:36:2010:28:14:72:540:574:12:g_d0_f2:12:g_d0_f2:We investigate the role of physician agency and competition in determining health care supply and
2:37:2107:14:14:72:540:560:12:g_d0_f2:12:g_d0_f2:patient outcomes. A 2005 change to Medicare fees had a large, negative impact on physician profit
2:38:2204:14:14:72:540:546:12:g_d0_f2:12:g_d0_f2:margins for providing chemotherapy treatment. In response to these cuts, physicians increased their
2:39:2303:14:14:72:540:532:12:g_d0_f2:12:g_d0_f2:provision of chemotherapy and changed the mix of chemotherapy drugs they administered. The increase
2:40:2402:14:14:72:540:518:12:g_d0_f2:12:g_d0_f2:in treatment improved patient survival. These changes were larger in states that experienced larger
2:41:2501:14:14:72:540:504:12:g_d0_f2:12:g_d0_f2:decreases in physician profit margins. Finally while physician response was larger in more competitive
2:42:2603:14:42:72:421:490:12:g_d0_f2:12:g_d0_f2:markets, survival improvements were larger in less competitive markets.
2:43:2674:42:14:72:158:448:12:g_d0_f2:12:g_d0_f2:Mireille Jacobson
2:44:2691:14:14:72:231:434:12:g_d0_f2:12:g_d0_f2:Paul Merage School of Business 
2:45:2722:14:14:72:228:420:12:g_d0_f2:12:g_d0_f2:University of California, Irvine  
2:46:2756:14:14:72:187:406:12:g_d0_f2:12:g_d0_f2:Irvine, CA 92697-3195 
2:47:2778:14:14:72:124:392:12:g_d0_f2:12:g_d0_f2:and NBER
2:48:2786:14:28:72:166:378:12:g_d0_f2:12:g_d0_f2:jacobson@nber.org
2:49:2803:28:14:72:144:350:12:g_d0_f2:12:g_d0_f2:Tom Y. Chang
2:50:2815:14:14:72:210:336:12:g_d0_f2:12:g_d0_f2:Marshall School of Business
2:51:2842:14:14:72:234:322:12:g_d0_f2:12:g_d0_f2:University of Southern California
2:52:2875:14:14:72:244:308:12:g_d0_f2:12:g_d0_f2:3670 Trousdale Parkway, room 308
2:53:2907:14:14:72:216:294:12:g_d0_f2:12:g_d0_f2:Los Angeles, CA 90089-0804
2:54:2933:14:0:72:157:280:12:g_d0_f2:12:g_d0_f2:tychang@usc.edu
2:55:2948:0:14:306:405:448:12:g_d0_f2:12:g_d0_f2:Joseph P. Newhouse
2:56:2966:14:14:306:551:434:12:g_d0_f2:12:g_d0_f2:Division of Health Policy  Research and Education
2:57:3015:14:14:306:399:420:12:g_d0_f2:12:g_d0_f2:Harvard University
2:58:3033:14:14:306:419:406:12:g_d0_f2:12:g_d0_f2:180 Longwood Avenue
2:59:3052:14:14:306:429:392:12:g_d0_f2:12:g_d0_f2:Boston, MA  02115-5899
2:60:3074:14:14:306:358:378:12:g_d0_f2:12:g_d0_f2:and NBER
2:61:3082:14:28:306:466:364:12:g_d0_f2:12:g_d0_f2:newhouse@hcp.med.harvard.edu
2:62:3110:28:14:306:406:336:12:g_d0_f2:12:g_d0_f2:Craig C. Earle, M.D.
2:63:3130:14:14:306:545:322:12:g_d0_f2:12:g_d0_f2:Cancer Care Ontario  and the Ontario Institute for
2:64:3180:14:14:306:480:308:12:g_d0_f2:12:g_d0_f2:Sunnybrook Health Sciences Centre
2:65:3213:14:14:306:518:294:12:g_d0_f2:12:g_d0_f2:2075 Bayview Avenue, G-Wing, Room 106
2:66:3250:14:14:306:387:280:12:g_d0_f2:12:g_d0_f2:Toronto, Ontario
2:67:3266:14:14:306:399:266:12:g_d0_f2:12:g_d0_f2:Canada, M4N 3M5
2:68:3281:14:0:306:415:252:12:g_d0_f2:12:g_d0_f2:craig.earle@ices.on.ca
3:69:3303:0:18:107:521:671:143:g_d0_f3:143:g_d0_f3:Understanding how physicians respond to financial incentives is a key health care
3:70:3384:18:18:89:521:653:143:g_d0_f3:143:g_d0_f3:policy issue. In the presence of asymmetric information, physicians may distort de-
3:71:3467:18:18:89:521:635:143:g_d0_f3:143:g_d0_f3:mand in socially sub-optimal but personally beneficial ways.  In the U.S. context,
3:72:3549:18:18:89:521:617:143:g_d0_f3:143:g_d0_f3:debate over this issue centers on physician-induced demand (PID) – the provision
3:73:3629:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:of excessive care in response to financial incentives (McGuire (2000); Chandra et al.
3:74:3714:18:18:89:129:581:143:g_d0_f3:143:g_d0_f3:(2012)).
3:75:3722:18:18:107:521:563:143:g_d0_f3:143:g_d0_f3:As the theoretical literature on PID makes clear, however, the relationship between
3:76:3805:18:18:89:521:545:143:g_d0_f3:143:g_d0_f3:administered price changes and the volume of physician services is a priori ambiguous
3:77:3890:18:18:89:521:527:143:g_d0_f3:143:g_d0_f3:and depends on the relative strength of the income and substitution e↵ects (McGuire
3:78:3973:18:18:89:522:509:143:g_d0_f3:143:g_d0_f3:and Pauly 1991).1When the substitution e↵ect dominates, physicians reduce the
3:79:4050:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:volume of services in response to a price reduction. When the income e↵ect dominates,
3:80:4135:18:17:90:522:473:143:g_d0_f3:143:g_d0_f3:the physician’s supply curve will have a negative slope such that volume increases as
3:81:4220:17:18:90:521:456:143:g_d0_f3:143:g_d0_f3:fees fall. The case of extremely large income e↵ects corresponds to a model of “literal
3:82:4307:18:18:90:522:438:143:g_d0_f3:143:g_d0_f3:target income,” where changes in administered prices are fully o↵set by changes in
3:83:4389:18:18:90:293:420:143:g_d0_f3:143:g_d0_f3:volume (assuming full o↵set is feasible).
3:84:4430:18:18:107:522:402:143:g_d0_f3:143:g_d0_f3:The empirical literature supports the importance of physician agency, with the ma-
3:85:4512:18:18:90:522:384:143:g_d0_f3:143:g_d0_f3:jority of papers finding a negative relationship between changes in fees and the supply
3:86:4599:18:18:90:521:366:143:g_d0_f3:143:g_d0_f3:of medical care, i.e. volume o↵sets (Rice and Labelle (1989); Rice (1983); Rice (1984);
3:87:4686:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:Christensen (1992); Yip (1998); Nguyen and Derrick (1997); Grant (2009); Gruber
3:88:4765:18:18:90:522:330:143:g_d0_f3:143:g_d0_f3:et al. (1999)).2Importantly the existing literature has found no direct evidence that
3:89:4850:18:18:90:481:312:143:g_d0_f3:64:g_d0_f5:such changes a↵ect patient health, although few studied measure outcomes.3
3:90:4924:18:18:107:521:294:143:g_d0_f3:143:g_d0_f3:We contribute to the literature on volume o↵sets in two ways.  First, using a
3:91:5001:18:18:89:521:276:143:g_d0_f3:143:g_d0_f3:very general theoretical model of physician utility, we show that physician agency
3:92:5083:18:18:89:521:258:143:g_d0_f3:143:g_d0_f3:can distort the provision of services away from the fully informed consumer’s optimal
3:93:5168:18:18:89:521:240:143:g_d0_f3:143:g_d0_f3:level of care in either direction. That is, physicians may provide excessive care or
3:94:5252:18:23:89:521:222:143:g_d0_f3:143:g_d0_f3:may ration care below the optimal amount. The implication of this theoretical point
3:95:5335:23:15:103:521:199:49:g_d0_f6:99:g_d0_f7:1This conclusion from McGuire and Pauly (1991) comes out of a model where physicians maximize
3:96:5428:15:12:90:522:184:99:g_d0_f7:99:g_d0_f7:utility that depends positively on net revenue and leisure and negatively on the amount of demand
3:97:5525:12:14:90:143:172:99:g_d0_f7:99:g_d0_f7:inducement.
3:98:5536:14:16:103:521:158:49:g_d0_f6:99:g_d0_f7:2Clemens and Gottlieb (2012); Hurley et al. (1990); Hurley and Labelle (1995); Escarce (1993)
3:99:5629:16:14:90:522:142:99:g_d0_f7:99:g_d0_f7:are notable exceptions that find a positive relationship between fees and the quantity of health care.
3:100:5731:14:15:103:521:128:49:g_d0_f6:99:g_d0_f7:3Clemens and Gottlieb (2012) is again an exception. Most evidence is indirect, drawn from the
3:101:5824:15:36:90:511:113:99:g_d0_f7:99:g_d0_f7:observation, for example, that elective C-sections have more complications than vaginal delivery.
3:102:5921:36:0:303:309:77:143:g_d0_f3:143:g_d0_f3:1
4:103:5922:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:is that a fee cut that generates an income e↵ect that dominates the substitution
4:104:6002:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:e↵ect can remedy an underprovision of care. Furthermore, we show that although
4:105:6080:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:the response to a payment change should be smaller in less competitive markets, the
4:106:6163:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:welfare e↵ects will be larger. The intuition is that in more competitive markets, those
4:107:6250:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:patients who need care are more likely to get it and care is at the ’flat of the curve.’
4:108:6338:18:18:107:521:581:143:g_d0_f3:143:g_d0_f3:Second, we analyze an important empirical case, a 2005 change to Medicare fees
4:109:6416:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:that likely had a large impact on the income of a particular specialist group, oncol-
4:110:6501:18:18:90:522:545:143:g_d0_f3:143:g_d0_f3:ogists. Specifically, we study a major reform to Medicare reimbursement policy for
4:111:6583:18:18:90:522:527:143:g_d0_f3:143:g_d0_f3:physician-administered (Part B) drugs, primarily injectable and intravenous oncol-
4:112:6665:18:18:90:522:509:143:g_d0_f3:143:g_d0_f3:ogy, rheumatology, urology and infectious disease agents. Unlike orally administered
4:113:6749:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:drugs, i.e. pills, physicians purchase Part B drugs from wholesalers, administer them
4:114:6834:18:18:90:522:473:143:g_d0_f3:143:g_d0_f3:in their clinics, and are reimbursed for them directly by payers. The 2005 reform,
4:115:6916:18:17:90:522:455:143:g_d0_f3:143:g_d0_f3:which replaced a reimbursement system based on list prices with one based on national
4:116:7001:17:18:90:522:438:143:g_d0_f3:143:g_d0_f3:average transaction prices, sought to remedy well known Medicare overpayments for
4:117:7082:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:Part B drugs. For chemotherapy, reimbursements averaged 29% above transaction
4:118:7159:18:18:90:521:402:143:g_d0_f3:143:g_d0_f3:prices in 1997 (O-ce of Inspector General (1997a)) and was 22% above by 2004, even
4:119:7241:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:after an initial fee reduction took e↵ect (Government Accountability O-ce (2004)).
4:120:7323:18:18:90:522:366:143:g_d0_f3:143:g_d0_f3:Beginning in 2005, margins were administratively set at 6% above the national average
4:121:7408:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:transaction price for each drug. Thus, margins fell by nearly a factor of five, although
4:122:7496:18:18:90:522:330:143:g_d0_f3:143:g_d0_f3:this reduction was not uniform across drugs. Since chemotherapy accounted for over
4:123:7578:18:18:90:522:312:143:g_d0_f3:143:g_d0_f3:three-quarters of oncologist practice revenues in 2005 (Akscin and Barr (2007)), the
4:124:7662:18:18:90:522:294:143:g_d0_f3:143:g_d0_f3:drug mark-up accounted for more than half of their reported net income (Butcher
4:125:7741:18:18:90:522:276:143:g_d0_f3:143:g_d0_f3:(2008)), and because Medicare is the primary payer for many cancers, the reform
4:126:7820:18:18:90:469:258:143:g_d0_f3:64:g_d0_f5:almost assuredly represented a large negative shock to oncologist income.4
4:127:7894:18:18:107:521:240:143:g_d0_f3:143:g_d0_f3:Our empirical analysis centers on comparing Medicare beneficiaries diagnosed with
4:128:7975:18:17:89:521:222:143:g_d0_f3:143:g_d0_f3:lung cancer in the few months before to the few months after the reform took e↵ect.
4:129:8058:17:18:89:521:205:143:g_d0_f3:143:g_d0_f3:After demonstrating that the observable characteristics of lung cancer patients were
4:130:8142:18:24:89:521:187:143:g_d0_f3:143:g_d0_f3:smooth across the payment change, we show that those diagnosed just after relative
4:131:8224:24:15:103:521:163:49:g_d0_f6:99:g_d0_f7:4Oncologists maintained that Medicare fees for other services, e.g., evaluation and management
4:132:8318:15:12:90:522:148:99:g_d0_f7:99:g_d0_f7:and drug administration, did not cover their expenses. However, GAO has found that these payments
4:133:8415:12:12:90:522:136:99:g_d0_f7:99:g_d0_f7:exceed expenses by 4% on average, which is similar to the mark-up received by other specialists
4:134:8510:12:47:90:279:124:99:g_d0_f7:99:g_d0_f7:(Government Accountability O-ce (2001)).
4:135:8550:47:0:303:309:77:143:g_d0_f3:143:g_d0_f3:2
5:136:8551:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:to just before the change were about 10% more likely to be treated with chemother-
5:137:8633:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:apy within 30 and 90 days of diagnosis. The change lines up with the timing of the
5:138:8715:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:2005 reform and is specific to the physician’s o-ce setting in contrast to the hospital
5:139:8802:18:18:90:521:617:143:g_d0_f3:143:g_d0_f3:outpatient setting, where the payment change did not take e↵ect until 2006 Barlas
5:140:8883:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:(2011). Furthermore, we show the mix of drugs used to treat patients changed in ways
5:141:8967:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:predicted by economic theory: drugs that lost the most margin were used less fre-
5:142:9048:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:quently among the chemotherapy-treated population and conversely, expensive drugs
5:143:9129:18:18:90:522:545:143:g_d0_f3:143:g_d0_f3:favored by the reform’s 6% margin on all drugs, were used more often than previously.
5:144:9214:18:18:107:520:527:143:g_d0_f3:143:g_d0_f3:Further, we find that the treatment changes improved survival:  the likelihood
5:145:9292:18:18:90:522:509:143:g_d0_f3:143:g_d0_f3:of death at 3, 6, and 9 months from diagnosis declined by 2–3%, suggesting that,
5:146:9372:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:consistent with the clinical literature, lung cancer may be undertreated in the elderly
5:147:9459:18:18:90:522:473:143:g_d0_f3:143:g_d0_f3:(Davido↵et al. (2010); Booth C. M. et al. (2010)). Indeed, despite similar relative
5:148:9542:18:17:90:522:455:143:g_d0_f3:143:g_d0_f3:treatment increases, the improvement in survival was 1.5 to 3 times larger in above
5:149:9625:17:18:90:522:438:143:g_d0_f3:143:g_d0_f3:vs. below median Medicare age patients, those most likely to be undertreated. We
5:150:9705:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:exploit geographic heterogeneity in treatment responses (Jacobson et al. (2011)) to
5:151:9788:18:18:90:522:402:143:g_d0_f3:143:g_d0_f3:show that survival improved more in states with larger treatment increases. We also
5:152:9871:18:18:90:522:384:143:g_d0_f3:143:g_d0_f3:exploit pre-reform prescribing patterns to show that both the treatment increase and
5:153:9955:18:18:90:522:366:143:g_d0_f3:143:g_d0_f3:survival improvements were larger in areas that experienced a larger decrease in profit
5:154:10042:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:margins. As best as we know, this is among the first evidence that physician agency
5:155:10125:18:18:90:522:330:143:g_d0_f3:143:g_d0_f3:can a↵ect health outcomes, not just treatment. Finally, consistent with our model, we
5:156:10210:18:18:90:522:312:143:g_d0_f3:143:g_d0_f3:find that, although the treatment change was more muted in less competitive counties
5:157:10294:18:18:90:522:294:143:g_d0_f3:143:g_d0_f3:(measured by the HHI or the number of patients per provider), survival improvements
5:158:10377:18:18:90:521:276:143:g_d0_f3:143:g_d0_f3:were larger. These results suggest that the competitive environment a↵ects both the
5:159:10460:18:18:89:521:258:143:g_d0_f3:143:g_d0_f3:size of physician response and patient welfare. To our knowledge, physician market
5:160:10542:18:18:89:521:240:143:g_d0_f3:143:g_d0_f3:power has not been studied in the context of changes in administered prices, perhaps
5:161:10626:18:45:89:463:222:143:g_d0_f3:143:g_d0_f3:because it was assumed to not be relevant to administered price regimes.
5:162:10698:45:29:90:331:177:296:g_d0_f9:296:g_d0_f9:1  Institutional Background
5:163:10725:29:18:90:522:148:143:g_d0_f3:143:g_d0_f3:Although Medicare did not o↵er a drug benefit for oral drugs (pills) until 2006, Medi-
5:164:10811:18:18:90:522:130:143:g_d0_f3:143:g_d0_f3:care Part B, which covers physician services, has from inception covered physician-
5:165:10894:18:35:90:522:112:143:g_d0_f3:143:g_d0_f3:administered drugs such as IV chemotherapy, anti-nausea, and pain medicine used in
5:166:10976:35:0:303:309:77:143:g_d0_f3:143:g_d0_f3:3
6:167:10977:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:cancer treatment. Rather than writing a prescription for these drugs that the patient
6:168:11062:18:18:90:521:653:143:g_d0_f3:143:g_d0_f3:fills at a pharmacy, the physician injects or infuses these drugs in an o-ce or clinic
6:169:11148:18:18:89:521:635:143:g_d0_f3:143:g_d0_f3:and then bills Medicare for them.5Since at least the mid-1990s, it was well under-
6:170:11230:18:18:89:521:617:143:g_d0_f3:143:g_d0_f3:stood that Medicare overpaid for many chemotherapy and other Part B drugs (O-ce
6:171:11309:18:18:89:522:599:143:g_d0_f3:143:g_d0_f3:of Inspector General (1997b); O-ce of Inspector General (1997a)). The Medicare
6:172:11387:18:18:89:521:581:143:g_d0_f3:143:g_d0_f3:Prescription Drug, Improvement and Modernization Act (MMA) of 2003 aimed to
6:173:11462:18:18:89:521:563:143:g_d0_f3:143:g_d0_f3:resolve the overpayment issue and reduce Medicare spending by redesigning the way
6:174:11543:18:18:89:398:545:143:g_d0_f3:143:g_d0_f3:Medicare reimburses physician-administered (Part B) drugs.
6:175:11601:18:18:107:521:527:143:g_d0_f3:143:g_d0_f3:Prior to the reform, Medicare reimbursed physicians and outpatient hospital clin-
6:176:11682:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:ics for these drugs as a percentage of the average wholesale price (AWP), a list price,
6:177:11769:18:18:89:521:491:143:g_d0_f3:143:g_d0_f3:published in several catalogues, that reflects neither wholesale nor average prices
6:178:11852:18:17:89:521:473:143:g_d0_f3:143:g_d0_f3:(Berndt and Newhouse (2012)).6From 1998 to 2003, reimbursements were 95% of
6:179:11927:17:18:90:522:456:143:g_d0_f3:143:g_d0_f3:AWP. To smooth the transition to a new payment system, the MMA reduced reim-
6:180:12003:18:18:90:522:438:143:g_d0_f3:143:g_d0_f3:bursements to 85% of AWP in 2004. In principle manufacturers could have changed
6:181:12082:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:list prices between 2003 and 2004 (or in other years); in practice, such changes were
6:182:12167:18:18:90:522:402:143:g_d0_f3:143:g_d0_f3:rare. Most importantly for our purposes, the AWP exceeded physician acquisition
6:183:12246:18:18:90:521:384:143:g_d0_f3:143:g_d0_f3:costs for many drugs from 13% to 34% (Government Accountability O-ce (2004)).
6:184:12323:18:18:90:522:366:143:g_d0_f3:143:g_d0_f3:Some agents, such as paclitaxel, a chemotherapy drug commonly used to treat lung,
6:185:12404:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:breast, and ovarian cancer, were reimbursed at prices that vastly exceeded acqui-
6:186:12485:18:18:90:522:330:143:g_d0_f3:143:g_d0_f3:sition costs (Government Accountability O-ce (2004)).  The reform replaced the
6:187:12563:18:18:90:522:312:143:g_d0_f3:143:g_d0_f3:AWP-based system with a new average sales price (ASP) payment system, whereby
6:188:12640:18:18:90:522:294:143:g_d0_f3:143:g_d0_f3:Part B drugs are reimbursed based on the national average of manufacturers’ sales
6:189:12721:18:18:90:521:276:143:g_d0_f3:143:g_d0_f3:prices, including rebates, from two quarters prior plus a 6% mark-up.7In 2005 the
6:190:12802:18:18:90:521:258:143:g_d0_f3:143:g_d0_f3:reform a↵ected physician’s o-ces, the primary setting for chemotherapy treatment,
6:191:12883:18:23:90:522:240:143:g_d0_f3:143:g_d0_f3:and in 2006 the outpatient hospital setting, the other main setting for chemotherapy.
6:192:12968:23:16:103:521:217:49:g_d0_f6:99:g_d0_f7:5In contrast, some private insurers deliver the drug to the physician’s o-ce or clinic and just pay
6:193:13067:16:13:90:256:201:99:g_d0_f7:99:g_d0_f7:the physician a fee for administration.
6:194:13106:13:18:103:405:188:49:g_d0_f6:99:g_d0_f7:6In the trade, AWP is sometimes referred to as “Ain’t What’s Paid.”
6:195:13173:18:16:103:521:170:49:g_d0_f6:99:g_d0_f7:7The ASP calculation does not take into account 340(B) discounts for Medicaid patients. Since
6:196:13266:16:12:90:522:154:99:g_d0_f7:99:g_d0_f7:about 2009 it is believed that hospitals began leveraging these discounts to purchase oncology drugs
6:197:13366:12:11:90:522:142:99:g_d0_f7:99:g_d0_f7:for all their patients and thereby increase the mark-ups they receive on oncology drugs administered
6:198:13466:11:12:90:522:131:99:g_d0_f7:99:g_d0_f7:to Medicare and commercially insured patients. This is a relatively recent practice that is unlikely
6:199:13566:12:42:90:273:119:99:g_d0_f7:99:g_d0_f7:to have occurred during our study period.
6:200:13607:42:0:303:309:77:143:g_d0_f3:143:g_d0_f3:4
7:201:13608:0:18:107:522:671:143:g_d0_f3:143:g_d0_f3:When this policy took e↵ect on January 1, 2005, the profit margins for many
7:202:13683:18:18:89:521:653:143:g_d0_f3:143:g_d0_f3:chemotherapy drugs were reduced substantially. Fees for chemotherapy administra-
7:203:13763:18:18:89:521:635:143:g_d0_f3:143:g_d0_f3:tion were increased in 2004 but reduced again in 2005, though the reduction did
7:204:13842:18:18:89:522:617:143:g_d0_f3:143:g_d0_f3:not fully o↵set the 2004 increase (Government Accountability O-ce (2004)). Impor-
7:205:13923:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:tantly, the administration fee changes were small in dollar terms (on the order of $50
7:206:14009:18:18:89:521:581:143:g_d0_f3:143:g_d0_f3:to $100 per session) compared with the 2004 to 2005 drug reimbursement change,
7:207:14087:18:18:89:521:563:143:g_d0_f3:143:g_d0_f3:which could total hundreds and even thousands of dollars for a monthly dose of some
7:208:14170:18:18:89:221:545:143:g_d0_f3:64:g_d0_f5:commonly infused drugs.8
7:209:14194:18:18:107:521:527:143:g_d0_f3:143:g_d0_f3:Two health policy papers have evaluated the claim by community oncologists that
7:210:14273:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:the policy change would make it too expensive to treat Medicare beneficiaries, forcing
7:211:14359:18:18:89:521:491:143:g_d0_f3:143:g_d0_f3:them to shift some patients to hospital settings where they would face unnecessary
7:212:14441:18:17:89:521:473:143:g_d0_f3:143:g_d0_f3:treatment delays (Community Oncology Alliance (2006)).  The papers find to the
7:213:14519:17:18:89:521:456:143:g_d0_f3:143:g_d0_f3:contrary; wait times, travel distance and treatment setting (outpatient hospital or
7:214:14602:18:18:89:521:438:143:g_d0_f3:143:g_d0_f3:physician o-ce) did not change in response to the payment change (Friedman J.
7:215:14679:18:18:89:521:420:143:g_d0_f3:143:g_d0_f3:Y. et al. (2007); Shea et al. (2008)). Neither paper evaluates treatment outcomes.
7:216:14761:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:Moreover, both studies – one, a web-survey of a convenience sample of patients un-
7:217:14843:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:dergoing chemotherapy (Friedman J. Y. et al. (2007)) and the other a 5% sample of
7:218:14924:18:18:89:521:366:143:g_d0_f3:143:g_d0_f3:claims from beneficiaries with leukemia, lymphoma or breast, colorectal, lung cancer
7:219:15008:18:18:89:521:348:143:g_d0_f3:143:g_d0_f3:receiving chemotherapy – condition on treatment, a potentially important margin of
7:220:15090:18:18:89:150:330:143:g_d0_f3:143:g_d0_f3:adjustment.
7:221:15101:18:18:107:522:312:143:g_d0_f3:143:g_d0_f3:Indeed, our prior work shows that the likelihood of chemotherapy treatment for
7:222:15179:18:18:89:521:294:143:g_d0_f3:143:g_d0_f3:lung cancer patients changed in response to the reform (Jacobson et al. (2010)).
7:223:15259:18:18:89:521:276:143:g_d0_f3:143:g_d0_f3:Our findings are consistent with analyses of aggregate chemotherapy billing data by
7:224:15342:18:18:89:521:258:143:g_d0_f3:143:g_d0_f3:the Medicare Payment Advisory Committee (MedPAC (2006)).  Other work finds
7:225:15416:18:18:89:521:240:143:g_d0_f3:143:g_d0_f3:important extensive margin responses. For example, in prostate cancer treatment,
7:226:15496:18:18:89:521:222:143:g_d0_f3:143:g_d0_f3:androgen-deprivation therapy (ADT) or medical castration, which was subject to
7:227:15574:18:17:89:521:204:143:g_d0_f3:143:g_d0_f3:AWP-reimbursement, declined while surgical castration, which did not face a payment
7:228:15657:17:18:89:521:187:143:g_d0_f3:143:g_d0_f3:change, increased (Weight et al. (2007)). Although analysis of ADT suggests that the
7:229:15741:18:18:89:521:169:143:g_d0_f3:143:g_d0_f3:decline was largest among those for whom the benefits were unclear (Shainian et al.
7:230:15824:18:23:89:459:151:143:g_d0_f3:64:g_d0_f5:(2010)), these welfare implications may not generalize to other cancers.9
7:231:15897:23:18:103:521:128:49:g_d0_f6:99:g_d0_f7:8Many regimens are given in 3-week cycles, meaning patients receive 1.33 treatments per month.
7:232:15991:18:33:103:521:110:49:g_d0_f6:99:g_d0_f7:9Colla et al. (2012) finds that in response to the reform chemotherapy treatment declined in the
7:233:16087:33:0:303:309:77:143:g_d0_f3:143:g_d0_f3:5
8:234:16088:0:18:107:521:671:143:g_d0_f3:143:g_d0_f3:An obvious question is whether these treatment changes were driven by physicians
8:235:16168:18:18:89:521:653:143:g_d0_f3:143:g_d0_f3:or patients; since Medicare beneficiaries face 20% coinsurance for Part B services, a
8:236:16253:18:18:89:521:635:143:g_d0_f3:143:g_d0_f3:decline in drug prices could have increased patient demand. In practice, however,
8:237:16334:18:18:89:521:617:143:g_d0_f3:143:g_d0_f3:about 90% of beneficiaries have supplemental insurance that pays this coinsurance
8:238:16415:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:(Kaiser Family Foundation (2010)). And anecdotal evidence suggests that oncologists
8:239:16498:18:18:89:521:581:143:g_d0_f3:143:g_d0_f3:were less likely to collect the coinsurance from the remaining patients when reimburse-
8:240:16585:18:18:89:521:563:143:g_d0_f3:143:g_d0_f3:ments were based on AWP, implying that out-of-pocket spending increased for some
8:241:16665:18:18:89:521:545:143:g_d0_f3:143:g_d0_f3:beneficiaries even as average drug costs declined for Medicare (Mullen (2007)). On
8:242:16747:18:45:89:409:527:143:g_d0_f3:143:g_d0_f3:balance, any e↵ects from patient demand should be negligible.
8:243:16808:45:30:90:288:482:296:g_d0_f9:296:g_d0_f9:2  Health Care Supply
8:244:16829:30:18:90:522:452:143:g_d0_f3:143:g_d0_f3:In this section we present a model of physician behavior in markets where physicians
8:245:16913:18:18:90:476:434:143:g_d0_f3:143:g_d0_f3:care about both their private utility as well as the welfare of their patients.
8:246:16992:18:18:107:521:416:143:g_d0_f3:143:g_d0_f3:Let there be J physicians operating in a marketk2{1,K}that serves a continuum
8:247:17069:18:17:90:522:398:143:g_d0_f3:143:g_d0_f3:of patients of measure one. A physicianj2{1,J}has local monopoly power over
8:248:17144:17:18:90:522:381:143:g_d0_f3:143:g_d0_f3:afraction⌘jof patients in marketkand can provide each patient a single unit of
8:249:17222:18:18:90:525:363:143:g_d0_f3:143:g_d0_f3:service q, which yields patient i a benefit b distributed over (-1,1)suchthatb(q)
8:250:17303:18:18:90:522:345:143:g_d0_f3:143:g_d0_f3:is a continuous, decreasing convex function. In addition, the distribution of patients
8:251:17389:18:18:90:522:327:143:g_d0_f3:143:g_d0_f3:each physician sees is identical to each other and to the overall distribution of types
8:252:17476:18:18:90:163:309:143:g_d0_f3:143:g_d0_f3:in the market.
8:253:17490:18:18:107:521:291:143:g_d0_f3:143:g_d0_f3:The physician earns a fixed price p and pays a fixed cost c for each unit of service
8:254:17574:18:18:90:522:273:143:g_d0_f3:143:g_d0_f3:provided.  Each unit of care requires a unit of physician time such that e(q), the
8:255:17656:18:18:90:522:255:143:g_d0_f3:143:g_d0_f3:disutility of physician e↵ort, is an increasing and convex function with e(0) = 0.
8:256:17738:18:18:90:522:237:143:g_d0_f3:143:g_d0_f3:Physician utility is assumed to be positive in net income with diminishing marginal
8:257:17821:18:18:90:522:219:143:g_d0_f3:143:g_d0_f3:returns. In addition, physicians are assumed to care directly about patient welfare.
8:258:17905:18:34:90:518:201:143:g_d0_f3:143:g_d0_f3:Assuming additive separability, the physician utility function can then be written as
8:259:17990:34:0:119:246:167:143:g_d0_f10:143:g_d0_f13:U(q)=V(⇡)-e(q)+↵⌘
8:260:18007:0:27:249:274:183:143:g_d0_f15:64:g_d0_f16:Zq/⌘
8:261:18011:27:0:256:260:156:64:g_d0_f5:64:g_d0_f5:0
8:262:18012:0:36:276:522:167:143:g_d0_f10:143:g_d0_f3:b(x)dx,(1)
8:263:18022:36:54:90:172:131:99:g_d0_f7:99:g_d0_f7:last 14 days of life.
8:264:18043:54:0:303:309:77:143:g_d0_f3:143:g_d0_f3:6
9:265:18044:0:18:90:521:671:143:g_d0_f3:143:g_d0_f3:where⇡=(p-c)qand↵represents the weight physicians place on patient benefit.
9:266:18119:18:18:89:521:653:143:g_d0_f3:143:g_d0_f3:Thus, a physician trades o↵her private utility from income with the disutility from
9:267:18202:18:18:89:346:635:143:g_d0_f3:143:g_d0_f3:of e↵ort as well as her concern for patient welfare.
9:268:18254:18:18:107:522:617:143:g_d0_f3:143:g_d0_f3:For notational simplicity, we define the profit marginm=(p-c). Then the first
9:269:18331:18:30:89:315:599:143:g_d0_f3:143:g_d0_f3:order condition for the physician is given by
9:270:18376:30:33:119:522:569:143:g_d0_f10:143:g_d0_f3:mV⇡-eq+↵b(q/⌘)=0.(2)
9:271:18396:33:18:107:522:536:143:g_d0_f3:143:g_d0_f3:Note that while concern for patient welfare (↵b(q/⌘)) pushes physicians towards
9:272:18475:18:18:89:522:518:143:g_d0_f3:143:g_d0_f3:providing what, from the patient’s perspective, is the optimal level of careqP,10in
9:273:18558:18:17:89:511:500:143:g_d0_f3:143:g_d0_f3:general physicians may either under or over provide care relative to this optimum.
9:274:18640:17:18:107:521:483:143:g_d0_f3:143:g_d0_f3:To determine physician response to profit margin (m) changes, we take the deriva-
9:275:18721:18:33:89:521:465:143:g_d0_f3:143:g_d0_f3:tive of equation 2 with respect to m. Rearranging, we get the following relationship:
9:276:18806:33:0:119:144:432:143:g_d0_f10:143:g_d0_f3:qm=
9:277:18809:0:17:149:200:440:143:g_d0_f10:143:g_d0_f13:V⇡+V⇡⇡⇡
9:278:18816:17:0:152:196:423:143:g_d0_f10:36:g_d0_f17:eqq+↵⌘b0
9:279:18824:0:32:202:522:432:143:g_d0_f10:143:g_d0_f3:.(3)
9:280:18828:32:17:107:522:400:143:g_d0_f3:143:g_d0_f3:Note that in generalqmcan be positive or negative. That is, it cannot be deter-
9:281:18907:17:18:89:521:383:143:g_d0_f3:143:g_d0_f3:mined ex-ante whether an increase in profitability leads to an increase or decrease in
9:282:18993:18:18:89:521:365:143:g_d0_f3:143:g_d0_f3:service provision. This ambiguity of changes in m on the quantity of service provided
9:283:19078:18:18:89:521:347:143:g_d0_f3:143:g_d0_f3:is a standard characteristic of PID (see for instance McGuire and Pauly (1991) and
9:284:19160:18:18:89:521:329:143:g_d0_f3:143:g_d0_f3:McGuire (2000)), and in the case of a fee cut is driven by the tradeo↵between decreas-
9:285:19246:18:18:89:521:311:143:g_d0_f3:143:g_d0_f3:ing marginal returns (the substitution e↵ect) and the increasing marginal returns to
9:286:19330:18:18:89:521:293:143:g_d0_f3:143:g_d0_f3:income (the income e↵ect). So if decreased returns to e↵ort dominates, a cut in mar-
9:287:19414:18:18:89:522:275:143:g_d0_f3:143:g_d0_f3:gins leads to a reduction in e↵ort (i.e. services provided). But when the income e↵ect
9:288:19500:18:18:89:521:257:143:g_d0_f3:143:g_d0_f3:dominates, a decrease in margins can generate a negatively sloped supply curve. In
9:289:19582:18:18:89:521:239:143:g_d0_f3:143:g_d0_f3:this case, a fee cut can lead to an increase in physician e↵ort. Thus the change in the
9:290:19669:18:18:89:525:221:143:g_d0_f3:143:g_d0_f3:marginal utility of income (i.e. the relative magnitudes ofV⇡andV⇡⇡)providessome
9:291:19749:18:18:89:522:203:143:g_d0_f3:143:g_d0_f3:guidance as to the sign of the response. When the magnitude of the income e↵ect
9:292:19828:18:18:89:522:185:143:g_d0_f10:143:g_d0_f3:V⇡⇡is small, then the substitution e↵ect dominates and physicians display a positive
9:293:19912:18:18:89:522:167:143:g_d0_f3:143:g_d0_f3:elasticity. But whenV⇡⇡is large, it reduces the impact of the substitution e↵ect, and
9:294:19997:18:23:89:521:149:143:g_d0_f3:143:g_d0_f3:if large enough, can lead to a negative elasticity of health care. In addition, regardless
9:295:20087:23:49:99:238:126:49:g_d0_f6:99:g_d0_f7:10In the limit↵!1,q⇤!qP.
9:296:20111:49:0:303:309:77:143:g_d0_f3:143:g_d0_f3:7
10:297:20112:0:18:90:526:671:143:g_d0_f3:143:g_d0_f3:of the sign ofqm,physicianresponseisattenuatedbytheweightphysician’splaceon
10:298:20187:18:18:90:354:653:143:g_d0_f3:143:g_d0_f3:patient welfare↵,andinthelimit↵!1,qm!0.
10:299:20226:18:18:107:521:635:143:g_d0_f3:143:g_d0_f3:As implied by the name, the literature frames physician-induced demand (PID)
10:300:20302:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:as the inducement of excess demand, and not the idea that physicians would “hold
10:301:20382:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:down” demand. But as the FOC in equation 2 makes clear, whether the equilibrium
10:302:20461:18:18:90:521:581:143:g_d0_f3:143:g_d0_f3:quantityq⇤is above or below the patient bliss pointqPis ambiguous: physician self-
10:303:20543:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:interest can distort the provision of services away fromqPin either direction.  In
10:304:20625:18:18:89:521:545:143:g_d0_f3:143:g_d0_f3:principle, though not in practice, PID could be defined as influencing patient demand
10:305:20710:18:18:89:521:527:143:g_d0_f3:143:g_d0_f3:away fromqP(either through under or over provision). Influencing patient demand
10:306:20789:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:towardsqPcould be defined as “useful agency.”  Importantly, whether changes in
10:307:20867:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:care are helpful or harmful to patient welfare depends not only on the direction of
10:308:20950:18:17:90:405:473:143:g_d0_f3:143:g_d0_f3:the change but also the original level of service relative toqP.
10:309:21014:17:18:107:521:456:143:g_d0_f3:143:g_d0_f3:While the idea of PID is complex,11for the purposes of this paper we define it
10:310:21092:18:18:90:522:438:143:g_d0_f3:143:g_d0_f3:based on the concept of distortions away from the care that would be demanded by
10:311:21172:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:the mythical, fully informed patient. Specifically we refer to the provision of services
10:312:21260:18:18:90:521:402:143:g_d0_f3:143:g_d0_f3:to a patient who receives a non-positive benefit (i.e.b0) as physician induced
10:313:21339:18:18:90:522:384:143:g_d0_f3:143:g_d0_f3:demand (PID). If, on the other hand, the patient would have received a net positive
10:314:21422:18:39:90:466:366:143:g_d0_f3:143:g_d0_f3:benefit from a service, we call such a distortion physician rationing (PR).
10:315:21497:39:26:90:434:327:206:g_d0_f9:206:g_d0_f9:2.1  Market concentration and physician agency
10:316:21543:26:18:90:521:301:143:g_d0_f9:143:g_d0_f23:Proposition 1For small↵⇡0, if there is an internal solution to the FOC in
10:317:21616:18:18:90:522:283:143:g_d0_f23:143:g_d0_f23:equation 2, the magnitude of the elasticity of market response to changes in profit
10:318:21699:18:30:90:410:265:143:g_d0_f23:143:g_d0_f23:margin will be negatively correlated with market concentration.
10:319:21762:30:31:90:205:235:143:g_d0_f9:143:g_d0_f3:Proof.See Appendix.
10:320:21781:31:18:90:522:204:143:g_d0_f9:143:g_d0_f23:Proposition 2For small↵⇡0, the magnitude of the change in patient benefit in a
10:321:21859:18:31:90:406:186:143:g_d0_f23:143:g_d0_f23:market will be positively correlated with market concentration.
10:322:21922:31:24:90:205:155:143:g_d0_f9:143:g_d0_f3:Proof.See Appendix.
10:323:21941:24:54:99:359:131:49:g_d0_f6:99:g_d0_f7:11See McGuire (2000) for a detailed discussion of this issue.
10:324:22002:54:0:303:309:77:143:g_d0_f3:143:g_d0_f3:8
11:325:22003:0:26:90:296:671:206:g_d0_f9:206:g_d0_f9:2.2  Summary of predictions
11:326:22030:26:18:90:522:645:143:g_d0_f3:143:g_d0_f3:In equilibrium, physicians may under or over provide care relative to what would be
11:327:22113:18:18:90:521:627:143:g_d0_f3:143:g_d0_f3:demanded if all consumers were perfectly informed (qP). In response to changes in
11:328:22194:18:18:89:524:609:143:g_d0_f3:143:g_d0_f3:profit marginsm,thedirectionofphysicianresponseisambiguousanddeterminedby
11:329:22267:18:18:89:521:591:143:g_d0_f3:143:g_d0_f3:the tradeo↵between increasing marginal returns and a wealth e↵ect. Additionally,
11:330:22347:18:18:89:521:573:143:g_d0_f3:143:g_d0_f3:the sign of any change in patient welfare cannot be determined by the sign of the
11:331:22428:18:18:89:514:555:143:g_d0_f3:143:g_d0_f3:change in the amount of care provided but depends also on the initial level of care.
11:332:22512:18:17:107:527:537:143:g_d0_f3:143:g_d0_f3:In terms of market response to changes inm,themagnitudeofthetreatment
11:333:22581:17:18:90:522:520:143:g_d0_f3:143:g_d0_f3:change (e.g., the share of patients receiving care) is negatively correlated with mar-
11:334:22667:18:18:90:522:502:143:g_d0_f3:143:g_d0_f3:ket concentration. In contrast, changes in average welfare are positively correlated
11:335:22751:18:18:90:522:484:143:g_d0_f3:143:g_d0_f3:with market concentration. While the relationship between market concentration and
11:336:22833:18:18:90:520:466:143:g_d0_f3:64:g_d0_f14:physician response is driven mostly by the mean physician market share  ̄⌘k=1J⌃Jj=1⌘j
11:337:22918:18:18:90:522:448:143:g_d0_f3:143:g_d0_f3:(e.g. the physician to population ratio), the welfare response is driven by both the
11:338:23002:18:18:90:530:430:143:g_d0_f3:143:g_d0_f3:mean anddistributionof physician market shares⌘j.Themeanphysicianmarket
11:339:23073:18:18:89:521:412:143:g_d0_f3:143:g_d0_f3:share determines how many additional patients get treated, the distribution of physi-
11:340:23158:18:18:89:522:394:143:g_d0_f3:143:g_d0_f3:cian market shares determinewhogets treated.  In short, although the treatment
11:341:23236:18:18:89:521:376:143:g_d0_f3:143:g_d0_f3:response to a payment change will be larger in more competitive markets, the welfare
11:342:23320:18:45:89:203:358:143:g_d0_f3:143:g_d0_f3:e↵ects will be smaller.
11:343:23343:45:30:90:278:313:296:g_d0_f9:296:g_d0_f9:3  Data and Methods
11:344:23362:30:18:90:521:283:143:g_d0_f3:143:g_d0_f3:To study the impact of physician profit margin changes on health care supply and
11:345:23442:18:18:90:522:265:143:g_d0_f3:143:g_d0_f3:patient well being, we analyze Medicare claims for beneficiaries who had at least
11:346:23523:18:18:90:521:247:143:g_d0_f3:143:g_d0_f3:one claim in a physician’s o-ce or an outpatient-hospital setting with a lung cancer
11:347:23607:18:18:90:522:229:143:g_d0_f3:143:g_d0_f3:diagnosis (ICD-9 162.0-162.9) between 2003 and 2005 (N=878,923). For these bene-
11:348:23687:18:17:90:522:211:143:g_d0_f3:143:g_d0_f3:ficiaries, we have all claims for physicians’ services, hospital outpatient care, durable
11:349:23776:17:18:90:522:194:143:g_d0_f3:143:g_d0_f3:medical equipment, short-stay, long-stay and skilled nursing facility services, and hos-
11:350:23864:18:18:90:521:176:143:g_d0_f3:143:g_d0_f3:pice care for 2002 to 2006.12These claims capture only Medicare fee-for-service, the
11:351:23948:18:24:89:522:158:143:g_d0_f3:143:g_d0_f3:care a↵ected by the reform. Although in principle care in Medicare Advantage (MA)
11:352:24029:24:16:99:521:134:49:g_d0_f6:99:g_d0_f7:12These data come from the Medicare Carrier, Outpatient, Durable Medical Equipment (DME),
11:353:24118:16:41:90:394:118:99:g_d0_f7:99:g_d0_f7:Medicare Provider Analysis and Review (MedPAR) and Hospice files.
11:354:24183:41:0:303:309:77:143:g_d0_f3:143:g_d0_f3:9
12:355:24184:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:plans, Medicare-approved private health plans that are paid a lump-sub on a risk-
12:356:24265:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:adjusted per-enrollee per month basis, could serve as a control, there is no comparable
12:357:24352:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:source of treatment data for this population.13Dates of death for our analytic cohort
12:358:24437:18:18:89:450:617:143:g_d0_f3:143:g_d0_f3:(defined below) are from the Medicare Vital Status File through 2012.
12:359:24506:18:18:107:526:599:143:g_d0_f3:143:g_d0_f3:Aclaimwithalungcancerdiagnosismaynotindicatecancerbutcouldcapture
12:360:24571:18:18:89:525:581:143:g_d0_f3:143:g_d0_f3:amiscodeddiagnosiscodeorevaluationforasuspectedcancerthatissubsequently
12:361:24642:18:18:89:521:563:143:g_d0_f3:143:g_d0_f3:deemed benign. To isolate lung cancer cases, we restrict to Medicare beneficiaries
12:362:24724:18:18:89:521:545:143:g_d0_f3:143:g_d0_f3:with two or more non-institutional (i.e., physician, durable medical equipment or
12:363:24805:18:18:89:521:527:143:g_d0_f3:143:g_d0_f3:outpatient hospital) claims separated by at least 28 days but no more than 365 days
12:364:24888:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:or one institutional (short-stay, long-stay, skilled nursing facility or hospice) claim
12:365:24975:18:18:89:521:491:143:g_d0_f3:143:g_d0_f3:with a lung cancer diagnosis. This is a common approach to defining cancer in claims
12:366:25059:18:17:89:521:473:143:g_d0_f3:143:g_d0_f3:data that has been shown to have high sensitivity (i.e., identify a high proportion
12:367:25142:17:18:89:521:456:143:g_d0_f3:143:g_d0_f3:of actual cancer cases) and very high specificity (i.e., exclude beneficiaries without
12:368:25228:18:18:89:521:438:143:g_d0_f3:143:g_d0_f3:cancer) in Medicare claims data (e.g., see Warren et al. (1999); Ramsey et al. (2009);
12:369:25314:18:18:89:520:420:143:g_d0_f3:143:g_d0_f3:Vera-Llonch et al. (2011)). To isolate lung cancer treatments, we exclude beneficiaries
12:370:25401:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:with more than one confirmed primary cancer. We use the first claim with a lung
12:371:25480:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:cancer diagnosis to date the onset of disease.  To ensure new diagnoses and thus
12:372:25560:18:18:89:521:366:143:g_d0_f3:143:g_d0_f3:treatment trajectories that were not influenced by prior clinical decisions, we restrict
12:373:25648:18:18:89:490:348:143:g_d0_f3:64:g_d0_f5:to beneficiaries with no cancer-related claims history in the 12 prior months.14
12:374:25728:18:18:107:520:330:143:g_d0_f3:143:g_d0_f3:We eliminate the roughly 5% of beneficiaries in the fee-for-service claims who were
12:375:25811:18:18:89:521:312:143:g_d0_f3:143:g_d0_f3:enrolled in a Medicare Advantage plan at some point during the study period and thus
12:376:25895:18:18:89:521:294:143:g_d0_f3:143:g_d0_f3:lacked complete treatment and billing information. The lung cancer cohort included
12:377:25977:18:18:89:521:276:143:g_d0_f3:143:g_d0_f3:216,119 beneficiaries enrolled in Medicare Parts A and B who were diagnosed between
12:378:26060:18:18:89:521:258:143:g_d0_f3:143:g_d0_f3:January 2003 and November 2005. We further restrict the primary analytic cohort
12:379:26139:18:18:89:521:240:143:g_d0_f3:143:g_d0_f3:to the 132,768 beneficiaries diagnosed between February 2004 and November 2005 to
12:380:26220:18:17:89:421:222:143:g_d0_f3:143:g_d0_f3:capture 11 months of data on either side of the payment change.
12:381:26283:17:24:107:522:205:143:g_d0_f3:143:g_d0_f3:Chemotherapy treatment is identified using relevant diagnosis and billing codes
12:382:26362:24:15:99:521:181:49:g_d0_f6:99:g_d0_f7:13Although national MA data are unavailable, we had access to Kaiser Northern California’s MA
12:383:26455:15:12:90:522:166:99:g_d0_f7:99:g_d0_f7:data to use as a control. However, the FFS treatment response to the MMA in Northern California
12:384:26550:12:12:90:522:154:99:g_d0_f7:99:g_d0_f7:was small, making this comparison less relevant. We do not have a good explanation for geographic
12:385:26647:12:14:90:500:142:99:g_d0_f7:99:g_d0_f7:variation in the response, although such variation is widespread in Medicare (Skinner (2012)).
12:386:26741:14:51:99:476:128:49:g_d0_f6:99:g_d0_f7:14Patients for whom we could not verify a 12-month cancer free period are eliminated.
12:387:26826:51:0:300:312:77:143:g_d0_f3:143:g_d0_f3:10
13:388:26828:0:18:90:521:671:143:g_d0_f3:143:g_d0_f3:(Warren et al. (2002)).15Beneficiary date of death is drawn from the Medicare Vital
13:389:26911:18:39:89:389:653:143:g_d0_f3:143:g_d0_f3:Status File, which we had updated through June 30, 2012.
13:390:26967:39:26:90:260:614:206:g_d0_f9:206:g_d0_f9:3.1  Analytic Approach
13:391:26989:26:18:90:521:588:143:g_d0_f3:143:g_d0_f3:To assess whether the January 2005 payment change plausibly a↵ected treatment and
13:392:27070:18:18:90:522:570:143:g_d0_f3:143:g_d0_f3:health outcomes, we take both a graphical and regression-based approach that initially
13:393:27156:18:18:90:522:552:143:g_d0_f3:143:g_d0_f3:analyzes patients by month of diagnosis relative to the reform. To begin, we plot
13:394:27237:18:18:90:521:534:143:g_d0_f3:143:g_d0_f3:estimated month-relative-to-reform (January 2005) fixed e↵ects along with 95 percent
13:395:27321:18:18:90:522:516:143:g_d0_f3:143:g_d0_f3:confidence intervals from a regression of the likelihood a newly diagnosed lung cancer
13:396:27407:18:17:90:522:498:143:g_d0_f3:143:g_d0_f3:patient received any chemotherapy treatment, chemotherapy treatment by setting
13:397:27485:17:18:90:521:481:143:g_d0_f3:143:g_d0_f3:(e.g., physician’s o-ce), treatment with specific agents conditional on receiving any
13:398:27570:18:18:90:522:463:143:g_d0_f3:143:g_d0_f3:chemotherapy, all within 30 days of diagnosis. We choose a 30-day treatment period
13:399:27652:18:18:90:522:445:143:g_d0_f3:143:g_d0_f3:because it enables us to relatively cleanly define treatment (diagnosed post-reform)
13:400:27736:18:18:90:521:427:143:g_d0_f3:143:g_d0_f3:and control (diagnosed pre-reform) cohorts.16The month-relative-to-reform fixed
13:401:27815:18:33:90:444:409:143:g_d0_f3:143:g_d0_f3:e↵ects are simply the set of coe-cients from the following regression:
13:402:27885:33:33:119:522:376:143:g_d0_f10:143:g_d0_f3:Yism=-0+Xism-+μs+-m-m⇤+✏ism,(4)
13:403:27916:33:18:89:522:343:143:g_d0_f3:143:g_d0_f3:whereYismis the treatment or survival outcome of individual i residing in state s
13:404:27997:18:18:90:522:325:143:g_d0_f3:143:g_d0_f3:and diagnosed in monthm,Xismare a set of patient characteristics including gender,
13:405:28079:18:17:89:521:307:143:g_d0_f3:143:g_d0_f3:race/ethnicity (7 categories), patient age and its square, pre-cancer comorbidities, as
13:406:28166:17:18:89:521:290:143:g_d0_f3:143:g_d0_f3:measured by the Deyo-Charlson score (Deyo et al. (1992); Charlson et al. (1987)),
13:407:28247:18:18:89:521:272:143:g_d0_f3:143:g_d0_f3:an indicator for metastatic disease at diagnosis, defined as 30 days from the date of
13:408:28332:18:24:89:522:254:143:g_d0_f3:143:g_d0_f3:diagnosis17;μsare state fixed e↵ects,-m-m⇤are month-relative-to-reform fixed e↵ects
13:409:28415:24:16:99:521:230:49:g_d0_f6:99:g_d0_f7:15We use ICD-9-CM procedure code 99.25 or diagnosis codes V58.1, V66.2 or V67.2, diagnosis-
13:410:28506:16:12:90:522:214:99:g_d0_f7:99:g_d0_f7:related group code 410, or HCPC codes 96400-96549, J9000-J9999 or Q0083 through Q0085, C8953-
13:411:28599:12:13:90:442:202:99:g_d0_f7:99:g_d0_f7:C8955 (2006 only), G0345-G0362 and revenue center codes 0331, 0332 and 0335.
13:412:28675:13:16:99:521:189:49:g_d0_f6:99:g_d0_f7:16Longer treatment windows capture cohorts diagnosed in the pre-reform period but receiving
13:413:28766:16:14:90:464:173:99:g_d0_f7:99:g_d0_f7:care in the post-reform period. We show results for these groups in sensitivity checks.
13:414:28853:14:16:99:521:159:49:g_d0_f6:99:g_d0_f7:17To confirm metastasis we require one institutional claim or two or more non-institutional claims
13:415:28951:16:11:90:522:143:99:g_d0_f7:99:g_d0_f7:separated by at least 28 and no more than 365 days with a secondary cancer diagnosis [ICD-9 codes:
13:416:29049:11:12:90:522:132:99:g_d0_f7:99:g_d0_f7:197-199]. Although this algorithm is likely to miss many beneficiaries with secondary cancer, it does
13:417:29150:12:43:90:522:120:99:g_d0_f7:99:g_d0_f7:have reasonable specificity (Earle et al. (2002)). Results are not sensitive to excluding this measure.
13:418:29253:43:0:300:312:77:143:g_d0_f3:143:g_d0_f3:11
14:419:29255:0:18:90:521:671:143:g_d0_f3:143:g_d0_f3:(e.g.mx-m⇤=-1 in December 2004 and +1 in February 2005) with January 2005
14:420:29328:18:18:89:521:653:143:g_d0_f3:143:g_d0_f3:omitted, and✏ismis an error term. Plotting these month fixed e↵ects helps verify that
14:421:29413:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:the time-series patterns are consistent with a causal impact of the reform. In addition,
14:422:29501:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:we use these plots to guide the specification of models estimating the magnitude of
14:423:29584:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:the reform’s impact. We focus on a window of 11 months prior to and 11 months
14:424:29661:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:post reform, which was chosen to balance the number of pre-reform months with the
14:425:29742:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:limited post-reform data available to us, although using all 24 months of pre-reform
14:426:29826:18:18:90:520:545:143:g_d0_f3:143:g_d0_f3:data yields similar results.18We show results for shorter windows - 9 months on either
14:427:29912:18:18:89:356:527:143:g_d0_f3:143:g_d0_f3:side of the reform - to hone in on the policy change.
14:428:29965:18:18:107:521:509:143:g_d0_f3:143:g_d0_f3:We use the same basic regression framework and visual approach to analyze both
14:429:30043:18:18:89:521:491:143:g_d0_f3:143:g_d0_f3:the characteristics of the cohorts diagnosed before and after January 2005 and the
14:430:30125:18:17:89:521:473:143:g_d0_f3:143:g_d0_f3:likelihood of death within 3, 6, 9, or 12 months of diagnosis. The goal in analyzing
14:431:30209:17:18:89:521:456:143:g_d0_f3:143:g_d0_f3:characteristics is to establish that individuals diagnosed just before relative to just
14:432:30296:18:18:89:521:438:143:g_d0_f3:143:g_d0_f3:after the payment change are similar on observable dimensions, a key identifying
14:433:30376:18:18:89:521:420:143:g_d0_f3:143:g_d0_f3:assumption for our analysis. For the survival analysis, we separately obtained dates
14:434:30460:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:of death from administrative records through June 30, 2012 to minimize any right
14:435:30540:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:truncation bias. Because of the low rate of lung cancer survival, this follow-up period
14:436:30627:18:18:89:334:366:143:g_d0_f3:143:g_d0_f3:captures almost 90% of deaths in both cohorts..
14:437:30674:18:18:107:521:348:143:g_d0_f3:143:g_d0_f3:Consistent with the plots, we model the e↵ect of the January 2005 switch to
14:438:30749:18:30:89:475:330:143:g_d0_f3:143:g_d0_f3:ASP-based payments using week rather than month of diagnosis as follows:
14:439:30821:30:35:121:522:300:143:g_d0_f3:143:g_d0_f3: ̄Yt=-0+-1⇤post+-2⇤(t-t⇤)+-3⇤(t-t⇤)⇤post+ ̄Xt-+✏ct,(5)
14:440:30875:35:18:107:522:265:143:g_d0_f3:143:g_d0_f3:where ̄Ytis an outcome such as the mean rate of chemotherapy treatment for
14:441:30949:18:18:90:521:247:143:g_d0_f3:143:g_d0_f3:beneficiaries diagnosed in weekt, post is an indicator equal to 1 after the payment
14:442:31032:18:18:90:521:229:143:g_d0_f3:143:g_d0_f3:change and 0 otherwise, (t-t⇤)isalinearfunctionoftimerelativetothereform,t⇤,
14:443:31108:18:18:89:521:211:143:g_d0_f3:143:g_d0_f3:that controls for smooth trends in outcomes around the time of the payment change
14:444:31189:18:18:89:522:193:143:g_d0_f3:143:g_d0_f3:and that we allow to di↵er on either side of the payment change. These regressions
14:445:31271:18:18:89:521:175:143:g_d0_f3:143:g_d0_f3:control for the share of patients by week that were male, the share by race/ethnicity,
14:446:31357:18:23:89:521:157:143:g_d0_f3:143:g_d0_f3:the median age and median age squared, the mean Deyo-Charlson score, and the
14:447:31433:23:16:99:522:134:49:g_d0_f6:99:g_d0_f8:18In principle we have 12 months of post-reform data but the cohort counts show a sharp drop o↵
14:448:31528:16:41:90:312:118:99:g_d0_f7:99:g_d0_f7:in December, suggesting the data were incomplete.
14:449:31577:41:0:300:312:77:143:g_d0_f3:143:g_d0_f3:12
15:450:31579:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:share with metastatic disease.  We computed Newey-West standard errors, which
15:451:31656:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:allow for heteroskedasticity and autocorrelation in the error of an unknown form up
15:452:31739:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:to a lag of 52 weeks (Newey and West (1987)). We allowed for this long a lag to
15:453:31818:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:account for correlation of annual events that a↵ect treatment, such as the Christmas
15:454:31902:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:holidays. However, inference is not meaningfully a↵ected by alternative lag structures.
15:455:31989:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:In sensitivity checks, we estimate regressions that include month-relative to January
15:456:32074:18:18:90:521:563:143:g_d0_f3:143:g_d0_f3:2005 trends or that omit these trends but include calendar month fixed e↵ects to
15:457:32154:18:45:90:307:545:143:g_d0_f3:143:g_d0_f3:control for cyclicality in treatment timing.
15:458:32198:45:34:90:181:500:296:g_d0_f9:296:g_d0_f9:4  Results
15:459:32208:34:26:90:276:466:206:g_d0_f9:206:g_d0_f9:4.1  Descriptive Statistics
15:460:32235:26:18:90:522:440:143:g_d0_f3:143:g_d0_f3:Table 1 shows demographic characteristics for our analytic sample overall and by
15:461:32315:18:18:90:522:422:143:g_d0_f3:143:g_d0_f3:diagnosis before versus after January 2005. As mentioned above, we focus on the
15:462:32394:18:18:90:522:404:143:g_d0_f3:143:g_d0_f3:11 months before and after the payment change – from February 2004 to Novem-
15:463:32470:18:17:90:522:386:143:g_d0_f3:143:g_d0_f3:ber 2005. Median age at diagnosis was 74 years. Just over half the patients were
15:464:32550:17:18:90:522:369:143:g_d0_f3:143:g_d0_f3:male, 88% were white, and 9% were black. Patients had an average Deyo-Charlson
15:465:32628:18:18:90:522:351:143:g_d0_f3:143:g_d0_f3:comorbidity score of 1.08, meaning one non-cancer comorbidity in the year leading
15:466:32709:18:18:90:522:333:143:g_d0_f3:143:g_d0_f3:up to diagnosis, and almost 29% had metastatic disease documented in claims within
15:467:32791:18:18:90:521:315:143:g_d0_f3:143:g_d0_f3:1monthofdiagnosis.19While the Charlson score and the proportion male are sta-
15:468:32868:18:18:89:522:297:143:g_d0_f3:143:g_d0_f3:tistically di↵erent for the pre and post-reform cohorts, neither di↵erence (0.02 more
15:469:32953:18:18:89:521:279:143:g_d0_f3:143:g_d0_f3:comorbidities or 0.4% fewer males) is meaningful in magnitude. There were no other
15:470:33035:18:18:89:362:261:143:g_d0_f3:143:g_d0_f3:di↵erences in observable demographic characteristics.
15:471:33088:18:18:107:520:243:143:g_d0_f3:143:g_d0_f3:We formally test the stability of patient characteristics, since our research design
15:472:33172:18:18:89:521:225:143:g_d0_f3:143:g_d0_f3:assumes newly diagnosed patients are similar just before and after ASP implementa-
15:473:33254:18:18:89:521:207:143:g_d0_f3:143:g_d0_f3:tion, by estimating variants of equation (1) with these characteristics as dependent
15:474:33338:18:18:89:521:189:143:g_d0_f3:143:g_d0_f3:variables. The coe-cients and 95 percent confidence intervals for the month rela-
15:475:33419:18:18:89:522:171:143:g_d0_f3:143:g_d0_f3:tive to reform fixed e↵ects are shown in Figure 1a-e. With the possible exception
15:476:33500:18:24:89:521:153:143:g_d0_f3:143:g_d0_f3:of the comorbidity score, which is noisy, these characteristics (e.g., share metastatic,
15:477:33588:24:15:99:521:129:49:g_d0_f6:99:g_d0_f7:19We use a 1-month period to define metastasis since our models capture monthly treatment.
15:478:33678:15:37:90:514:114:99:g_d0_f7:99:g_d0_f7:Given this relatively short period, this measure should yield conservative estimates of metastasis.
15:479:33777:37:0:300:312:77:143:g_d0_f3:143:g_d0_f3:13
16:480:33779:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:white, male and log age) are smooth across the reform (time 0).  The estimated
16:481:33857:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:discontinuities in these variables on January 2005 are in Appendix Table 1. As ex-
16:482:33939:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:pected, the estimates tend to be small and indistinguishable from zero. When the
16:483:34019:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:estimates are distinguishable from zero (specifically, log age and the share of patients
16:484:34107:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:of other/unknown race), they are modest in size. To the extent that the gap in age
16:485:34189:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:is real, it should bias us against finding improvements in survival. On balance we
16:486:34271:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:interpret the results in Figure 1 and Appendix Table 1, as evidence that a key identi-
16:487:34357:18:18:90:522:545:143:g_d0_f3:143:g_d0_f3:fying assumption of the empirical approach – the stability of the population of newly
16:488:34442:18:18:90:409:527:143:g_d0_f3:143:g_d0_f3:diagnosed lung cancer patients across the reform – is satisfied.
16:489:34506:18:18:107:521:509:143:g_d0_f3:143:g_d0_f3:Table 1 and Figure 2 provide evidence that the reform had bite by showing pay-
16:490:34584:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:ment changes for several drugs commonly used to treat lung cancer. Payment rates
16:491:34664:18:18:90:522:473:143:g_d0_f3:143:g_d0_f3:declined after the reform for carboplatin, paclitaxel, and etoposide.  The changes
16:492:34746:18:17:90:522:455:143:g_d0_f3:143:g_d0_f3:were most striking for carboplatin and paclitaxel; reimbursement rates for a standard
16:493:34831:17:18:90:522:438:143:g_d0_f3:143:g_d0_f3:monthly dose declined from over $2,270 to $225 for paclitaxel and from $1,845 to
16:494:34911:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:$930 for carboplatin. As shown in Figure 2, the changes in quarterly carboplatin and
16:495:34995:18:18:90:522:402:143:g_d0_f3:143:g_d0_f3:paclitaxel reimbursements occurred around the time the new payment system took
16:496:35073:18:18:90:522:384:143:g_d0_f3:143:g_d0_f3:e↵ect (time 0)). The large discrepancy between payment rates and acquisition costs
16:497:35155:18:18:90:521:366:143:g_d0_f3:143:g_d0_f3:for these drugs was identified as early as 1997. In 2001, the General Accounting O-ce
16:498:35240:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:(now the Government Accountability O-ce) reported widely available discounts of
16:499:35319:18:18:90:521:330:143:g_d0_f3:143:g_d0_f3:about 20% below AWP for both drugs (Government Accountability O-ce (2001)); a
16:500:35396:18:18:90:522:312:143:g_d0_f3:143:g_d0_f3:later analysis showed that 2004 paclitaxel reimbursements were six times higher than
16:501:35480:18:18:90:522:294:143:g_d0_f3:143:g_d0_f3:cost (Government Accountability O-ce (2004)).  Payments were relatively flat for
16:502:35560:18:18:90:522:276:143:g_d0_f3:143:g_d0_f3:docetaxel, a high-priced drug at about $2,500 per standardized monthly dose, and
16:503:35640:18:18:90:522:258:143:g_d0_f3:143:g_d0_f3:gemcitabine at $1,300 per monthly dose, indicating the reform di↵erentially a↵ected
16:504:35723:18:18:90:322:240:143:g_d0_f3:143:g_d0_f3:drugs, depending on the pre-reform mark-up.
16:505:35766:18:18:107:527:222:143:g_d0_f3:143:g_d0_f3:Acomplicationinthepaymentchangeisthatcarboplatinwento↵patentin
16:506:35828:18:18:90:522:204:143:g_d0_f3:143:g_d0_f3:October 2004, the quarter before ASP implementation. Because of the lag in Average
16:507:35910:18:17:90:522:186:143:g_d0_f3:143:g_d0_f3:Sales Price determination – quarterly reimbursements are based on wholesale prices
16:508:35992:17:18:90:522:169:143:g_d0_f3:143:g_d0_f3:two quarters prior – carboplatin likely maintained a margin above the 6% mandated
16:509:36073:18:24:90:521:151:143:g_d0_f3:143:g_d0_f3:by the legislation for at least the first quarter of 2005.20To ensure that our results for
16:510:36163:24:15:99:521:127:49:g_d0_f6:99:g_d0_f7:20Upon its patent expiration in October 2004, at least 5 generic manufacturers had secured FDA
16:511:36257:15:35:90:522:112:99:g_d0_f7:99:g_d0_f7:approval to enter the carboplatin market. The gradual decline in carboplatin’s payment rates in
16:512:36352:35:0:300:312:77:143:g_d0_f3:143:g_d0_f3:14
17:513:36354:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:chemotherapy are not driven entirely by carboplatin, where the observed changes in
17:514:36436:18:18:90:521:653:143:g_d0_f3:143:g_d0_f3:reimbursement combine the e↵ects of the patent expiration and the payment reform,
17:515:36517:18:18:90:493:635:143:g_d0_f3:143:g_d0_f3:we examine both chemotherapy use of regimens with and without carboplatin.
17:516:36591:18:18:107:521:617:143:g_d0_f3:143:g_d0_f3:Table 2 provides summary statistics for our key outcomes of interest.  These
17:517:36667:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:descriptive statistics indicate significant changes in the likelihood of chemotherapy
17:518:36752:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:treatment after the payment change. Whereas 16.6% of patients diagnosed in the 11
17:519:36833:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:months prior to the reform received chemotherapy within 1 month of diagnosis, those
17:520:36916:18:18:90:522:545:143:g_d0_f3:143:g_d0_f3:diagnosed in the 11 months after were almost 2 percentage points (or 11% o↵the pre-
17:521:36999:18:18:90:522:527:143:g_d0_f3:143:g_d0_f3:reform base) more likely to receive chemotherapy within 1 month of diagnosis. Nearly
17:522:37083:18:18:90:522:509:143:g_d0_f3:143:g_d0_f3:three-quarters of this increase (1.5 percentage points) was among patients receiving
17:523:37167:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:regimens without carboplatin. In addition, this increase came almost entirely from
17:524:37249:18:18:90:521:473:143:g_d0_f3:143:g_d0_f3:treatment in physician o-ces rather than outpatient hospital clinics, which were not
17:525:37333:18:17:90:522:455:143:g_d0_f3:143:g_d0_f3:subject to a reimbursement change in 2005. The relative increase in chemotherapy
17:526:37413:17:18:90:521:438:143:g_d0_f3:143:g_d0_f3:treatment was similar within 3 months (a 3.2 percentage point increase o↵a pre-
17:527:37492:18:18:90:473:420:143:g_d0_f3:143:g_d0_f3:reform base of 26%) as was the composition of the changes across settings.
17:528:37566:18:18:107:522:402:143:g_d0_f3:143:g_d0_f3:Conditional on treatment within 1 month of diagnosis, the percent of patients
17:529:37643:18:18:90:522:384:143:g_d0_f3:143:g_d0_f3:receiving carboplatin declined from almost 56 to 53, and the percent receiving pa-
17:530:37725:18:18:90:522:366:143:g_d0_f3:143:g_d0_f3:clitaxel declined from 30 to 26, consistent with the large payment decline for these
17:531:37809:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:drugs. Since carboplatin and paclitaxel are often given in combination and because
17:532:37891:18:18:90:522:330:143:g_d0_f3:143:g_d0_f3:carboplatin likely retained a margin above 6% for a few quarters, some of carbo-
17:533:37971:18:18:90:522:312:143:g_d0_f3:143:g_d0_f3:platin’s decline may be driven by the sharp reduction in paclitaxel’s profitability.
17:534:38055:18:18:90:521:294:143:g_d0_f3:143:g_d0_f3:Trends in use of etoposide were comparatively flat while use of docetaxel, a relatively
17:535:38142:18:18:90:521:276:143:g_d0_f3:143:g_d0_f3:high-priced alternative to palitaxel, increased 1.3 percentage points o↵a base of just
17:536:38228:18:18:90:509:258:143:g_d0_f3:64:g_d0_f5:8.3%, possibly reflecting the incentive from the uniform 6% margin on all drugs.21
17:537:38310:18:18:107:522:240:143:g_d0_f3:143:g_d0_f3:Among cohorts diagnosed in the 11 months prior to January 2005, 33.7% died
17:538:38384:18:27:89:521:222:143:g_d0_f3:143:g_d0_f3:within 3, 46.7% within 6, 52.4% within 9, and 61.6% within 12 months of diagnosis.
17:539:38466:27:11:90:522:195:99:g_d0_f7:99:g_d0_f7:Figure 2, which may capture switching to generics, suggests it maintained a margin above 6% for
17:540:38561:11:14:90:250:184:99:g_d0_f7:99:g_d0_f7:longer than the first quarter of 2005.
17:541:38599:14:16:99:521:170:49:g_d0_f6:99:g_d0_f7:21Although  the  rise  in  prescription  drug  shortages  began  around  2005,  the  rise
17:542:38688:16:12:90:522:154:99:g_d0_f7:99:g_d0_f7:in  oncology  drug  shortages  occurred  much  later,  around  2008.For  details  see
17:543:38773:12:12:90:505:142:99:g_d0_f7:99:g_d0_f7:http://healtha↵airs.org/blog/2012/05/29/prescription-drug-shortages-reconsidering-the-role-of-
17:544:38867:12:12:90:522:130:99:g_d0_f7:99:g_d0_f7:medicare-payment-policies/ Paclitaxel and Carboplatin were not in short supply until 2009 and
17:545:38960:12:41:90:493:118:99:g_d0_f7:99:g_d0_f7:2010, respectively. Thus, shortages are unlikely to explain the drug switching observed here.
17:546:39053:41:0:300:312:77:143:g_d0_f3:143:g_d0_f3:15
18:547:39055:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:For cohorts diagnosed in the 11 months after January 2005, the proportion dying was
18:548:39138:18:39:90:430:653:143:g_d0_f3:143:g_d0_f3:1-2 percentage points (3%-4%) lower in each of these four periods.
18:549:39204:39:26:90:284:614:206:g_d0_f9:206:g_d0_f9:4.2  Changes in Treatment
18:550:39229:26:18:90:522:588:143:g_d0_f3:143:g_d0_f3:Figures 3a-3d show the regression-adjusted mean changes in the likelihood that pa-
18:551:39311:18:18:90:522:570:143:g_d0_f3:143:g_d0_f3:tients received any chemotherapy, any chemotherapy regimen excluding carboplatin,
18:552:39392:18:18:90:521:552:143:g_d0_f3:143:g_d0_f3:any chemotherapy in a physician’s o-ce, and any chemotherapy in an outpatient
18:553:39469:18:18:89:521:534:143:g_d0_f3:143:g_d0_f3:clinic by month of diagnosis relative to January 2005.  With the exception of the
18:554:39550:18:18:89:521:516:143:g_d0_f3:143:g_d0_f3:outpatient clinic setting (Fig 3d), which did not face a payment change until 2006, all
18:555:39637:18:17:89:521:498:143:g_d0_f3:143:g_d0_f3:the panels show a discrete increase in the likelihood of chemotherapy treatment for
18:556:39720:17:18:89:521:481:143:g_d0_f3:143:g_d0_f3:lung cancer patients diagnosed just after relative to just before January 2005 (time
18:557:39804:18:18:89:521:463:143:g_d0_f3:143:g_d0_f3:0). The timing of the increase and that most of the increase came in physician o-ces,
18:558:39889:18:18:89:521:445:143:g_d0_f3:143:g_d0_f3:the only setting subject to the payment reform in 2005, suggest that the switch to the
18:559:39975:18:18:89:521:427:143:g_d0_f3:143:g_d0_f3:ASP system drove the change. The similarity when carboplatin is excluded confirms
18:560:40056:18:18:89:508:409:143:g_d0_f3:143:g_d0_f3:that the increase in treatment is not driven by the sustained margin on this drug.
18:561:40138:18:18:107:521:391:143:g_d0_f3:143:g_d0_f3:Table 3 shows estimates of the discontinuous jump in chemotherapy treatment for
18:562:40217:18:18:89:521:373:143:g_d0_f3:143:g_d0_f3:those diagnosed just after January 2005. The estimates are based on the specification
18:563:40302:18:18:89:521:355:143:g_d0_f3:143:g_d0_f3:in (5) using 11 months (col 2) or 9 months (col 3) on either side of the payment change.
18:564:40390:18:18:89:521:337:143:g_d0_f3:143:g_d0_f3:The overall change in the likelihood of chemotherapy treatment rates within 1 month
18:565:40473:18:18:89:522:319:143:g_d0_f3:143:g_d0_f3:of diagnosis is about 1.5 percentage points. O↵a base of 16.6% of those diagnosed
18:566:40554:18:18:89:521:301:143:g_d0_f3:143:g_d0_f3:prior to the reform who receive treatment within one month, this represents about a
18:567:40637:18:18:89:521:283:143:g_d0_f3:143:g_d0_f3:9% increase in the likelihood of treatment in response to the reform. When we look
18:568:40719:18:18:89:521:265:143:g_d0_f3:143:g_d0_f3:at treatment that does not include carboplatin, the relative increase is much larger
18:569:40803:18:18:89:526:247:143:g_d0_f3:143:g_d0_f3:–almost20%(1.2to1.4percentagepointso↵abaseof7.3%). Thisimpliesthat
18:570:40869:18:17:89:521:229:143:g_d0_f3:143:g_d0_f3:the overall change in chemotherapy treatment is not driven solely by the interaction
18:571:40953:17:18:89:521:212:143:g_d0_f3:143:g_d0_f3:between the payment reform and the patent expiration of carboplatin. In addition,
18:572:41034:18:18:89:521:194:143:g_d0_f3:143:g_d0_f3:the increase is driven by treatment in the physician’s o-ce setting, which was the
18:573:41116:18:18:89:521:176:143:g_d0_f3:143:g_d0_f3:setting subject to the reform. As shown in Appendix Table 2, the results are largely
18:574:41200:18:18:89:521:158:143:g_d0_f3:143:g_d0_f3:insensitive to the use of relative month trends (cols 1 and 2) or calendar month fixed
18:575:41286:18:18:89:522:140:143:g_d0_f3:143:g_d0_f3:e↵ects (cols 3 and 4) instead of relative-week trends. The main di↵erence is that the
18:576:41371:18:45:89:522:122:143:g_d0_f3:143:g_d0_f3:e↵ects are slightly larger when calendar month instead of relative-week or relative-
18:577:41455:45:0:300:312:77:143:g_d0_f3:143:g_d0_f3:16
19:578:41457:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:month trends are used, suggesting a 10% increase in treatment and an increase in
19:579:41537:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:treatment in the outpatient setting. However, the patterns in Figure 3 suggest that
19:580:41620:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:the specification with relative trends that are allowed to vary on either side of January
19:581:41709:18:18:90:515:617:143:g_d0_f3:143:g_d0_f3:1, 2005 more appropriately captures treatment trendfs before and after the reform.
19:582:41791:18:18:107:521:599:143:g_d0_f3:143:g_d0_f3:Figures 4a-4d and Table 4 consider chemotherapy service counts within thirty
19:583:41867:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:days of diagnosis.  Changes in service counts, unlike the likelihood of treatment,
19:584:41949:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:combine both extensive and intensive margin changes. The trends in Figure 4 are
19:585:42028:18:18:90:522:545:143:g_d0_f3:143:g_d0_f3:analogous to those in Figure 3 but appear larger, at least outside of the outpatient
19:586:42112:18:18:90:522:527:143:g_d0_f3:143:g_d0_f3:clinic setting, where the change was essentially zero. As shown in Table 4, the mean
19:587:42196:18:18:90:522:509:143:g_d0_f3:143:g_d0_f3:number of chemotherapy services within 30 days was 1 prior to the reform; among
19:588:42275:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:those diagnosed after the reform, services increased almost 33%. Given the 9% in-
19:589:42356:18:18:90:522:473:143:g_d0_f3:143:g_d0_f3:crease in treatment on the extensive margin, these results suggest that chemotherapy
19:590:42440:18:17:90:522:455:143:g_d0_f3:143:g_d0_f3:services likely increased even among those who would have received treatment absent
19:591:42523:17:18:90:522:438:143:g_d0_f3:143:g_d0_f3:the reform.  As on the extensive margin, the increase occurs in patients receiving
19:592:42605:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:treatments that do not contain carboplatin, implying that the interaction of the re-
19:593:42689:18:18:90:522:402:143:g_d0_f3:143:g_d0_f3:form and carboplatin’s patent expiration cannot fully explain our main treatment
19:594:42769:18:18:90:522:384:143:g_d0_f3:143:g_d0_f3:result. The increase in physician o-ces accounts for almost all (about 94% or 0.916
19:595:42852:18:18:90:522:366:143:g_d0_f3:143:g_d0_f3:*0.347/0.339) of the change.  Services increase somewhat in the outpatient clinic
19:596:42933:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:setting as well, about 1.3%, although this change is modest compared to the 34%
19:597:43012:18:18:90:522:330:143:g_d0_f3:143:g_d0_f3:increase in physician o-ces. As with the likelihood of any treatment, models with
19:598:43093:18:18:90:521:312:143:g_d0_f3:143:g_d0_f3:relative-month trends or calendar month fixed e↵ects (Appendix Table 3) yield results
19:599:43178:18:18:90:380:294:143:g_d0_f3:143:g_d0_f3:that are similar, albeit larger without linear time trends.
19:600:43237:18:18:107:522:276:143:g_d0_f3:143:g_d0_f3:As a more formal test of a structural break in treatment, we adopt an approach
19:601:43315:18:18:90:522:258:143:g_d0_f3:143:g_d0_f3:from the time series literature.  Specifically, we employ a Quandt likelihood ratio
19:602:43398:18:18:90:522:240:143:g_d0_f3:143:g_d0_f3:(QLR) test (Quandt 1960) that tests for structural breaks at all possible dates between
19:603:43485:18:17:90:530:222:143:g_d0_f3:143:g_d0_f3:two time periods,⌧0to⌧1.Operationally,thetestisamodifiedsetofsequential
19:604:43556:17:18:90:521:205:143:g_d0_f3:143:g_d0_f3:Chow tests based on equation (2), where a post-period is defined at each cuto↵date
19:605:43638:18:18:89:525:187:143:g_d0_f13:143:g_d0_f3:⌧between the two time periods, i.e.post=1(t-⌧⇤)isanindicatorequaltozerofor
19:606:43712:18:18:90:522:169:143:g_d0_f3:143:g_d0_f3:all weeks before⌧⇤and one for all subsequent weeks; this indicator is also interacted
19:607:43797:18:18:90:520:151:143:g_d0_f3:64:g_d0_f16:with the linear trend. Under the null hypothesis of no break, the coe-cients onpost⌧
19:608:43881:18:18:90:526:133:143:g_d0_f3:143:g_d0_f3:andpost⌧⇤(t-t⇤)arejointlyequaltozero. TheQLRstatistic,alsoknownasthe
19:609:43949:18:38:89:521:115:143:g_d0_f3:143:g_d0_f3:sub-Wald statistic, is just the maximal of the F-statistics testing the null of no break
19:610:44037:38:0:300:312:77:143:g_d0_f3:143:g_d0_f3:17
20:611:44039:0:18:90:525:671:143:g_d0_f3:143:g_d0_f3:at all dates between⌧0to⌧1;itprovidesanestimateofthestructuralbreakdate.To
20:612:44113:18:18:90:521:653:143:g_d0_f3:143:g_d0_f3:implement this test, we adopt the conventional choice for⌧0to⌧1of 0.15T and 0.85T
20:613:44194:18:18:89:521:635:143:g_d0_f3:143:g_d0_f3:or -34 weeks and + 33 weeks relative to the first week, i.e. week 0, in January 2005.
20:614:44279:18:18:89:525:617:143:g_d0_f3:143:g_d0_f3:In this way, the post period cuto↵or break date,⌧⇤,issequentiallydefinedoverthe
20:615:44358:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:inner 70% of the 96 week sample. We take the critical values of the QLR statistic for
20:616:44443:18:18:89:521:581:143:g_d0_f3:143:g_d0_f3:the endpoints 0.15T and 0.85T and two restrictions tested from Stock and Watson
20:617:44522:18:18:89:347:563:143:g_d0_f3:64:g_d0_f5:(2003), which are adapted from Andrews (2003).22
20:618:44570:18:18:107:521:545:143:g_d0_f3:143:g_d0_f3:Appendix Figure 1 plots the F-statistics testing for a break at -34 to +33 weeks
20:619:44650:18:18:89:521:527:143:g_d0_f3:143:g_d0_f3:relative to week 0. We show these tests for the following 30-day treatment series:
20:620:44732:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:any chemotherapy, chemotherapy that does not include carboplatin, chemotherapy
20:621:44810:18:18:89:521:491:143:g_d0_f3:143:g_d0_f3:in a physician’s o-ce, and chemotherapy in an outpatient hospital setting. Based on
20:622:44893:18:17:89:521:473:143:g_d0_f3:143:g_d0_f3:the QLR statistic, a structural break in treatment occurs two weeks prior to January
20:623:44977:17:18:89:521:456:143:g_d0_f3:143:g_d0_f3:2005 for any chemotherapy treatment (App Fig 1a) and treatment in a physician’s
20:624:45056:18:18:89:521:438:143:g_d0_f3:143:g_d0_f3:o-ce (App Fig 1c). Excluding Carboplatin, the break occurs 1 week prior to ASP
20:625:45134:18:18:89:521:420:143:g_d0_f3:143:g_d0_f3:implementation (App Fig 1b). The pre-implementation break is not worrisome given
20:626:45214:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:that we are analyzing 30-day treatment and patients diagnosed at the end of 2004
20:627:45294:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:likely began treatment after the new payment system took e↵ect on January 1 rather
20:628:45376:18:18:89:521:366:143:g_d0_f3:143:g_d0_f3:than during the Christmas holidays. In all three cases, the maximal F-statistic exceeds
20:629:45463:18:18:89:521:348:143:g_d0_f3:143:g_d0_f3:the 1% critical value of 7.78, implying we can reject the null of no structural break
20:630:45548:18:18:89:521:330:143:g_d0_f3:143:g_d0_f3:in treatment. In contrast, we cannot reject the null at any point for chemotherapy
20:631:45630:18:18:89:372:312:143:g_d0_f3:143:g_d0_f3:treatment in the outpatient setting (Appendix Fig 1d).
20:632:45684:18:18:107:522:294:143:g_d0_f3:143:g_d0_f3:The results above indicate that chemotherapy treatment within 30 days of diag-
20:633:45762:18:18:89:521:276:143:g_d0_f3:143:g_d0_f3:nosis increased on both the extensive and intensive margins. As another check, we
20:634:45843:18:18:89:521:258:143:g_d0_f3:143:g_d0_f3:analyze the likelihood of treatment within 90 days of diagnosis. The 90 day period
20:635:45925:18:18:89:521:240:143:g_d0_f3:143:g_d0_f3:captures those diagnosed just before the reform but who were a↵ected by the reform
20:636:46007:18:18:89:521:222:143:g_d0_f3:143:g_d0_f3:if they survived past implementation. Consistent with this, Appendix Figures 2a-
20:637:46087:18:17:89:521:204:143:g_d0_f3:143:g_d0_f3:2c show a gradual increase in 90-day treatment for those cohorts diagnosed within
20:638:46168:17:18:89:521:187:143:g_d0_f3:143:g_d0_f3:three to one months prior to the reform. The change flattens out for those cohorts
20:639:46250:18:18:89:521:169:143:g_d0_f3:143:g_d0_f3:diagnosed just after the reform, suggesting that the earlier increase captures partial
20:640:46336:18:24:89:521:151:143:g_d0_f3:143:g_d0_f3:exposure to the reform. As indicated in Appendix Table 4, once this gradual rise is
20:641:46419:24:15:99:522:127:49:g_d0_f6:99:g_d0_f7:22The QLR critical values are larger than the critical value for a single F-test; they are e↵ectively
20:642:46520:15:35:90:445:112:99:g_d0_f7:99:g_d0_f7:corrected for multiple-hypothesis testing induced by searching over many F-tests.
20:643:46601:35:0:300:312:77:143:g_d0_f3:143:g_d0_f3:18
21:644:46603:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:accounted for (via an indicator for diagnosis in the quarter prior to the reform), the
21:645:46689:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:increase in 90-day treatment for those fully exposed to the reform, i.e. diagnosed in
21:646:46774:18:18:90:521:635:143:g_d0_f3:143:g_d0_f3:2005, was about 11% overall and almost 15% in the physician’s o-ce-setting. In a
21:647:46854:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:parallel fashion, Figure 3d shows that cohorts diagnosed in the last few months of
21:648:46936:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:2005 experienced an increase in the likelihood of treatment in the outpatient setting,
21:649:47022:18:18:90:521:581:143:g_d0_f3:143:g_d0_f3:after the payment reform took e↵ect in this setting. In other words, the treatment
21:650:47104:18:18:90:460:563:143:g_d0_f3:143:g_d0_f3:response to the payment change in the physician’s setting is not unique.
21:651:47176:18:18:107:521:545:143:g_d0_f3:143:g_d0_f3:We next analyze changes in the types of drugs used. Figure 5a-5e show regression-
21:652:47257:18:18:90:522:527:143:g_d0_f3:143:g_d0_f3:adjusted changes in the probability that chemotherapy-treated patients received car-
21:653:47341:18:18:90:522:509:143:g_d0_f3:143:g_d0_f3:boplatin, paclitaxel, docetaxel, etoposide and gemcitabine, the most commonly pre-
21:654:47423:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:scribed agents in our sample. Patients treated within 30 days of diagnosis were less
21:655:47507:18:18:90:522:473:143:g_d0_f3:143:g_d0_f3:likely to receive a mix of agents that included carboplatin or paclitaxel. The timing
21:656:47592:18:17:90:522:455:143:g_d0_f3:143:g_d0_f3:of the decline in use of these agents preceded the introduction of the average sales
21:657:47676:17:18:90:522:438:143:g_d0_f3:143:g_d0_f3:price payment system by about 3 months, which may reflect the quarterly purchasing
21:658:47758:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:common among oncologists.23Given the publicity the reform received among oncolo-
21:659:47838:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:gists, physicians likely understood that the reduction in payment rates for these drugs
21:660:47925:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:would be large and were reducing their inventory of these agents in advance. Failure
21:661:48009:18:18:89:521:366:143:g_d0_f3:143:g_d0_f3:to do so could have meant a considerable loss of income. In contrast to the pattern
21:662:48092:18:18:89:521:348:143:g_d0_f3:143:g_d0_f3:for paclitaxel, the probability of receiving docetaxel, an expensive agent implicitly
21:663:48177:18:18:89:521:330:143:g_d0_f3:143:g_d0_f3:favored by the 6% margin on all drugs, increased modestly for patients receiving
21:664:48257:18:18:89:521:312:143:g_d0_f3:143:g_d0_f3:chemotherapy treatment. The increase preceded the reform by about a month, fur-
21:665:48336:18:18:89:521:294:143:g_d0_f3:143:g_d0_f3:ther evidence that physicians were rearranging their stock of agents in anticipation
21:666:48420:18:18:89:521:276:143:g_d0_f3:143:g_d0_f3:of the ASP system. The likelihood of receiving etoposide or gemcitabine and other
21:667:48501:18:18:89:384:258:143:g_d0_f3:143:g_d0_f3:less commonly used agents did not change systematically.
21:668:48557:18:18:107:521:240:143:g_d0_f3:143:g_d0_f3:Table 5 quantifies the changes illustrated in Figure 5 but first considers the un-
21:669:48639:18:17:89:521:222:143:g_d0_f3:143:g_d0_f3:conditional change in use within 30 days. Whereas carboplatin use did not change
21:670:48719:17:18:89:521:205:143:g_d0_f3:143:g_d0_f3:unconditionally, use of paclitaxel, the drug that lost the most margin, declined by
21:671:48802:18:18:89:521:187:143:g_d0_f3:143:g_d0_f3:about 10% and docetaxel and etoposide increased by about 30% and 9%, respectively.
21:672:48884:18:18:89:521:169:143:g_d0_f3:143:g_d0_f3:These changes combine the change in chemotherapy treatment and the choice of drugs.
21:673:48967:18:24:89:521:151:143:g_d0_f3:143:g_d0_f3:Conditional on any treatment, physicians were less likely to give patients carboplatin
21:674:49053:24:50:99:489:127:49:g_d0_f6:99:g_d0_f7:23We thank the community oncologist from Phoenix, AZ who first relayed this fact to us.
21:675:49140:50:0:300:312:77:143:g_d0_f3:143:g_d0_f3:19
22:676:49142:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:or paclitaxel after ASP implementation. The probability that chemotherapy-treated
22:677:49223:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:patients received carboplatin declined 3 to 4 percentage points. The decline in the
22:678:49306:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:probability of receiving paclitaxel was more dramatic – about 6 to 7 percentage points
22:679:49392:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:or over 20%. Some physicians switched patients to docetaxel, an expensive agent fa-
22:680:49475:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:vored by the 6% uniform mark-up. The docetaxel increase was about 2.6 percentage
22:681:49555:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:points or over 30% o↵a base of 8.3%. Accounting for pre-reform switching increases
22:682:49637:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:the magnitude of these changes (see Appendix Table 5). The change for etoposide
22:683:49716:18:18:90:522:545:143:g_d0_f3:143:g_d0_f3:is small, indistinguishable from zero and changes sign as the study window narrows.
22:684:49799:18:18:90:522:527:143:g_d0_f3:143:g_d0_f3:The estimate for gemcitabine is larger in relative terms (0.7 percentage points o↵a
22:685:49882:18:39:90:471:509:143:g_d0_f3:143:g_d0_f3:base of 10%), but based on Fig 5e may not reflect a policy-related change.
22:686:49956:39:25:90:268:470:206:g_d0_f9:206:g_d0_f9:4.3  Changes in Survival
22:687:49980:25:18:90:522:445:143:g_d0_f3:143:g_d0_f3:The results above demonstrate that chemotherapy treatment increased on both the
22:688:50059:18:18:90:522:427:143:g_d0_f3:143:g_d0_f3:intensive and likely extensive margin for lung cancer patients diagnosed just after
22:689:50142:18:18:90:522:409:143:g_d0_f3:143:g_d0_f3:relative to just before the reform. The mix of drugs administered also changed, with
22:690:50226:18:18:90:522:391:143:g_d0_f3:143:g_d0_f3:drugs that lost the most margin used less and expensive agents favored by the 6%
22:691:50306:18:18:90:522:373:143:g_d0_f3:143:g_d0_f3:average margin used slightly more. Although cancer treatment is constantly evolving,
22:692:50390:18:18:90:522:355:143:g_d0_f3:143:g_d0_f3:no other change in management was so suddenly implemented that could account for
22:693:50470:18:18:90:522:337:143:g_d0_f3:143:g_d0_f3:changes of the magnitude we observed.  Evidence for adjuvant chemotherapy was
22:694:50547:18:18:90:522:319:143:g_d0_f3:143:g_d0_f3:emerging in the mid-2000s but the timing of major presentations and publications on
22:695:50630:18:18:90:522:301:143:g_d0_f3:143:g_d0_f3:this subject are unlikely to have caused a sudden change in practice in January 2005
22:696:50714:18:18:90:522:283:143:g_d0_f3:143:g_d0_f3:(Le Chevalier (2003); Arriagada R. et al. (2004); Winton T. et al. (2004); Winton
22:697:50795:18:18:90:522:265:143:g_d0_f3:143:g_d0_f3:T. et al. (2005); Struass G. et al. (2004); Struass G. et al. (2006); Struass G. et al.
22:698:50882:18:17:90:522:247:143:g_d0_f3:143:g_d0_f3:(2008); Douillard J. et al. (2005); Douillard J. et al. (2006)). Furthermore, evidence
22:699:50968:17:18:90:522:230:143:g_d0_f3:143:g_d0_f3:on uptake of adjuvant chemotherapy suggests utilization was stable across the policy
22:700:51052:18:18:90:522:212:143:g_d0_f3:143:g_d0_f3:change (Booth C. M. et al. (2010)), and our own data (not shown) show no increase in
22:701:51136:18:18:90:521:194:143:g_d0_f3:143:g_d0_f3:the use of cisplatin-based regimens, as would be expected if the di↵usion of adjuvant
22:702:51221:18:18:90:311:176:143:g_d0_f3:143:g_d0_f3:chemotherapy were to explain our findings.
22:703:51263:18:18:107:521:158:143:g_d0_f3:143:g_d0_f3:The treatment changes shown here beg the question of what happened to patient
22:704:51340:18:18:90:522:140:143:g_d0_f3:143:g_d0_f3:welfare.  We have one important measure of welfare – survival – that we exploit
22:705:51419:18:45:90:522:122:143:g_d0_f3:143:g_d0_f3:to address this issue.  A limitation is that we cannot measure changes in quality
22:706:51500:45:0:300:312:77:143:g_d0_f3:143:g_d0_f3:20
23:707:51502:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:of life, which could deteriorate in response to harsh chemotherapy treatment (e.g.,
23:708:51585:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:see Ballatori et al. (2007)). Despite the common view that chemotherapy decreases
23:709:51666:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:quality of life, however, a recent randomized trial in patients with advanced lung
23:710:51748:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:cancer found that, compared to placebo, chemotherapy not only increased survival
23:711:51828:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:but also improved some measures of quality of life (e.g., the worsening of pain and
23:712:51911:18:18:90:511:581:143:g_d0_f3:143:g_d0_f3:coughing up of blood) while leaving others unchanged (Belani C. P. et al. (2012)).
23:713:51993:18:18:107:521:563:143:g_d0_f3:143:g_d0_f3:To begin, Appendix Figure 3 plots the unadjusted Kaplan-Meier survival curves
23:714:52070:18:18:90:522:545:143:g_d0_f3:143:g_d0_f3:for patients diagnosed in the 11 months before and after the reform. The median sur-
23:715:52154:18:18:90:522:527:143:g_d0_f3:143:g_d0_f3:vival based on the Kaplan-Meier estimator was 261 and 284 days for those diagnosed
23:716:52236:18:18:90:522:509:143:g_d0_f3:143:g_d0_f3:in the pre and post-reform periods, respectively, a di↵erence of about 3 weeks. To
23:717:52318:18:18:90:522:491:143:g_d0_f3:143:g_d0_f3:assess whether this di↵erence is related to the reform, Figures 6a-6d plot by month of
23:718:52404:18:18:90:522:473:143:g_d0_f3:143:g_d0_f3:diagnosis relative to the January 2005 reform, the regression-adjusted mean changes
23:719:52487:18:17:90:522:455:143:g_d0_f3:143:g_d0_f3:in the proportion of patients dying within 3, 6, 9 and 12 months of diagnosis. These
23:720:52571:17:18:90:522:438:143:g_d0_f3:143:g_d0_f3:figures show a discrete decline in the likelihood of dying within each interval for the
23:721:52658:18:18:90:522:420:143:g_d0_f3:143:g_d0_f3:post-reform cohorts. The decline, at least for death within 3 and 9 months, corre-
23:722:52740:18:18:90:522:402:143:g_d0_f3:143:g_d0_f3:sponds closely to the timing of ASP implementation and the previously demonstrated
23:723:52822:18:18:90:278:384:143:g_d0_f3:143:g_d0_f3:increase in chemotherapy utilization.
23:724:52859:18:18:107:522:366:143:g_d0_f3:143:g_d0_f3:Table 6 quantifies the mortality changes in Figure 6a-6d. Among patients diag-
23:725:52937:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:nosed just after relative to just before the reform, the likelihood of death within 3
23:726:53022:18:18:90:522:330:143:g_d0_f3:143:g_d0_f3:months of diagnosis decreased about 1 percentage point or about 4% relative to the
23:727:53104:18:18:90:522:312:143:g_d0_f3:143:g_d0_f3:base of 33.9% dying in this interval. The results are virtually identical using patients
23:728:53192:18:18:90:522:294:143:g_d0_f3:143:g_d0_f3:diagnosed 9 months before to 9 months after the payment change (col 3) or using
23:729:53271:18:18:90:522:276:143:g_d0_f3:143:g_d0_f3:alternative specifications (see Appendix Table 6). At 6 months from diagnosis, the
23:730:53353:18:18:90:522:258:143:g_d0_f3:143:g_d0_f3:reduction in the likelihood of death is about 1.6 percentage points or 3.4% relative
23:731:53437:18:18:90:521:240:143:g_d0_f3:143:g_d0_f3:to the base rate of 46.9%. At 9 months the e↵ect is 1.1 percentage points, a relative
23:732:53522:18:18:89:521:222:143:g_d0_f3:143:g_d0_f3:decrease in mortality of about 2.1%. At 1 year, the survival e↵ects seem to disap-
23:733:53604:18:18:90:522:204:143:g_d0_f3:143:g_d0_f3:pear. While the reductions in the likelihood of death at 3 to 9 months post-diagnosis
23:734:53689:18:17:90:522:186:143:g_d0_f3:143:g_d0_f3:are seemingly small, these estimates average survival across all patients, whereas the
23:735:53775:17:18:90:522:169:143:g_d0_f3:143:g_d0_f3:reform increased chemotherapy in less than 2 out of every 100 patients. The reform
23:736:53857:18:18:90:521:151:143:g_d0_f3:143:g_d0_f3:also changed the intensity of treatment and the drugs used, making it di-cult to
23:737:53937:18:18:90:338:133:143:g_d0_f3:143:g_d0_f3:isolate the specific source of the survival change.
23:738:53988:18:38:107:520:115:143:g_d0_f3:143:g_d0_f3:We take several approaches to testing whether the survival changes were caused
23:739:54066:38:0:300:312:77:143:g_d0_f3:143:g_d0_f3:21
24:740:54068:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:by the reform rather than capturing patterns unaccounted for by the week trends in
24:741:54150:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:the two periods. First, we take advantage of substantial geographic variation in the
24:742:54234:18:18:90:522:635:143:g_d0_f3:143:g_d0_f3:response to the payment change. Jacobson et al. (2011) shows that after the reform
24:743:54316:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:the likelihood of chemotherapy treatment was virtually unchanged in some states
24:744:54395:18:18:90:522:599:143:g_d0_f3:143:g_d0_f3:(e.g., CA and MO), increased more than twice the national average in others (e.g.,
24:745:54477:18:18:90:522:581:143:g_d0_f3:143:g_d0_f3:MN, CT) and even declined in a few states (e.g., OK, ID). If reform-related changes
24:746:54560:18:18:90:522:563:143:g_d0_f3:143:g_d0_f3:in chemotherapy improved survival, these e↵ects should be concentrated in the most
24:747:54642:18:18:89:521:545:143:g_d0_f3:143:g_d0_f3:responsive states.  To this end, Figures 7a-7d show the likelihood of death within
24:748:54724:18:18:89:521:527:143:g_d0_f3:143:g_d0_f3:3-12 months of diagnosis for patients in states with above median 30-day treatment
24:749:54806:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:response; Figures 7e-7h show analogous plots for states with below median response.
24:750:54889:18:18:89:521:491:143:g_d0_f3:143:g_d0_f3:As expected, declines in the likelihood of death at 3, 6, and 9 months are greater
24:751:54971:18:18:89:521:473:143:g_d0_f3:143:g_d0_f3:for the above-median response states than for the whole sample. The below-median
24:752:55051:18:17:89:521:455:143:g_d0_f3:143:g_d0_f3:response states show no clear break in survival for cohorts diagnosed just after relative
24:753:55140:17:18:89:521:438:143:g_d0_f3:143:g_d0_f3:to just before the reform. Table 7 confirms the visual patterns: while the likelihood
24:754:55225:18:18:89:521:420:143:g_d0_f3:143:g_d0_f3:of death declined by 3%-6% within 3-6 months of diagnosis and 1.5%-3% within 9
24:755:55303:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:months of diagnosis in the most responsive states survival declined, if anything, in the
24:756:55391:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:least responsive states. More plausibly, based on the plots and the estimated changes
24:757:55476:18:18:89:522:366:143:g_d0_f3:143:g_d0_f3:within 6-9 months of diagnosis, survival in the last responsive states was una↵ected
24:758:55560:18:18:90:522:348:143:g_d0_f3:143:g_d0_f3:by the reform.  These results support the view that the increase in chemotherapy
24:759:55640:18:18:90:311:330:143:g_d0_f3:143:g_d0_f3:generated by the reform improved survival.
24:760:55682:18:18:107:521:312:143:g_d0_f3:143:g_d0_f3:As a second approach, we stratify states based on whether they had above or below
24:761:55763:18:18:90:522:294:143:g_d0_f3:143:g_d0_f3:median pre-reform rates of paclitaxel use in chemotherapy-treated patients. Heavy
24:762:55844:18:18:90:522:276:143:g_d0_f3:143:g_d0_f3:reliance on paclitaxel pre-reform meant that the payment change had larger bite,
24:763:55924:18:18:90:522:258:143:g_d0_f3:143:g_d0_f3:i.e. doctors in these areas had greater exposure to the payment cuts. As shown in
24:764:56005:18:18:90:522:240:143:g_d0_f3:143:g_d0_f3:Appendix Figures 4a-4c, 30-day chemotherapy treatment changes are quite sharp in
24:765:56085:18:18:90:522:222:143:g_d0_f3:143:g_d0_f3:states with high pre-reform reliance on paclitaxel. Treatment also increased in states
24:766:56171:18:18:90:522:204:143:g_d0_f3:143:g_d0_f3:with lower pre-reform paclitaxel use (see Appendix Figures 4e-4g) but the plots are
24:767:56254:18:17:90:522:186:143:g_d0_f3:143:g_d0_f3:considerably noisier and the estimates in Appendix Table 7 are more sensitive to
24:768:56334:17:18:90:522:169:143:g_d0_f3:143:g_d0_f3:the study window.  Moving from the 11 to 9-month study window, the estimated
24:769:56410:18:18:90:522:151:143:g_d0_f3:143:g_d0_f3:treatment changes increase slightly in above-median states but fall by as much as
24:770:56491:18:18:90:522:133:143:g_d0_f3:143:g_d0_f3:65% in below-median states. Based on 9-months on either side of the reform, 30-day
24:771:56573:18:38:90:522:115:143:g_d0_f3:143:g_d0_f3:chemotherapy treatment rates increased by 2.4 percentage points or 14% in states with
24:772:56658:38:0:300:312:77:143:g_d0_f3:143:g_d0_f3:22
25:773:56660:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:above-median pre-reform use of paclitaxel but only 3% in states with below median
25:774:56741:18:18:90:521:653:143:g_d0_f3:143:g_d0_f3:use. These treatment di↵erences, which are statistically significant using the 9-month
25:775:56827:18:18:89:521:635:143:g_d0_f3:143:g_d0_f3:study window, translate into survival di↵erences, as shown in Appendix Figures 5a-5h
25:776:56911:18:18:89:521:617:143:g_d0_f3:143:g_d0_f3:and the second panel of Appendix Table 7. The decline in the likelihood of dying
25:777:56991:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:within 3-9 months is sharper in the above versus below median pre-reform paclitaxel
25:778:57074:18:18:89:521:581:143:g_d0_f3:143:g_d0_f3:use states.  While the likelihood of death declined by 4%-6% within 3-9 months
25:779:57152:18:18:89:521:563:143:g_d0_f3:143:g_d0_f3:in the above-median states, the estimated changes for the below-median states are
25:780:57233:18:18:89:521:545:143:g_d0_f3:143:g_d0_f3:small, often positive and, with the exception of one estimate at 1-year out, never
25:781:57315:18:18:89:521:527:143:g_d0_f3:143:g_d0_f3:statistically distinguishable from zero. Across states with high and low pre-reform
25:782:57398:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:rates of paclitaxel use, the di↵erences in survival are statistically distinguishable at 3
25:783:57488:18:18:89:521:491:143:g_d0_f3:143:g_d0_f3:months when using the short study window and at 6 and 9 months for both the long
25:784:57568:18:17:89:229:473:143:g_d0_f3:64:g_d0_f5:and short study windows.24
25:785:57594:17:18:107:522:456:143:g_d0_f3:143:g_d0_f3:As a final approach to assessing the credibility of the survival e↵ects, we split
25:786:57675:18:18:89:521:438:143:g_d0_f3:143:g_d0_f3:the sample by above and below median age patients. Since older patients are more
25:787:57755:18:18:89:522:420:143:g_d0_f3:143:g_d0_f3:likely to be undertreated (Davido↵et al. (2010); Booth C. M. et al. (2010)), they
25:788:57836:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:should benefit most from increased treatment. Appendix Figures 6a-6d and 6e-6h
25:789:57914:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:show changes in the likelihood of chemotherapy use for above and below-median
25:790:57991:18:18:89:521:366:143:g_d0_f3:143:g_d0_f3:age patients, respectively. Appendix Figures 7a-7d and 7e-7h show changes in the
25:791:58071:18:18:89:521:348:143:g_d0_f3:143:g_d0_f3:likelihood of death, for the same groups. Although treatment increases sharply for
25:792:58153:18:18:89:521:330:143:g_d0_f3:143:g_d0_f3:both groups (in all but the outpatient setting), a sharp reform-related decline in
25:793:58235:18:18:89:521:312:143:g_d0_f3:143:g_d0_f3:survival is clearest for the above-median age patients. Table 8 and Appendix Table 8
25:794:58319:18:18:89:521:294:143:g_d0_f3:143:g_d0_f3:show the estimated changes in treatment and survival. Above-median age patients,
25:795:58399:18:18:89:521:276:143:g_d0_f3:143:g_d0_f3:who are almost half as likely to receive chemotherapy within 30 days, experience
25:796:58479:18:18:89:521:258:143:g_d0_f3:143:g_d0_f3:about an 8% increase in the likelihood of treatment; the increase is about 11% for the
25:797:58565:18:18:89:521:240:143:g_d0_f3:143:g_d0_f3:younger group. In contrast, the survival e↵ects are substantially larger for the older
25:798:58651:18:18:89:521:222:143:g_d0_f3:143:g_d0_f3:group. The likelihood of death within 3 months declines by about 0.6 percentage
25:799:58730:18:17:89:521:204:143:g_d0_f3:143:g_d0_f3:points for the younger group but 2.3 percentage points for the older group. At 6 and
25:800:58814:17:18:89:521:187:143:g_d0_f3:143:g_d0_f3:9 months of diagnosis, the declines are 2.6-3.2 percentage points in the older group
25:801:58898:18:18:89:521:169:143:g_d0_f3:143:g_d0_f3:and 1.2-2 percentage points in the younger group. Relative to baseline survival, these
25:802:58984:18:24:89:521:151:143:g_d0_f3:143:g_d0_f3:changes represent a decrease in the likelihood of death within 3-9 months of 5-6%
25:803:59065:24:15:99:522:127:49:g_d0_f6:99:g_d0_f7:24Using the long study window, the 6-month di↵erence is only distinguishable at the 10% level.
25:804:59159:15:35:90:397:112:99:g_d0_f7:99:g_d0_f7:All other 6-9 month di↵erences are significant well below the 5% level.
25:805:59230:35:0:300:312:77:143:g_d0_f3:143:g_d0_f3:23
26:806:59232:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:for the older group compared to 2-4% for the younger group.  The di↵erences in
26:807:59310:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:treatment and survival at 3-9 months across above and below median age patients
26:808:59389:18:39:90:259:635:143:g_d0_f3:64:g_d0_f5:are statistically distinguishable.25
26:809:59425:39:26:90:373:596:206:g_d0_f9:206:g_d0_f9:4.4  Market Concentration Interactions
26:810:59463:26:18:90:521:570:143:g_d0_f3:143:g_d0_f3:To test whether the changes in treatment and survival are related to market concen-
26:811:59546:18:18:90:522:552:143:g_d0_f3:143:g_d0_f3:tration, we compare the response of low concentration (i.e. more competitive) and
26:812:59627:18:18:90:522:534:143:g_d0_f3:143:g_d0_f3:high concentration (i.e. less competitive) markets in response to the policy change.
26:813:59711:18:18:90:522:516:143:g_d0_f3:143:g_d0_f3:Our primary measure of market concentration is a county level Herfindahl-Hirshman
26:814:59792:18:17:90:522:498:143:g_d0_f3:143:g_d0_f3:Index (HHI) for chemotherapy providers. Specifically we calculate the HHI as the sum
26:815:59876:17:18:90:521:481:143:g_d0_f3:143:g_d0_f3:of each provider’s share of a county’s chemotherapy administrationspre-reform.26Fol-
26:816:59960:18:18:89:521:463:143:g_d0_f3:143:g_d0_f3:lowing the US DOJ Horizontal Merger Guidelines (2010), we define a county as high
26:817:60041:18:18:89:521:445:143:g_d0_f3:143:g_d0_f3:concentration if the HHI is greater than 0.25. As an alternative measure, we calcu-
26:818:60124:18:18:89:521:427:143:g_d0_f3:143:g_d0_f3:late the pre-reform ratio of patients to providers in a county, and define a country as
26:819:60211:18:18:89:503:409:143:g_d0_f3:143:g_d0_f3:highly concentrated if a county’s ratio is above the median value for all counties.
26:820:60294:18:18:107:520:391:143:g_d0_f3:143:g_d0_f3:We show the change in chemotherapy treatment for patients in high concentration
26:821:60373:18:18:89:521:373:143:g_d0_f3:143:g_d0_f3:counties in Figures 8a-8d and for medium/low concentration counties in Figures 8e-
26:822:60455:18:18:89:521:355:143:g_d0_f3:143:g_d0_f3:8h. On the extensive margin, we see no compelling evidence of a change in treatment
26:823:60538:18:18:89:521:337:143:g_d0_f3:143:g_d0_f3:probabilities in high concentration markets but a sharp increase right after the reform
26:824:60625:18:18:89:521:319:143:g_d0_f3:143:g_d0_f3:in less concentrated counties. When we consider service counts, a mix of intensive and
26:825:60711:18:18:89:521:301:143:g_d0_f3:143:g_d0_f3:extensive margin changes, we see a small increase in treatment in more concentrated
26:826:60794:18:18:89:521:283:143:g_d0_f3:143:g_d0_f3:markets (Appendix Figures 8a -8d) and again a sharper and larger increase in less
26:827:60875:18:18:89:521:265:143:g_d0_f3:143:g_d0_f3:concentrated markets. These visual patterns are confirmed in Table 9 and Appendix
26:828:60956:18:17:89:520:247:143:g_d0_f3:143:g_d0_f3:Table 9, where estimates of the change in chemotherapy treatment on the extensive
26:829:61037:17:18:89:521:230:143:g_d0_f3:143:g_d0_f3:margin are small and generally insignificant in high concentration counties but imply
26:830:61122:18:18:89:521:212:143:g_d0_f3:143:g_d0_f3:about a 12% increase in 30-day treatment probabilities in less concentrated counties.
26:831:61207:18:24:89:521:194:143:g_d0_f3:143:g_d0_f3:Chemotherapy service counts increase by about 20% in more concentrated markets
26:832:61285:24:17:99:522:170:49:g_d0_f6:99:g_d0_f7:25Using the 9-month window, the chemotherapy di↵erence is only distinguishable at the 10% level.
26:833:61381:17:16:99:521:153:49:g_d0_f6:99:g_d0_f7:26Since we have any billing-provider, irrespective of whether she is an oncologist, we restrict
26:834:61476:16:12:90:522:137:99:g_d0_f7:99:g_d0_f7:to those who billed for chemotherapy for any patient in the unrestricted sample of over 800,000
26:835:61571:12:12:90:522:125:99:g_d0_f7:99:g_d0_f7:beneficiaries.  Because we have only a patient’s county, providers can contribute to the HHI of
26:836:61666:12:36:90:167:113:99:g_d0_f7:99:g_d0_f7:multiple counties.
26:837:61684:36:0:300:312:77:143:g_d0_f3:143:g_d0_f3:24
27:838:61686:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:– indicating some change in treatment patterns in response to the reform – but by
27:839:61767:18:18:90:522:653:143:g_d0_f3:143:g_d0_f3:almost 40% in less concentrated markets.  The di↵erences in treatment rates and
27:840:61846:18:18:90:457:635:143:g_d0_f3:143:g_d0_f3:service counts are in all cases statistically di↵erent across market types.
27:841:61921:18:18:107:522:617:143:g_d0_f3:143:g_d0_f3:In contrast to the more modest treatment changes in highly concentrated markets,
27:842:62001:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:Figures 9a-9h show that the likelihood of death within 3-9 months declined in both
27:843:62083:18:18:89:521:581:143:g_d0_f3:143:g_d0_f3:market types. The last panel of Table 9 shows that survival improved more in both
27:844:62164:18:18:89:521:563:143:g_d0_f3:143:g_d0_f3:absolute and relative terms in more concentrated markets. The likelihood of death
27:845:62245:18:18:89:521:545:143:g_d0_f3:143:g_d0_f3:within 6 months declines by about 2.2 percentage points or 4.6% in highly concen-
27:846:62326:18:18:89:522:527:143:g_d0_f3:143:g_d0_f3:trated counties but 1.4 or 3% in less concentrated counties. This survival di↵erence
27:847:62410:18:18:89:521:509:143:g_d0_f3:143:g_d0_f3:across markets is statistically significant, although only using the long study window.
27:848:62497:18:18:89:522:491:143:g_d0_f3:143:g_d0_f3:At 9 months the di↵erence is starker, with a 1.9 percentage point or 3.5% decline in
27:849:62581:18:18:89:521:473:143:g_d0_f3:143:g_d0_f3:highly concentrated markets and a 0.007 percentage point or 1.3% decline in compet-
27:850:62664:18:17:89:498:455:143:g_d0_f3:143:g_d0_f3:itive markets. This di↵erence is statistically significant for both study windows.
27:851:62746:17:18:107:521:438:143:g_d0_f3:143:g_d0_f3:These patterns are broadly confirmed using a less formal definition of concentra-
27:852:62827:18:18:89:521:420:143:g_d0_f3:143:g_d0_f3:tion – above vs. below median patients per providers. The likelihood of chemotherapy
27:853:62911:18:18:89:521:402:143:g_d0_f3:143:g_d0_f3:treatment increases modestly in counties with above median patients per providers
27:854:62992:18:18:89:521:384:143:g_d0_f3:143:g_d0_f3:(Appendix Figures 9a-9d) but more starkly in more competitive counties with below
27:855:63073:18:18:89:521:366:143:g_d0_f3:143:g_d0_f3:median patients per providers (Appendix Figures 9e-9h). As shown in Appendix Ta-
27:856:63153:18:18:89:521:348:143:g_d0_f3:143:g_d0_f3:ble 10, the extensive margin (any treatment) increases are about 1.3 percentage points
27:857:63239:18:18:89:521:330:143:g_d0_f3:143:g_d0_f3:or 7.5% in more concentrated (i.e., above median patients per provider) counties and
27:858:63323:18:18:89:521:312:143:g_d0_f3:143:g_d0_f3:1.7% or 11% in less concentrated (i.e., below median patients per provider) counties,
27:859:63408:18:18:89:522:294:143:g_d0_f3:143:g_d0_f3:although these di↵erences are not statistically distinguisable. The same basic pattern
27:860:63494:18:18:89:521:276:143:g_d0_f3:143:g_d0_f3:is found for service counts (Appendix Figures 10a-10h). The comparison for survival
27:861:63577:18:18:89:521:258:143:g_d0_f3:143:g_d0_f3:is flipped. The visual patterns show a break in survival in more concentrated counties
27:862:63663:18:18:89:521:240:143:g_d0_f3:143:g_d0_f3:(Appendix Figures 11a-11d) but seem to reflect cyclical changes in less concentrated
27:863:63747:18:18:89:521:222:143:g_d0_f3:143:g_d0_f3:counties (Appendix Figures 11e-11h). The last panel of Appendix Table 10 confirms
27:864:63828:18:18:89:521:204:143:g_d0_f3:143:g_d0_f3:these assessments, though the estimates are somewhat unstable across study win-
27:865:63907:18:17:89:521:186:143:g_d0_f3:143:g_d0_f3:dows. Using the narrow 9-month window, which more credibly isolates the impact
27:866:63985:17:18:89:521:169:143:g_d0_f3:143:g_d0_f3:of the reform, the likelihood of death within 6 months of diagnosis declines by 2.2
27:867:64068:18:18:89:521:151:143:g_d0_f3:143:g_d0_f3:percentage points or 4.6% in more concentrated counties but by an insignificant 0.3
27:868:64151:18:18:89:521:133:143:g_d0_f3:143:g_d0_f3:percentage points or 0.6% in less concentrated counties. At 9 months from diagnosis,
27:869:64235:18:38:89:521:115:143:g_d0_f3:143:g_d0_f3:the likelihood of death declines by 5% in more concentrated markets but is positive
27:870:64318:38:0:300:312:77:143:g_d0_f3:143:g_d0_f3:25
28:871:64320:0:18:90:521:671:143:g_d0_f3:143:g_d0_f3:(but insignificant) in less concentrated markets. These di↵erences in survival at 3, 6
28:872:64406:18:45:90:431:653:143:g_d0_f3:143:g_d0_f3:and 9 months are statistically distinguishable across market types.
28:873:64473:45:30:90:212:608:296:g_d0_f9:296:g_d0_f9:5  Conclusion
28:874:64486:30:18:90:522:578:143:g_d0_f3:143:g_d0_f3:In this paper, we find that among U.S. oncologists, physician agency is an important
28:875:64570:18:18:90:522:560:143:g_d0_f3:143:g_d0_f3:determinant of both the supply of heath care and patient outcomes. We find that a
28:876:64651:18:18:90:522:542:143:g_d0_f3:143:g_d0_f3:decrease in profit margins led to an increases in care, as measured by chemotherapy
28:877:64734:18:18:90:522:524:143:g_d0_f3:143:g_d0_f3:rates on both the intensive and extensive margins. The decrease in profit margins
28:878:64815:18:18:90:522:506:143:g_d0_f3:143:g_d0_f3:for chemotherapy drugs also led physicians to change the mix of drugs they use,
28:879:64894:18:18:90:522:488:143:g_d0_f3:143:g_d0_f3:shifting away from drugs that were more profitable before the reform to those that
28:880:64976:18:18:90:312:470:143:g_d0_f3:143:g_d0_f3:were relatively more profitable post-reform.
28:881:65020:18:18:107:521:452:143:g_d0_f3:143:g_d0_f3:More surprisingly, given the widespread assumption that the key issue with physi-
28:882:65101:18:18:90:522:434:143:g_d0_f3:143:g_d0_f3:cian agency is the inducement of unwarranted demand, we find that the increases in
28:883:65183:18:18:90:522:416:143:g_d0_f3:143:g_d0_f3:chemotherapy care improved survival. Cross-sectionally, the treatment and survival
28:884:65265:18:17:90:522:398:143:g_d0_f3:143:g_d0_f3:increases were larger in areas where the pre-reform mix of chemotherapy drugs meant
28:885:65348:17:18:90:526:381:143:g_d0_f3:143:g_d0_f3:alargeraveragedecreaseinmarginsfromthereform.Theseresultsindicatethat,in
28:886:65420:18:18:90:522:363:143:g_d0_f3:143:g_d0_f3:the presence of significant physician agency e↵ects, an over-generous payment scheme
28:887:65504:18:18:89:521:345:143:g_d0_f3:143:g_d0_f3:can lead to physician rationing - i.e. the underprovision of care - and that better
28:888:65587:18:18:89:521:327:143:g_d0_f3:143:g_d0_f3:aligning payments to costs can lead to better outcomes at lower total cost. While
28:889:65668:18:18:89:521:309:143:g_d0_f3:143:g_d0_f3:we discuss under-provision in terms of rationing, the results are also consistent with
28:890:65754:18:18:89:521:291:143:g_d0_f3:143:g_d0_f3:doctors mistakenly believing they were providing the optimal amount of care prior
28:891:65835:18:18:89:521:273:143:g_d0_f3:143:g_d0_f3:to the reform and thus intentionally providing excess care post-reform. This alterna-
28:892:65920:18:18:89:521:255:143:g_d0_f3:143:g_d0_f3:tive scenario is consistent with our model, but, if true, suggests an additional policy
28:893:66007:18:18:89:521:237:143:g_d0_f3:143:g_d0_f3:lever. Specifically e↵orts to promote evidence-based medicine might have improved
28:894:66088:18:18:89:521:219:143:g_d0_f3:143:g_d0_f3:outcomes even in the absence of payment reform, although without the cost-savings
28:895:66169:18:18:89:215:201:143:g_d0_f3:143:g_d0_f3:generated by the reform.
28:896:66193:18:18:107:520:183:143:g_d0_f3:143:g_d0_f3:We also investigated the interaction between physician agency and the competitive
28:897:66274:18:18:89:521:165:143:g_d0_f3:143:g_d0_f3:environment. Consistent with our model, we found that increases in care were larger
28:898:66357:18:18:89:521:147:143:g_d0_f3:143:g_d0_f3:in more competitive (i.e. less concentrated) markets, while increases in survival rates
28:899:66444:18:17:89:521:129:143:g_d0_f3:143:g_d0_f3:were higher in less competitive (i.e. more concentrated) markets. This result suggest
28:900:66529:17:35:89:521:112:143:g_d0_f3:143:g_d0_f3:that while competition among providers can lead to less rationing of care, it also
28:901:66611:35:0:300:312:77:143:g_d0_f3:143:g_d0_f3:26
29:902:66613:0:40:90:355:671:143:g_d0_f3:143:g_d0_f3:makes them more responsive to financial incentives.
29:903:66664:40:27:90:181:631:296:g_d0_f9:296:g_d0_f9:References
29:904:66674:27:14:90:521:604:143:g_d0_f3:143:g_d0_f3:Akscin, J. and T. R. Barr (2007). Key practice indicators in o-ce-based oncology
29:905:66754:14:24:101:518:590:143:g_d0_f3:143:g_d0_f3:practices: 2007 report on 2006 data.Journal of Oncology Practice 3(4), 200–203.
29:906:66833:24:15:90:522:566:143:g_d0_f3:143:g_d0_f3:Andrews, D. W. (2003). Tests for parameter instability and structural change with
29:907:66914:15:24:101:464:551:143:g_d0_f3:143:g_d0_f3:unknown change point: A corrigendum.Econometrica 71(1), 395–397.
29:908:66978:24:15:89:521:527:143:g_d0_f3:143:g_d0_f3:Arriagada R. et al. (2004). Cisplatin-based adjuvant chemotherapy in patients with
29:909:67060:15:14:101:521:512:143:g_d0_f3:143:g_d0_f3:completely resected non-small-cell lung cancer.New England Journal of Medicine,
29:910:67139:14:25:101:145:498:143:g_d0_f3:143:g_d0_f3:351–360.
29:911:67147:25:14:89:521:473:143:g_d0_f3:143:g_d0_f3:Ballatori, E., F. Roila, B. Ruggeri, M. Betti, S. sarti, G. Soru, G. Cruciani, M. D.
29:912:67231:14:14:101:521:459:143:g_d0_f3:143:g_d0_f3:Maio, B. Andrea, and R. Deuson (2007). The impact of chemotherapy-induced nau-
29:913:67309:14:15:101:521:445:143:g_d0_f3:143:g_d0_f3:sea and vomiting on health-related quality of life.Supportive Care in Cancer 15(2),
29:914:67392:15:24:101:145:430:143:g_d0_f3:143:g_d0_f3:179–185.
29:915:67400:24:15:89:521:406:143:g_d0_f3:143:g_d0_f3:Barlas, S. (2011). Hospital outpatient pharmacies win higher medicare payments for
29:916:67482:15:24:101:350:391:143:g_d0_f3:143:g_d0_f3:2011.Pharmacy and Therapeutics 36(1), 11–21.
29:917:67526:24:15:89:521:367:143:g_d0_f3:143:g_d0_f3:Belani C. P. et al. (2012). Quality of life in patients with advanced non-small-cell
29:918:67610:15:14:101:521:352:143:g_d0_f3:143:g_d0_f3:lung cancer given maintenance treatment with pemetrexed versus placebo (h3e-
29:919:67686:14:14:101:521:338:143:g_d0_f3:143:g_d0_f23:mc-jmen): Results from a randomised, double-blind, phase 3 study.The Lancet
29:920:67761:14:25:101:231:324:143:g_d0_f23:143:g_d0_f3:Oncology 13(3), 292–299.
29:921:67785:25:14:89:521:299:143:g_d0_f3:143:g_d0_f3:Berndt, E. and J. P. Newhouse (2012). Pricing and reimbursement in u.s. pharma-
29:922:67864:14:15:101:521:285:143:g_d0_f3:143:g_d0_f23:ceutical markets. In P. M. Danzon and S. Nicholson (Eds.),The Oxford Handbook
29:923:67941:15:24:101:501:270:143:g_d0_f23:143:g_d0_f3:of the Economics of the Biopharmaceutical Industry, pp. 201–265. Oxford UP.
29:924:68016:24:15:89:521:246:143:g_d0_f3:143:g_d0_f3:Booth C. M. et al. (2010). Adoption of adjuvant chemotherapy for non-small-cell lung
29:925:68100:15:14:101:521:231:143:g_d0_f3:143:g_d0_f3:cancer: a population-based outcomes study.Journal of Clinical Oncology 28(21),
29:926:68178:14:24:101:157:217:143:g_d0_f3:143:g_d0_f3:3472–3478.
29:927:68188:24:15:89:521:193:143:g_d0_f3:143:g_d0_f3:Butcher, L. (2008, April). Insurers and oncologists forge a better cancer drug policy.
29:928:68274:15:24:101:231:178:143:g_d0_f23:143:g_d0_f3:Managed Care Magazine.
29:929:68296:24:15:89:521:154:143:g_d0_f3:143:g_d0_f3:Chandra, A., D. M. Cutler, and Z. Song (2012). Who ordered that? the economics
29:930:68374:15:14:101:521:139:143:g_d0_f3:143:g_d0_f3:of treatment choices in medical care. In P. P. Barros, T. G. McGuire, and M. V.
29:931:68453:14:48:101:484:125:143:g_d0_f3:143:g_d0_f3:Pauly (Eds.),Handbook of Health Economics. Amsterdam: North-Holland.
29:932:68521:48:0:300:312:77:143:g_d0_f3:143:g_d0_f3:27
30:933:68523:0:15:90:522:671:143:g_d0_f3:143:g_d0_f3:Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie (1987). A new method
30:934:68603:15:14:101:521:656:143:g_d0_f3:143:g_d0_f3:of classifying prognostic comorbidity in longitudinal studies:  Development and
30:935:68682:14:25:101:384:642:143:g_d0_f3:143:g_d0_f3:validation.Journal of Chronic Disease 40(5), 373–383.
30:936:68735:25:14:90:522:617:143:g_d0_f3:143:g_d0_f3:Christensen, S. (1992). Volume responses to exogenous changes in medicare’s payment
30:937:68818:14:24:101:346:603:143:g_d0_f3:143:g_d0_f3:policies.Health Services Research 27(1), 65–79.
30:938:68865:24:15:90:522:579:143:g_d0_f3:143:g_d0_f3:Clemens, J. and J. Gottlieb (2012). Do physicians’ financial incentives a↵ect medical
30:939:68950:15:24:101:429:564:143:g_d0_f3:143:g_d0_f3:treatment and patient health? SIEPR Discussion Paper 11-017.
30:940:69010:24:15:90:522:540:143:g_d0_f3:143:g_d0_f3:Colla, C. H., N. E. Morden, J. S. Skinner, J. R. Hoverman, and E. Meara (2012).
30:941:69089:15:14:101:522:525:143:g_d0_f3:143:g_d0_f23:Impact of payment reform on chemotherapy at the end of life.Journal of Oncology
30:942:69168:14:25:101:228:511:143:g_d0_f23:143:g_d0_f3:Practice 8(3s), e6s–e13s.
30:943:69193:25:14:90:522:486:143:g_d0_f3:143:g_d0_f3:Community Oncology Alliance (2006). Community oncology alliance gathers in wash-
30:944:69273:14:24:101:459:472:143:g_d0_f3:143:g_d0_f3:ington to address crisis in access to cancer care.Medical News Today.
30:945:69342:24:15:89:522:448:143:g_d0_f3:143:g_d0_f3:Davido↵, A. J., M. Tang, B. Seal, and M. J. Edelman (2010). Chemotherapy and sur-
30:946:69423:15:14:101:522:433:143:g_d0_f3:143:g_d0_f23:vival benefit in elderly patients with advanced non-small-cell lung cancer.Journal
30:947:69505:14:25:101:288:419:143:g_d0_f23:143:g_d0_f3:of Clinical Oncology 28,2191–2197.
30:948:69539:25:14:89:521:394:143:g_d0_f3:143:g_d0_f3:Deyo, R. A., D. C. Cherkin, and M. A. Ciol (1992).  Adapting a clinical comor-
30:949:69617:14:15:101:521:380:143:g_d0_f3:143:g_d0_f23:bidity index for use with icd-9 cm administrative databases.Journal of Clinical
30:950:69696:15:24:101:253:365:143:g_d0_f23:143:g_d0_f3:Epidemiology 45(6), 613–619.
30:951:69724:24:15:89:521:341:143:g_d0_f3:143:g_d0_f3:Douillard J. et al. (2005). Anita: Phase iii adjuvant vinorelbine (n) and cisplatin (p)
30:952:69811:15:14:101:521:326:143:g_d0_f3:143:g_d0_f3:versus observation (obs) in completely resected (stage i-iii) non-small-cell lung can-
30:953:69897:14:14:101:522:312:143:g_d0_f3:143:g_d0_f23:cer (nsclc) patients (pts): Final results after 70-month median follow-up.Journal
30:954:69978:14:25:101:423:298:143:g_d0_f23:143:g_d0_f3:of Clinical Oncology 23(16S June 1 Supplement)(Abstr. 7013).
30:955:70038:25:14:89:521:273:143:g_d0_f3:143:g_d0_f3:Douillard J. et al. (2006). Adjuvant vinorelbine plus cisplatin versus observation in
30:956:70123:14:15:101:521:259:143:g_d0_f3:143:g_d0_f3:patients with completely resected stage ib-iiia non-small-cell lung cancer (anita): a
30:957:70208:15:24:101:410:244:143:g_d0_f3:143:g_d0_f3:randomised controlled trial.Lancet Oncology 7(9), 719–727.
30:958:70266:24:15:89:521:220:143:g_d0_f3:143:g_d0_f3:Earle, C. C., A. B. Nattinger, and A. L. Potosky (2002). Identifying cancer relapse
30:959:70349:15:24:101:469:205:143:g_d0_f3:143:g_d0_f3:using seer-medicare data.Medical Care 40(8 Supplemental), IV: 75–81.
30:960:70417:24:14:89:521:181:143:g_d0_f3:143:g_d0_f3:Encaoua, D. and A. Jacquemin (1980). Degree of monopoly, indices of concentration
30:961:70498:14:25:101:437:167:143:g_d0_f3:143:g_d0_f3:and threat of entry.Internation Economic Review 21(1), 87–105.
30:962:70560:25:14:89:521:142:143:g_d0_f3:143:g_d0_f3:Escarce, J. (1993). Medicare patients’ use of overpriced procedures before and af-
30:963:70642:14:15:101:521:128:143:g_d0_f3:143:g_d0_f23:ter the omnibus budget reconciliation act of 1987.American Journal of Public
30:964:70718:15:36:101:218:113:143:g_d0_f23:143:g_d0_f3:Health 83(3), 346–355.
30:965:70740:36:0:300:312:77:143:g_d0_f3:143:g_d0_f3:28
31:966:70742:0:15:90:522:671:143:g_d0_f3:143:g_d0_f3:Friedman J. Y. et al. (2007). The medicare modernization act and reimbursement
31:967:70820:15:14:101:521:656:143:g_d0_f3:143:g_d0_f23:for outpatient chemotherapy: do patients perceive changes in access to care?Can-
31:968:70900:14:24:101:225:642:143:g_d0_f23:143:g_d0_f3:cer 110(10), 2304–2312.
31:969:70923:24:15:90:521:618:143:g_d0_f3:143:g_d0_f3:Government Accountability O-ce (2001). Medicare physician fee schedule: Practice
31:970:71003:15:24:101:484:603:143:g_d0_f3:143:g_d0_f3:payments to oncologists indicate need for overall refinements.GAO-02-53.
31:971:71075:24:14:90:521:579:143:g_d0_f3:143:g_d0_f3:Government Accountability O-ce (2004). Medicare chemotherapy payments: new
31:972:71149:14:24:101:483:565:143:g_d0_f3:143:g_d0_f3:drug and administration fees are closer to providers’ costs.GAO-05-142R.
31:973:71221:24:15:90:522:541:143:g_d0_f3:143:g_d0_f3:Grant, D. (2009).  Physician financial incentives and cesarean delivery: New con-
31:974:71302:15:14:101:521:526:143:g_d0_f3:143:g_d0_f23:clusions from the healthcare cost and utilization project.Journal of Health Eco-
31:975:71382:14:24:101:222:512:143:g_d0_f23:143:g_d0_f3:nomics 28(1), 244–250.
31:976:71404:24:15:90:522:488:143:g_d0_f3:143:g_d0_f3:Gruber, J., J. Kim, and D. Mayzlin (1999). Physician fees and procedure intensity:
31:977:71486:15:24:101:486:473:143:g_d0_f3:143:g_d0_f3:the case of cesarean delivery.Journal of Health Economics 18(4), 473–490.
31:978:71559:24:15:89:521:449:143:g_d0_f3:143:g_d0_f3:Hurley, J. and R. Labelle (1995).  Relative fees and the utilization of physician’s
31:979:71642:15:24:101:359:434:143:g_d0_f3:143:g_d0_f3:services in canada.Health Economics 4,419–438.
31:980:71688:24:14:89:521:410:143:g_d0_f3:143:g_d0_f3:Hurley, J., R. Labelle, and T. Rice (1990). The relationship between physician fees
31:981:71771:14:15:101:521:396:143:g_d0_f3:143:g_d0_f23:and the utilization of medical services in ontario.Advances in Health Economics
31:982:71850:15:24:101:311:381:143:g_d0_f23:143:g_d0_f3:and Health Services Research 11,49–78.
31:983:71888:24:14:89:521:357:143:g_d0_f3:143:g_d0_f3:Jacobson, M., C. C. Earle, and J. P. Newhouse (2010). How medicare’s payment cuts
31:984:71969:14:15:101:521:343:143:g_d0_f3:143:g_d0_f3:for cancer chemotherapy drugs changed patterns of treatment.Health A↵airs 29,
31:985:72046:15:24:101:157:328:143:g_d0_f3:143:g_d0_f3:1391–1399.
31:986:72056:24:14:89:521:304:143:g_d0_f3:143:g_d0_f3:Jacobson, M., C. C. Earle, and J. P. Newhouse (2011). Geographic variation in physi-
31:987:72140:14:15:101:521:290:143:g_d0_f3:143:g_d0_f3:cians’ response to a reimbursement change.New England Journal of Medicine 365,
31:988:72218:15:24:101:157:275:143:g_d0_f3:143:g_d0_f3:2049–2052.
31:989:72228:24:24:89:502:251:143:g_d0_f3:143:g_d0_f3:Kaiser Family Foundation (2010). Kaiser family foundation medicare chartbook.
31:990:72305:24:14:89:521:227:143:g_d0_f3:143:g_d0_f3:Le Chevalier, T. (2003). Results of the randomized international adjuvant lung cancer
31:991:72390:14:15:101:521:213:143:g_d0_f3:143:g_d0_f3:trial (ialt): cisplatin-based chemotherapy (ct) vs no ct in 1867 patients (pts) with
31:992:72474:15:14:101:522:198:143:g_d0_f3:143:g_d0_f23:resected non-small cell lung cancer (nsclc).Proceedings of the American Society of
31:993:72556:14:24:101:259:184:143:g_d0_f23:143:g_d0_f3:Clinical Oncology 22(Abstr 6).
31:994:72586:24:15:89:521:160:143:g_d0_f3:143:g_d0_f3:McGuire, T. G. (2000). Physician agency. In A. J. Culyer and J. P. Newhouse (Eds.),
31:995:72669:15:24:101:412:145:143:g_d0_f23:143:g_d0_f3:Handbook of Health Economics, pp. 462–217. North-Holland.
31:996:72726:24:14:89:521:121:143:g_d0_f3:143:g_d0_f3:McGuire, T. G. and M. V. Pauly (1991).  Physician response to fee changes with
31:997:72804:14:30:101:420:107:143:g_d0_f3:143:g_d0_f3:multiple payers.Journal of Health Economics 10(4), 385–410.
31:998:72863:30:0:300:312:77:143:g_d0_f3:143:g_d0_f3:29
32:999:72865:0:15:90:522:671:143:g_d0_f3:143:g_d0_f3:MedPAC (2006). Report to the congress: e↵ects of medicare payment changes on
32:1000:72941:15:24:101:192:656:143:g_d0_f3:143:g_d0_f3:oncology services.
32:1001:72959:24:15:90:521:632:143:g_d0_f3:143:g_d0_f3:Mullen, P. (2007, June). The arrival of average sales price.Biotechnology Healthcare,
32:1002:73044:15:24:101:134:617:143:g_d0_f3:143:g_d0_f3:48–53.
32:1003:73050:24:14:90:522:593:143:g_d0_f3:143:g_d0_f3:Newey, W. and K. West (1987). A simple, positive semi-definite, heteroscedastic and
32:1004:73133:14:25:101:478:579:143:g_d0_f3:143:g_d0_f3:autocorrelation consistent covariance matrix.Econometrica 55,703–708.
32:1005:73202:25:14:89:521:554:143:g_d0_f3:143:g_d0_f3:Nguyen, N. X. and F. W. Derrick (1997). Physician behavioral response to a medicare
32:1006:73285:14:25:101:378:540:143:g_d0_f3:143:g_d0_f3:price reduction.Health Services Research 3,283–298.
32:1007:73336:25:14:89:521:515:143:g_d0_f3:143:g_d0_f3:O-ce of Inspector General (1997a, December). Department of health and human
32:1008:73411:14:25:101:513:501:143:g_d0_f3:143:g_d0_f3:services. excessive medicare payment for prescription drugs, no. oei-03-97-00290.
32:1009:73492:25:14:90:521:476:143:g_d0_f3:143:g_d0_f3:O-ce of Inspector General (1997b, December). Department of health and human
32:1010:73567:14:24:101:513:462:143:g_d0_f3:143:g_d0_f3:services. excessive medicare payment for prescription drugs, no. oei-03-97-00290.
32:1011:73648:24:15:90:522:438:143:g_d0_f3:143:g_d0_f3:Ramsey, S. D., J. F. Scoggins, D. K. Blough, C. L. McDermott, and C. M. Reyes
32:1012:73725:15:14:101:521:423:143:g_d0_f3:143:g_d0_f3:(2009). Sensitivity of administrative claims to identify incident cases of lung cancer:
32:1013:73812:14:15:101:522:409:143:g_d0_f3:143:g_d0_f3:acomparisonof3healthplans.Journal of Managed Care Pharmacy 15(8), 659–
32:1014:73882:15:24:101:122:394:143:g_d0_f3:143:g_d0_f3:668.
32:1015:73886:24:15:90:522:370:143:g_d0_f3:143:g_d0_f3:Rice, T. (1983). The impact of changing medicare reimbursement rates on physician-
32:1016:73968:15:24:101:332:355:143:g_d0_f3:143:g_d0_f3:induced demand.Medical Care 21,803–815.
32:1017:74007:24:14:89:521:331:143:g_d0_f3:143:g_d0_f3:Rice, T. (1984). Physician-induced demand for medical care: New evidence from the
32:1018:74088:14:15:101:521:317:143:g_d0_f3:143:g_d0_f3:medicare program.Advances in Health Economics and Health Services Research 5,
32:1019:74165:15:24:101:145:302:143:g_d0_f3:143:g_d0_f3:129–160.
32:1020:74173:24:15:89:521:278:143:g_d0_f3:143:g_d0_f3:Rice, T. and R. Labelle (1989). Do physicians induce demand for medical services?
32:1021:74254:15:24:101:365:263:143:g_d0_f23:143:g_d0_f3:Journal of Health Politics Policy Law 14,587–600.
32:1022:74303:24:15:89:521:239:143:g_d0_f3:143:g_d0_f3:Shainian, V. B., Y. Kuo, and S. Gilbert (2010). Reimbursement policy and androgen-
32:1023:74385:15:14:101:521:224:143:g_d0_f3:143:g_d0_f3:deprivation therapy for prostate cancer.New England Journal of Medicine 363,
32:1024:74461:14:24:101:157:210:143:g_d0_f3:143:g_d0_f3:1822–1832.
32:1025:74471:24:15:89:521:186:143:g_d0_f3:143:g_d0_f3:Shea, A. M., L. H. Curtis, B. G. Hammill, L. D. DiMartino, A. P. Abernethy, and
32:1026:74550:15:14:101:521:171:143:g_d0_f3:143:g_d0_f3:K. A. Schulman (2008). Association between the medicare modernization act of
32:1027:74626:14:15:101:521:157:143:g_d0_f3:143:g_d0_f3:2003 and patient wait times and travel distance for chemotherapy.JAMA 300(2),
32:1028:74703:15:65:101:145:142:143:g_d0_f3:143:g_d0_f3:189–196.
32:1029:74711:65:0:300:312:77:143:g_d0_f3:143:g_d0_f3:30
33:1030:74713:0:15:90:522:671:143:g_d0_f3:143:g_d0_f3:Skinner, J. (2012). Causes and consequences of regional variations in health care.
33:1031:74795:15:14:101:521:656:143:g_d0_f3:143:g_d0_f23:In P. P. Barros, T. G. McGuire, and M. V. Pauly (Eds.),Handbook of Health
33:1032:74868:14:25:101:364:642:143:g_d0_f23:143:g_d0_f3:Economics, Volume 2. Amsterdam: North-Holland.
33:1033:74914:25:14:90:532:617:143:g_d0_f3:143:g_d0_f3:Stock, J. H. and M. W. Watson (2003).Introduction to Econometrics.Pearson
33:1034:74987:14:24:101:180:603:143:g_d0_f3:143:g_d0_f3:Education, Inc.
33:1035:75002:24:15:90:522:579:143:g_d0_f3:143:g_d0_f3:Struass G. et al. (2004, July). Randomized clinical trial of adjuvant chemotherapy
33:1036:75084:15:14:101:521:564:143:g_d0_f3:143:g_d0_f3:with paclitaxel and carboplatin following resection in stage ib non-small cell lung
33:1037:75167:14:15:101:521:550:143:g_d0_f3:143:g_d0_f23:cancer (nsclc): Report of cancer and leukemia group b (calgb) protocol 9633.Jour-
33:1038:75248:15:24:101:273:535:143:g_d0_f23:143:g_d0_f3:nal of Clinical Oncology 22(14S).
33:1039:75281:24:15:90:522:511:143:g_d0_f3:143:g_d0_f3:Struass G. et al. (2006, June).  Adjuvant chemotherapy in stage ib non-small cell
33:1040:75362:15:14:101:521:496:143:g_d0_f3:143:g_d0_f3:lung cancer (nsclc): Update of cancer and leukemia group b (calgb) protocol 9633.
33:1041:75443:14:25:101:296:482:143:g_d0_f23:143:g_d0_f3:Journal of Clinical Oncology 24(18S).
33:1042:75480:25:14:90:522:457:143:g_d0_f3:143:g_d0_f3:Struass G. et al. (2008).  Adjuvant paclitaxel plus carboplatin compared with ob-
33:1043:75561:14:14:101:521:443:143:g_d0_f3:143:g_d0_f23:servation in stage ib non-small-cell lung cancer: Calgb 9633.Journal of Clinical
33:1044:75641:14:25:101:249:429:143:g_d0_f23:143:g_d0_f3:Oncology 26(31), 5043–5051.
33:1045:75668:25:14:90:522:404:143:g_d0_f3:143:g_d0_f3:Vera-Llonch, M., D. Weycker, and A. Glass (2011). Healthcare cost in patients with
33:1046:75750:14:15:101:521:390:143:g_d0_f3:143:g_d0_f3:metastatic lung cancer receiving chemotherapy.BMC Health Services Research 11,
33:1047:75828:15:24:101:122:375:143:g_d0_f3:143:g_d0_f3:305.
33:1048:75832:24:15:90:522:351:143:g_d0_f3:143:g_d0_f3:Warren, J. L., E. Feuer, A. L. Potosky, G. F. riley, and C. F. Lynch (1999). Use of
33:1049:75915:15:14:101:522:336:143:g_d0_f3:143:g_d0_f23:medicare hospital and physician data to assess breast cancer incidence.Medical
33:1050:75993:14:24:101:210:322:143:g_d0_f23:143:g_d0_f3:Care 37(5), 445–456.
33:1051:76013:24:15:90:522:298:143:g_d0_f3:143:g_d0_f3:Warren, J. L., L. C. Harlan, A. Fahey, B. A. Virnig, J. L. Freeman, C. N. Klabunde,
33:1052:76096:15:14:101:521:283:143:g_d0_f3:143:g_d0_f3:G. S. Cooper, and K. B. Knoft (2002). Utility of the seer-medicare data to identify
33:1053:76179:14:25:101:412:269:143:g_d0_f3:143:g_d0_f3:chemotherapy use.Medical Care 40 Supplemental, IV:55–61.
33:1054:76235:25:14:89:521:244:143:g_d0_f3:143:g_d0_f3:Weight, C. J., E. J. Klein, and J. S. Jones (2007). Androgen deprivation falls as or-
33:1055:76320:14:15:101:521:230:143:g_d0_f3:143:g_d0_f3:chiectomy rates rise after changes in reimbursement in the u.s. medicare population.
33:1056:76404:15:24:101:227:215:143:g_d0_f23:143:g_d0_f3:Cancer 110,2304–2312.
33:1057:76425:24:14:89:521:191:143:g_d0_f3:143:g_d0_f3:Winton T. et al. (2004, July). A prospective randomised trial of adjuvant vinorelbine
33:1058:76510:14:15:101:521:177:143:g_d0_f3:143:g_d0_f3:(vin) and cisplatin (cis) in completely resected stage 1b and ii non small cell lung
33:1059:76594:15:24:101:465:162:143:g_d0_f3:143:g_d0_f3:cancer (nsclc) intergroup jbr.10.Journal of Clinical Oncology 22(14S).
33:1060:76664:24:15:89:521:138:143:g_d0_f3:143:g_d0_f3:Winton T. et al. (2005). Vinorelbine plus cisplatin vs. observation in resected non-
33:1061:76748:15:46:101:502:123:143:g_d0_f3:143:g_d0_f3:small-cell lung cancer.New England Journal of Medicine 352(25), 2589–2597.
33:1062:76822:46:0:300:312:77:143:g_d0_f3:143:g_d0_f3:31
34:1063:76824:0:15:90:522:671:143:g_d0_f3:143:g_d0_f3:Yip, W. C. (1998). Physician response to medicare fee reductions: Changes in the
34:1064:76904:15:14:101:521:656:143:g_d0_f3:143:g_d0_f3:volume of coronary artery bypass graft (cabg) surgeries in the medicare and private
34:1065:76987:14:565:101:364:642:143:g_d0_f3:143:g_d0_f3:sectors.Journal of Health Economics 17,675–699.
34:1066:77034:565:38:300:312:77:143:g_d0_f3:143:g_d0_f3:32
35:1067:77036:38:0:72:74:39:121:g_d0_f25:121:g_d0_f25:-
35:1068:77037:0:22:474:477:425:144:g_d0_f26:144:g_d0_f26: 
35:1069:77037:22:305:72:75:403:121:g_d0_f26:121:g_d0_f26: 
35:1070:77037:305:0:474:477:98:121:g_d0_f26:121:g_d0_f26: 
35:1071:77057:0:92:346:455:595:42:g_d0_f26:42:g_d0_f26:-12-9-6-3036912
35:1072:77072:92:0:110:337:503:42:g_d0_f26:42:g_d0_f26:-12-9-6-3036912-12-9-6-3036912
35:1073:77102:0:92:118:442:669:79:g_d0_f26:79:g_d0_f26:Fig 1a. Share MetastaticFig 1b. Comorbidity ScoreFig 1c. Share White
35:1074:77170:92:103:128:338:577:79:g_d0_f26:79:g_d0_f26:Fig 1d. Share MaleFig 1e. Log Age Diagnosed
35:1075:77213:103:14:186:408:474:63:g_d0_f26:63:g_d0_f26:Reg-adjusted DifferenceLower Bound 95% CI
35:1076:77254:14:0:186:261:460:63:g_d0_f26:63:g_d0_f26:Upper Bound 95% CI
35:1077:77307:0:49:230:327:491:63:g_d0_f26:63:g_d0_f26:Month Relative to Jan 2005
35:1078:77333:49:0:95:180:442:63:g_d0_f26:63:g_d0_f26:Graphs by characteristic
35:1079:77357:0:11:162:390:696:122:g_d0_f26:122:g_d0_f26:Change in Observables by Month of Diagnosis
35:1080:77400:11:508:140:410:685:122:g_d0_f26:122:g_d0_f26:Relative to the January 2005 ASP Implementation Date
35:1081:77504:508:8:111:459:177:63:g_d0_f26:63:g_d0_f26:-12-8-404812
35:1082:77516:8:20:229:346:169:63:g_d0_f26:63:g_d0_f26:Quarter Relative to January 2005
35:1083:77548:20:14:227:384:149:63:g_d0_f26:63:g_d0_f26:CarboplatinPaclitaxel
35:1084:77569:14:14:227:385:135:63:g_d0_f26:63:g_d0_f26:DocetaxelEtoposide
35:1085:77587:14:0:227:290:121:63:g_d0_f26:63:g_d0_f26:Gemcitabine HCL
35:1086:77602:0:11:151:419:368:122:g_d0_f26:122:g_d0_f26:Figure 2. Change in Nominal Quarterly  Chemotherapy
35:1087:77653:11:318:140:428:357:122:g_d0_f26:122:g_d0_f26:Payments Rates for Select Drugs Relative to January 2005
36:1088:77709:318:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
36:1089:77739:0:0:111:456:502:45:g_d0_f28:45:g_d0_f28:-12-9-6-3036912-12-9-6-3036912
36:1090:77769:0:85:156:433:668:88:g_d0_f28:88:g_d0_f28:Fig 3a. All SettingsFig 3b. Excluding Carboplatin
36:1091:77818:85:108:143:409:583:88:g_d0_f28:88:g_d0_f28:Fig 3c. Physician's OfficeFig 3d. Outpatient
36:1092:77862:108:15:228:368:475:17:g_d0_f28:17:g_d0_f28:Reg-adjusted DifferenceLower Bound 95% CI
36:1093:77903:15:0:228:266:460:17:g_d0_f28:17:g_d0_f28:Upper Bound 95% CI
36:1094:77956:0:49:223:335:490:63:g_d0_f28:63:g_d0_f28:Month Relative to January 2005
36:1095:77986:49:0:95:157:441:63:g_d0_f28:63:g_d0_f28:Graphs by setting
36:1096:78003:0:11:115:436:695:122:g_d0_f28:122:g_d0_f28:Change in the Share Given Chemotherapy by Month of Diagnosis
36:1097:78063:11:260:140:411:684:122:g_d0_f28:122:g_d0_f28:Relative to the January 2005 ASP Implementation Date
36:1098:78115:260:22:475:478:424:122:g_d0_f29:122:g_d0_f29: 
36:1099:78115:22:310:72:75:402:122:g_d0_f29:122:g_d0_f29: 
36:1100:78115:310:0:474:477:92:122:g_d0_f29:122:g_d0_f29: 
36:1101:78133:0:0:111:456:171:45:g_d0_f28:45:g_d0_f28:-12-9-6-3036912-12-9-6-3036912
36:1102:78163:0:85:156:432:337:88:g_d0_f28:88:g_d0_f28:Fig 4a. All SettingsFig 4b. Excluding Carboplatin
36:1103:78212:85:109:143:408:252:88:g_d0_f28:88:g_d0_f28:Fig 4c. Physician's OfficeFig 4d. Outpatient
36:1104:78256:109:14:228:368:143:17:g_d0_f28:17:g_d0_f28:Reg-adjusted DifferenceLower Bound 95% CI
36:1105:78297:14:0:228:266:129:17:g_d0_f28:17:g_d0_f28:Upper Bound 95% CI
36:1106:78350:0:49:223:335:159:63:g_d0_f28:63:g_d0_f28:Month Relative to January 2005
36:1107:78380:49:0:95:157:110:63:g_d0_f28:63:g_d0_f28:Graphs by setting
36:1108:78397:0:11:100:451:363:122:g_d0_f28:122:g_d0_f28:Percent Change in Chemotherapy Service Count by Month of Diagnosis
36:1109:78463:11:313:140:410:352:122:g_d0_f28:122:g_d0_f28:Relative to the January 2005 ASP Implementation Date
37:1110:78515:313:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
37:1111:78515:0:22:474:477:424:122:g_d0_f29:122:g_d0_f29: 
37:1112:78515:22:25:72:75:402:122:g_d0_f29:122:g_d0_f29: 
37:1113:78515:25:295:483:486:377:122:g_d0_f29:122:g_d0_f29: 
37:1114:78515:295:0:72:75:82:122:g_d0_f29:122:g_d0_f29: 
37:1115:78547:0:92:346:455:594:42:g_d0_f30:42:g_d0_f30:-12-9-6-3036912
37:1116:78562:92:0:108:337:502:42:g_d0_f30:42:g_d0_f30:-12-9-6-3036912-12-9-6-3036912
37:1117:78592:0:91:127:436:668:79:g_d0_f30:79:g_d0_f30:Fig 5a. CarboplatinFig 5b. PaclitaxelFig 5c. Docetaxel
37:1118:78646:91:102:129:332:577:79:g_d0_f30:79:g_d0_f30:Fig 5d. EtoposideFig 5e. Gemcitabine HCl
37:1119:78686:102:14:228:368:475:17:g_d0_f30:17:g_d0_f30:Reg-adjusted DifferenceLower Bound 95% CI
37:1120:78727:14:0:228:266:461:17:g_d0_f30:17:g_d0_f30:Upper Bound 95% CI
37:1121:78780:0:50:223:335:491:63:g_d0_f30:63:g_d0_f30:Month Relative to January 2005
37:1122:78810:50:0:95:151:441:63:g_d0_f30:63:g_d0_f30:Graphs by Type
37:1123:78824:0:11:128:423:695:122:g_d0_f30:122:g_d0_f30:Change in the Use of Specific Agents by Month of Diagnosis
37:1124:78882:11:513:139:413:684:122:g_d0_f30:122:g_d0_f30:Relative to the January 2005 ASP Implementation  Date
37:1125:78965:513:0:111:456:171:45:g_d0_f30:45:g_d0_f30:-12-9-6-3036912-12-9-6-3036912
37:1126:78995:0:84:131:434:336:88:g_d0_f30:88:g_d0_f30:Fig 6a. Death Within 3 MonthsFig 6b. Death Within 6 Months
37:1127:79053:84:111:132:437:252:88:g_d0_f30:88:g_d0_f30:Fig 6c. Death Within 9 MonthsFig 6d. Death Within 12 Months
37:1128:79112:111:14:186:408:141:63:g_d0_f30:63:g_d0_f30:Reg-adjusted DifferenceLower Bound 95% CI
37:1129:79153:14:0:186:261:127:63:g_d0_f30:63:g_d0_f30:Upper Bound 95% CI
37:1130:79206:0:50:230:327:159:63:g_d0_f30:63:g_d0_f30:Month Relative to Jan 2005
37:1131:79232:50:0:95:156:109:63:g_d0_f30:63:g_d0_f30:Graphs by period
37:1132:79248:0:11:143:409:363:122:g_d0_f30:122:g_d0_f30:Change in the Proportion Dying by Month of Diagnosis
37:1133:79300:11:313:140:410:352:122:g_d0_f30:122:g_d0_f30:Relative to the January 2005 ASP Implementation Date
38:1134:79352:313:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
38:1135:79352:0:322:495:497:410:122:g_d0_f27:122:g_d0_f27: 
38:1136:79352:322:0:495:497:88:122:g_d0_f27:122:g_d0_f27: 
38:1137:79382:0:0:113:475:492:50:g_d0_f31:50:g_d0_f31:-12-9-6-3036912-12-9-6-3036912
38:1138:79412:0:89:134:452:666:97:g_d0_f31:97:g_d0_f31:Fig 7a. Death Within 3 MonthsFig 7b. Death Within 6 Months
38:1139:79470:89:116:135:455:577:97:g_d0_f31:97:g_d0_f31:Fig 7c. Death Within 9 MonthsFig 7d. Death Within 12 Months
38:1140:79529:116:15:191:425:461:69:g_d0_f31:69:g_d0_f31:Reg-adjusted DifferenceLower Bound 95% CI
38:1141:79570:15:0:191:270:446:69:g_d0_f31:69:g_d0_f31:Upper Bound 95% CI
38:1142:79623:0:52:238:340:479:69:g_d0_f31:69:g_d0_f31:Month Relative to Jan 2005
38:1143:79649:52:0:96:160:427:69:g_d0_f31:69:g_d0_f31:Graphs by period
38:1144:79665:0:12:97:475:694:135:g_d0_f31:135:g_d0_f31:Change in Share Dying by Month of Diagnosis in Most Responsive States
38:1145:79734:12:512:144:428:682:135:g_d0_f31:135:g_d0_f31:Relative to the January 2005 ASP Implementation Date
38:1146:79816:512:0:113:475:170:50:g_d0_f31:50:g_d0_f31:-12-9-6-3036912-12-9-6-3036912
38:1147:79846:0:89:134:451:344:97:g_d0_f31:97:g_d0_f31:Fig 7e. Death Within 3 MonthsFig 7f. Death Within 6 Months
38:1148:79904:89:116:134:455:255:97:g_d0_f31:97:g_d0_f31:Fig 7g. Death Within 9 MonthsFig 7h. Death Within 12 Months
38:1149:79963:116:14:191:425:139:69:g_d0_f31:69:g_d0_f31:Reg-adjusted DifferenceLower Bound 95% CI
38:1150:80004:14:0:191:270:125:69:g_d0_f31:69:g_d0_f31:Upper Bound 95% CI
38:1151:80057:0:51:238:340:157:69:g_d0_f31:69:g_d0_f31:Month Relative to Jan 2005
38:1152:80083:51:0:96:160:106:69:g_d0_f31:69:g_d0_f31:Graphs by period
38:1153:80099:0:11:95:476:372:135:g_d0_f31:135:g_d0_f31:Change in Share Dying by Month of Diagnosis in Least Responsive States
38:1154:80169:11:322:142:429:361:135:g_d0_f31:135:g_d0_f31:Relative to the January 2005 ASP  Implementation Date
39:1155:80222:322:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
39:1156:80222:0:322:495:498:410:99:g_d0_f29:99:g_d0_f29: 
39:1157:80222:322:0:495:498:88:122:g_d0_f29:122:g_d0_f29: 
39:1158:80242:0:0:113:475:492:50:g_d0_f32:50:g_d0_f32:-12-9-6-3036912-12-9-6-3036912
39:1159:80272:0:89:160:450:666:97:g_d0_f32:97:g_d0_f32:Fig 8a. All SettingsFig 8b. Excluding Carboplatin
39:1160:80321:89:114:146:426:577:97:g_d0_f32:97:g_d0_f32:Fig 8c. Physician's OfficeFig 8d. Outpatient
39:1161:80365:114:15:236:383:463:18:g_d0_f32:18:g_d0_f32:Reg-adjusted DifferenceLower Bound 95% CI
39:1162:80406:15:0:236:276:448:18:g_d0_f32:18:g_d0_f32:Upper Bound 95% CI
39:1163:80459:0:52:231:349:479:69:g_d0_f32:69:g_d0_f32:Month Relative to January 2005
39:1164:80489:52:0:96:161:427:69:g_d0_f32:69:g_d0_f32:Graphs by setting
39:1165:80506:0:12:104:467:694:135:g_d0_f32:135:g_d0_f32:Change in Share Given Chemotherapy in High Concentration Counties
39:1166:80571:12:511:142:429:682:135:g_d0_f32:135:g_d0_f32:Relative to the January 2005 ASP  Implementation Date
39:1167:80654:511:0:113:475:171:50:g_d0_f32:50:g_d0_f32:-12-9-6-3036912-12-9-6-3036912
39:1168:80684:0:90:160:449:345:97:g_d0_f32:97:g_d0_f32:Fig 8e. All SettingsFig 8f. Excluding Carboplatin
39:1169:80733:90:114:146:426:255:97:g_d0_f32:97:g_d0_f32:Fig 8g. Physician's OfficeFig 8h. Outpatient
39:1170:80777:114:14:236:383:141:18:g_d0_f32:18:g_d0_f32:Reg-adjusted DifferenceLower Bound 95% CI
39:1171:80818:14:0:236:276:127:18:g_d0_f32:18:g_d0_f32:Upper Bound 95% CI
39:1172:80871:0:52:231:349:158:69:g_d0_f32:69:g_d0_f32:Month Relative to January 2005
39:1173:80901:52:0:96:161:106:69:g_d0_f32:69:g_d0_f32:Graphs by setting
39:1174:80918:0:12:105:465:373:135:g_d0_f32:135:g_d0_f32:Change in Share Given Chemotherapy in Low Concentration Counties
39:1175:80982:12:322:144:428:361:135:g_d0_f32:135:g_d0_f32:Relative to the January 2005 ASP Implementation Date
40:1176:81034:322:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
40:1177:81034:0:10:495:497:410:122:g_d0_f27:122:g_d0_f27: 
40:1178:81034:10:313:72:74:400:122:g_d0_f27:122:g_d0_f27: 
40:1179:81034:313:11:495:497:87:122:g_d0_f27:122:g_d0_f27: 
40:1180:81034:11:0:72:75:76:122:g_d0_f29:122:g_d0_f29: 
40:1181:81056:0:0:113:475:492:50:g_d0_f33:50:g_d0_f33:-12-9-6-3036912-12-9-6-3036912
40:1182:81086:0:89:135:452:666:97:g_d0_f33:97:g_d0_f33:Fig 9a. Death Within 3 MonthsFig 9c. Death Within 9 Months
40:1183:81144:89:116:132:450:577:97:g_d0_f33:97:g_d0_f33:Fig 9d. Death Within 12 MonthsFig b. Death Within 6 Months
40:1184:81202:116:15:191:425:461:69:g_d0_f33:69:g_d0_f33:Reg-adjusted DifferenceLower Bound 95% CI
40:1185:81243:15:0:191:270:446:69:g_d0_f33:69:g_d0_f33:Upper Bound 95% CI
40:1186:81296:0:52:238:340:479:69:g_d0_f33:69:g_d0_f33:Month Relative to Jan 2005
40:1187:81322:52:0:96:160:427:69:g_d0_f33:69:g_d0_f33:Graphs by period
40:1188:81338:0:12:144:427:694:135:g_d0_f33:135:g_d0_f33:Change in Share Dying in High Concentration Counties
40:1189:81390:12:513:142:429:682:135:g_d0_f33:135:g_d0_f33:Relative to the  January 2005 ASP Implementation Date
40:1190:81473:513:0:113:475:169:50:g_d0_f33:50:g_d0_f33:-12-9-6-3036912-12-9-6-3036912
40:1191:81503:0:89:135:451:343:97:g_d0_f33:97:g_d0_f33:Fig 9e. Death Within 3 MonthsFig 9f. Death Within 6 Months
40:1192:81561:89:116:135:455:254:97:g_d0_f33:97:g_d0_f33:Fig 9g. Death Within 9 MonthsFig 9h. Death Within 12 Months
40:1193:81620:116:15:191:425:138:69:g_d0_f33:69:g_d0_f33:Reg-adjusted DifferenceLower Bound 95% CI
40:1194:81661:15:0:191:270:123:69:g_d0_f33:69:g_d0_f33:Upper Bound 95% CI
40:1195:81714:0:52:238:340:156:69:g_d0_f33:69:g_d0_f33:Month Relative to Jan 2005
40:1196:81740:52:0:96:160:104:69:g_d0_f33:69:g_d0_f33:Graphs by period
40:1197:81756:0:12:146:427:371:135:g_d0_f33:135:g_d0_f33:Change in Share Dying in Low Concentration Counties
40:1198:81807:12:320:144:428:359:135:g_d0_f33:135:g_d0_f33:Relative to the January 2005 ASP Implementation Date
41:1199:81859:320:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
41:1200:81859:0:22:72:537:709:144:g_d0_f34:144:g_d0_f34:Table 1. Sample Characteristics overall and in the11 Months Pre versus Post Jan 2005 Reform*  
41:1201:81953:22:13:180:357:687:144:g_d0_f34:144:g_d0_f34: Overall 
41:1202:81960:13:0:309:367:674:144:g_d0_f34:144:g_d0_f34:N=132,768 
41:1203:81969:0:13:413:432:687:144:g_d0_f34:144:g_d0_f34:Pre 
41:1204:81972:13:0:397:448:674:144:g_d0_f34:144:g_d0_f34:N=66,501 
41:1205:81980:0:13:496:520:687:144:g_d0_f34:144:g_d0_f34:Post 
41:1206:81984:13:27:482:533:674:144:g_d0_f34:144:g_d0_f34:N=66,267 
41:1207:81992:27:26:72:536:647:144:g_d0_f34:144:g_d0_f34:Age at Diagnosis – mean (sd) 74.0 (8.35) 74.0 (8.32) 74.1 (8.38) 
41:1208:82052:26:26:72:523:621:144:g_d0_f34:144:g_d0_f34:Share Male  0.513 0.516 0.510 
41:1209:82078:26:26:72:223:595:144:g_d0_f34:144:g_d0_f34:Distribution by Race/ethnicity  
41:1210:82109:26:25:72:523:569:144:g_d0_f34:144:g_d0_f34:  White 0.877 0.876 0.877 
41:1211:82131:25:26:72:523:544:144:g_d0_f34:144:g_d0_f34:  African-American 0.089 0.090 0.088 
41:1212:82164:26:26:72:523:518:144:g_d0_f34:144:g_d0_f34:  Asian 0.0108 0.0105 0.011 
41:1213:82188:26:26:72:526:492:144:g_d0_f34:144:g_d0_f34:  Other/Unknown 0.0091 0.0087 0.0095 
41:1214:82221:26:26:72:527:466:144:g_d0_f34:144:g_d0_f34:  Hispanic   0.0102 0.0104  0.0099 
41:1215:82250:26:26:72:526:440:144:g_d0_f34:144:g_d0_f34:  Native American 0.0039 0.0038 0.0039 
41:1216:82285:26:26:72:536:414:144:g_d0_f34:144:g_d0_f34:Deyo-Charlson Score – mean (sd) 1.07 (1.30) 1.06 (1.30) 1.08 (1.31) 
41:1217:82348:26:26:72:523:388:144:g_d0_f34:144:g_d0_f34:Metastasis within 1 month  0.289 0.289 0.289 
41:1218:82389:26:25:72:383:362:144:g_d0_f34:144:g_d0_f34:Quarterly Reimbursement Rates Per Standard Monthly Dose ($) 
41:1219:82448:25:26:72:533:337:144:g_d0_f34:144:g_d0_f34:  carboplatin 1540 (153) 1845 (29) 930 (261) 
41:1220:82489:26:26:72:534:311:144:g_d0_f34:144:g_d0_f34:  paclitaxel 1590 (294) 2272 (70.9) 225 (9.28) 
41:1221:82532:26:26:72:537:285:144:g_d0_f34:144:g_d0_f34:  docetaxel 2657 (58.4) 2732 (74.8) 2506 (6.87) 
41:1222:82576:26:26:72:537:259:144:g_d0_f34:144:g_d0_f34:  etoposide 77.6 (27.8) 111(36.8) 11.4(0.369) 
41:1223:82618:26:23:72:537:233:144:g_d0_f34:144:g_d0_f34:  gemcitabine 1311 (13.5) 1313 (20.6) 1305 (1.71) 
41:1224:82664:23:11:72:537:210:81:g_d0_f34:81:g_d0_f34:* The pre-period is Feb-Dec 2004 and the post-period is Jan-Nov 2005. Standard deviations are in parentheses. Percentages may 
41:1225:82790:11:10:72:527:199:81:g_d0_f34:81:g_d0_f34:not sum to one due to rounding. Reimbursement rates are from the CMS website. The sample includes Medicare beneficiaries 
41:1226:82911:10:11:72:516:189:81:g_d0_f34:81:g_d0_f35:diagnosed with  lung  cancer  from  Feb  2004  to  Nov  2005.  Chemotherapy  “excluding  carboplatin”  means  the  share  receiving  
41:1227:83044:11:11:72:513:178:81:g_d0_f34:81:g_d0_f34:chemotherapy but not carboplatin. The Deyo-Charlson score is a comorbidity index measured in the year prior to a cancer 
41:1228:83164:11:128:72:116:167:81:g_d0_f34:99:g_d0_f34:diagnosis.   
42:1229:83177:128:0:72:74:39:117:g_d0_f36:117:g_d0_f36:!
42:1230:83178:0:15:72:488:708:144:g_d0_f37:144:g_d0_f37: Table 2. Summary Outcomes Overall and in the 11 Months Pre versus Post Reform*  
42:1231:83259:15:13:180:357:693:144:g_d0_f37:144:g_d0_f37: Overall 
42:1232:83267:13:0:309:366:680:144:g_d0_f37:144:g_d0_f37:N=132,768 
42:1233:83277:0:13:413:432:693:144:g_d0_f37:144:g_d0_f37:Pre 
42:1234:83281:13:0:397:448:680:144:g_d0_f37:144:g_d0_f37:N=66,501 
42:1235:83290:0:13:496:520:693:144:g_d0_f37:144:g_d0_f37:Post 
42:1236:83295:13:27:482:533:680:144:g_d0_f37:144:g_d0_f37:N=66,267 
42:1237:83304:27:14:72:333:653:144:g_d0_f37:144:g_d0_f37:Share of Patients Receiving Chemotherapy Within ... 
42:1238:83356:14:26:72:523:639:144:g_d0_f37:144:g_d0_f37:  1 month 0.175 0.166 0.185 
42:1239:83384:26:25:72:523:613:144:g_d0_f37:144:g_d0_f37:  1 month, excluding carboplatin 0.080 0.073 0.087 
42:1240:83435:25:26:72:523:588:144:g_d0_f37:144:g_d0_f37:  1 month, physician’s office 0.140 0.130 0.149 
42:1241:83483:26:26:72:526:562:144:g_d0_f37:144:g_d0_f37:  1 month, outpatient hospital 0.0285 0.0295 0.0275 
42:1242:83535:26:26:72:522:536:144:g_d0_f37:144:g_d0_f37:  3 months 0.279 0.263         0.295 
42:1243:83572:26:26:72:523:510:144:g_d0_f37:144:g_d0_f37:  3 months, excluding carboplatin 0.103 0.093 0.113 
42:1244:83624:26:26:72:523:484:144:g_d0_f37:144:g_d0_f37:  3 months, physician’s office 0.228 0.213 0.244 
42:1245:83673:26:26:72:523:458:144:g_d0_f37:144:g_d0_f37:  3 months, outpatient hospital 0.067 0.065 0.069 
42:1246:83723:26:26:72:381:432:144:g_d0_f37:144:g_d0_f37:Chemotherapy Drugs Conditional on Treatment within 1 month 
42:1247:83782:26:25:72:523:406:144:g_d0_f37:144:g_d0_f37: Share carboplatin 0.543 0.557 0.531 
42:1248:83819:25:26:72:523:381:144:g_d0_f37:144:g_d0_f37: Share paclitaxel  0.285 0.315 0.257 
42:1249:83856:26:26:72:523:355:144:g_d0_f37:144:g_d0_f37: Share docetaxel  0.090 0.083 0.096 
42:1250:83892:26:26:72:523:329:144:g_d0_f37:144:g_d0_f37: Share etoposide 0.208 0.211 0.206 
42:1251:83927:26:26:72:523:303:144:g_d0_f37:144:g_d0_f37: Share gemcitabine 0.092 0.100 0.085 
42:1252:83964:26:26:72:509:277:144:g_d0_f37:144:g_d0_f37:Patients Dying Within...     
42:1253:83990:26:26:72:523:251:144:g_d0_f37:144:g_d0_f37:  3 months 0.333 0.337 0.328 
42:1254:84019:26:26:72:523:225:144:g_d0_f37:144:g_d0_f37:  6 months  0.458 0.467 0.449 
42:1255:84049:26:25:72:523:199:144:g_d0_f37:144:g_d0_f37:  9 months   0.516 0.525 0.507 
42:1256:84080:25:26:72:523:174:144:g_d0_f37:144:g_d0_f37:  12 months  0.605  0.616 0.594 
42:1257:84112:26:7:72:158:148:144:g_d0_f37:144:g_d0_f37:No date of death  
42:1258:84130:7:17:323:523:141:144:g_d0_f37:144:g_d0_f37:0.110 0.100 0.120 
42:1259:84148:17:10:72:537:124:79:g_d0_f37:79:g_d0_f37:* The pre-period is Feb-Dec 2004 and the post-period is Jan-Nov 2005. Standard deviations are in parentheses. Percentages may 
42:1260:84274:10:11:72:528:114:79:g_d0_f37:79:g_d0_f37:not sum to one due to rounding. Reimbursement rates are from the CMS website. The sample includes Medicare beneficiaries 
42:1261:84395:11:10:72:517:103:79:g_d0_f37:79:g_d0_f37:diagnosed with lung cancer from Feb 2004 to Nov 2005. Chemotherapy “excluding carboplatin” means the share receiving 
42:1262:84512:10:11:72:513:93:79:g_d0_f37:79:g_d0_f37:chemotherapy but not carboplatin. The Deyo-Charlson score is a comorbidity index measured in the year prior to a cancer 
42:1263:84632:11:43:72:116:82:79:g_d0_f37:97:g_d0_f37:diagnosis.   
43:1264:84645:43:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
43:1265:84645:0:16:72:498:709:144:g_d0_f38:144:g_d0_f38:Table 3. Changes in Chemotherapy Treatment After the January 2005 Payment Change  
43:1266:84727:16:16:72:75:693:144:g_d0_f38:144:g_d0_f38: 
43:1267:84727:16:0:72:75:677:144:g_d0_f38:144:g_d0_f38: 
43:1268:84727:0:13:352:388:693:144:g_d0_f38:144:g_d0_f38:Before 
43:1269:84734:13:0:353:387:680:144:g_d0_f38:144:g_d0_f38:Jan/05 
43:1270:84740:0:13:422:462:693:144:g_d0_f38:144:g_d0_f38:Feb/04  
43:1271:84747:13:0:418:466:680:144:g_d0_f39:144:g_d0_f38:–Nov/05  
43:1272:84755:0:13:493:533:693:144:g_d0_f38:144:g_d0_f38:Apr/04  
43:1273:84762:13:19:488:534:680:144:g_d0_f39:144:g_d0_f38:–Sept/05 
43:1274:84770:19:14:72:346:661:144:g_d0_f39:144:g_d0_f38:Share  of  Patients  Receiving  Chemotherapy  Treatment... 
43:1275:84828:14:14:72:455:647:144:g_d0_f38:144:g_d0_f38:  within 1 month of Diagnosis  0.166 0.015 
43:1276:84866:14:0:421:460:633:144:g_d0_f38:144:g_d0_f38:(0.003) 
43:1277:84873:0:14:496:526:647:144:g_d0_f38:144:g_d0_f38:0.014 
43:1278:84878:14:25:492:530:633:144:g_d0_f38:144:g_d0_f38:(0.002) 
43:1279:84885:25:14:72:270:608:144:g_d0_f38:144:g_d0_f38:  within 1 month, excluding carboplatin   
43:1280:84922:14:0:72:78:594:144:g_d0_f38:144:g_d0_f38:  
43:1281:84922:0:14:355:455:608:144:g_d0_f38:144:g_d0_f38:0.073 0.014 
43:1282:84932:14:0:421:460:594:144:g_d0_f38:144:g_d0_f38:(0.002) 
43:1283:84939:0:14:496:526:608:144:g_d0_f38:144:g_d0_f38:0.012 
43:1284:84944:14:26:492:530:594:144:g_d0_f38:144:g_d0_f38:(0.002) 
43:1285:84951:26:14:72:270:568:144:g_d0_f38:144:g_d0_f38: within 1 month, in  a  Physician’s  Office   
43:1286:84994:14:0:72:78:554:144:g_d0_f38:144:g_d0_f38:  
43:1287:84994:0:14:355:455:568:144:g_d0_f38:144:g_d0_f38:0.130 0.016 
43:1288:85004:14:0:421:460:554:144:g_d0_f38:144:g_d0_f38:(0.003) 
43:1289:85011:0:14:496:526:568:144:g_d0_f38:144:g_d0_f38:0.016 
43:1290:85016:14:26:492:530:554:144:g_d0_f38:144:g_d0_f38:(0.003) 
43:1291:85023:26:14:72:457:528:144:g_d0_f38:144:g_d0_f38:  within 1 month, in an outpatient hospital clinic 0.028 -0.001 
43:1292:85082:14:0:421:460:514:144:g_d0_f38:144:g_d0_f38:(0.001) 
43:1293:85089:0:14:494:528:528:144:g_d0_f38:144:g_d0_f38:-0.001 
43:1294:85095:14:25:492:530:514:144:g_d0_f38:144:g_d0_f38:(0.001) 
43:1295:85102:25:12:72:519:489:144:g_d0_f38:144:g_d0_f38:Number of Observations (weeks) 48 96 72 
43:1296:85138:12:10:72:525:477:81:g_d0_f38:81:g_d0_f38:Notes: Means in column 1 are for the dependent variable prior to ASP implementation, Feb-Dec 2004. Columns 2 - 3 present 
43:1297:85259:10:11:72:529:467:81:g_d0_f38:81:g_d0_f38:estimates from separate time-series regressions. Estimates are the coefficients on an indicator for the pot-reform/ASP payment 
43:1298:85385:11:10:72:530:456:81:g_d0_f38:81:g_d0_f38:period. Regressions control for mean patient characteristics (see Table 1) and relative-week trends that are allowed to differ on 
43:1299:85515:10:10:72:526:446:81:g_d0_f38:81:g_d0_f38:either side of the payment change. Excluding carboplatin”  means  the  share  of  patients  treated  with  chemotherapy and without 
43:1300:85647:10:13:72:489:436:81:g_d0_f38:81:g_d0_f38:carboplatin. Newey-West standard errors allowing for autocorrelation up to 52-week lags are given in parentheses.  
43:1301:85762:13:18:72:75:423:122:g_d0_f38:122:g_d0_f38: 
43:1302:85762:18:20:72:75:405:122:g_d0_f38:122:g_d0_f38: 
43:1303:85762:20:15:72:514:385:144:g_d0_f38:144:g_d0_f38:Table 4. Change in Chemotherapy Service Counts after the January 2005 Payment Change  
43:1304:85848:15:14:72:388:370:144:g_d0_f38:144:g_d0_f38: Before 
43:1305:85855:14:0:353:387:356:144:g_d0_f38:144:g_d0_f38:Jan/05 
43:1306:85861:0:14:422:462:370:144:g_d0_f38:144:g_d0_f38:Feb/04  
43:1307:85868:14:0:418:466:356:144:g_d0_f39:144:g_d0_f38:–Nov/05  
43:1308:85876:0:14:493:533:370:144:g_d0_f38:144:g_d0_f38:Apr/04  
43:1309:85883:14:26:488:534:356:144:g_d0_f39:144:g_d0_f38:–Sept/05 
43:1310:85891:26:26:72:331:330:144:g_d0_f38:144:g_d0_f38:Percent Change in  Monthly  Chemotherapy  Service... 
43:1311:85943:26:13:72:455:304:144:g_d0_f38:144:g_d0_f38:  within 1 month of Diagnosis  1.00 0.339 
43:1312:85980:13:0:421:460:291:144:g_d0_f38:144:g_d0_f38:(0.046) 
43:1313:85987:0:13:498:525:304:144:g_d0_f38:144:g_d0_f38:0331 
43:1314:85991:13:26:492:530:291:144:g_d0_f38:144:g_d0_f38:(0.044) 
43:1315:85998:26:14:72:270:265:144:g_d0_f38:144:g_d0_f38:  within 1 month, excluding carboplatin   
43:1316:86035:14:0:72:78:251:144:g_d0_f38:144:g_d0_f38:  
43:1317:86035:0:14:355:455:265:144:g_d0_f38:144:g_d0_f38:0.304 0.203 
43:1318:86045:14:0:421:460:251:144:g_d0_f38:144:g_d0_f38:(0.025) 
43:1319:86052:0:14:496:526:265:144:g_d0_f38:144:g_d0_f38:0.209 
43:1320:86057:14:26:492:530:251:144:g_d0_f38:144:g_d0_f38:(0.022) 
43:1321:86064:26:14:72:270:225:144:g_d0_f38:144:g_d0_f38: within 1 month, in  a  Physician’s  Office   
43:1322:86107:14:0:72:78:211:144:g_d0_f38:144:g_d0_f38:  
43:1323:86107:0:14:355:455:225:144:g_d0_f38:144:g_d0_f38:0.916 0.347 
43:1324:86117:14:0:421:460:211:144:g_d0_f38:144:g_d0_f38:(0.047) 
43:1325:86124:0:14:496:526:225:144:g_d0_f38:144:g_d0_f38:0.340 
43:1326:86129:14:25:492:530:211:144:g_d0_f38:144:g_d0_f38:(0.046) 
43:1327:86136:25:14:72:455:186:144:g_d0_f38:144:g_d0_f38:  within 1 month, in an outpatient hospital clinic 0.087 0.013 
43:1328:86194:14:0:421:460:172:144:g_d0_f38:144:g_d0_f38:(0.003) 
43:1329:86201:0:14:496:526:186:144:g_d0_f38:144:g_d0_f38:0.013 
43:1330:86206:14:26:492:530:172:144:g_d0_f38:144:g_d0_f38:(0.004) 
43:1331:86213:26:12:72:519:146:144:g_d0_f38:144:g_d0_f38:Number of Observations (weeks) 48 96 72 
43:1332:86249:12:10:72:177:134:81:g_d0_f38:81:g_d0_f38:Notes: See  notes to Table 3. 
43:1333:86279:10:13:72:74:124:81:g_d0_f38:81:g_d0_f38: 
43:1334:86279:13:20:72:75:111:144:g_d0_f38:144:g_d0_f38: 
43:1335:86279:20:14:72:75:91:144:g_d0_f38:144:g_d0_f38: 
43:1336:86279:14:38:72:75:77:144:g_d0_f38:144:g_d0_f38: 
44:1337:86279:38:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
44:1338:86279:0:16:72:325:709:144:g_d0_f40:144:g_d0_f40:Table 5. Changes in Types of Chemotherapy Drugs  
44:1339:86328:16:25:72:75:693:144:g_d0_f40:144:g_d0_f40: 
44:1340:86328:25:0:72:75:668:144:g_d0_f40:144:g_d0_f40: 
44:1341:86328:0:13:352:388:693:144:g_d0_f40:144:g_d0_f40:Before 
44:1342:86335:13:0:353:387:680:144:g_d0_f40:144:g_d0_f40:Jan/05 
44:1343:86341:0:13:422:462:693:144:g_d0_f40:144:g_d0_f40:Feb/04  
44:1344:86348:13:0:418:466:680:144:g_d0_f41:144:g_d0_f40:–Nov/05  
44:1345:86356:0:13:493:533:693:144:g_d0_f40:144:g_d0_f40:Apr/04  
44:1346:86363:13:27:488:534:680:144:g_d0_f41:144:g_d0_f40:–Sept/05 
44:1347:86371:27:18:72:223:653:144:g_d0_f41:144:g_d0_f40:Share  of  Patients  Receiving...   
44:1348:86406:18:14:72:455:635:144:g_d0_f40:144:g_d0_f40:  carboplatin  0.092 0.001 
44:1349:86427:14:0:421:460:621:144:g_d0_f40:144:g_d0_f40:(0.001) 
44:1350:86434:0:14:493:529:635:144:g_d0_f40:144:g_d0_f40:0.0017 
44:1351:86440:14:18:489:533:621:144:g_d0_f40:144:g_d0_f40:(0.0017) 
44:1352:86448:18:14:72:460:603:144:g_d0_f40:144:g_d0_f40:  paclitaxel 0.053 -0.0053 
44:1353:86470:14:0:418:463:589:144:g_d0_f40:144:g_d0_f40:(0.0014) 
44:1354:86478:0:14:491:531:603:144:g_d0_f40:144:g_d0_f40:-0.0051 
44:1355:86485:14:19:492:533:589:144:g_d0_f40:144:g_d0_f40:(0.002)  
44:1356:86493:19:13:72:458:570:144:g_d0_f40:144:g_d0_f40:  docetaxel  0.014 0.0043 
44:1357:86513:13:0:421:460:557:144:g_d0_f40:144:g_d0_f40:(0.002) 
44:1358:86520:0:13:493:529:570:144:g_d0_f40:144:g_d0_f40:0.0037 
44:1359:86526:13:19:492:530:557:144:g_d0_f40:144:g_d0_f40:(0.002) 
44:1360:86533:19:14:72:458:538:144:g_d0_f40:144:g_d0_f40:  etoposide 0.035 0.0032 
44:1361:86553:14:0:421:460:524:144:g_d0_f40:144:g_d0_f40:(0.001) 
44:1362:86560:0:14:493:529:538:144:g_d0_f40:144:g_d0_f40:0.0044 
44:1363:86566:14:19:492:530:524:144:g_d0_f40:144:g_d0_f40:(0.001) 
44:1364:86573:19:13:72:458:505:144:g_d0_f40:144:g_d0_f40:  gemcitabine 0.017 0.0002 
44:1365:86595:13:0:418:463:492:144:g_d0_f40:144:g_d0_f40:(0.0008) 
44:1366:86603:0:14:496:526:506:144:g_d0_f40:144:g_d0_f40:0.001 
44:1367:86608:14:19:489:533:492:144:g_d0_f40:144:g_d0_f40:(0.0007) 
44:1368:86616:19:18:72:333:473:144:g_d0_f40:144:g_d0_f40:Share of Chemotherapy-treated  Patients  Receiving...   
44:1369:86671:18:14:72:457:455:144:g_d0_f40:144:g_d0_f40:  carboplatin  0.557 -0.039 
44:1370:86693:14:0:421:460:441:144:g_d0_f40:144:g_d0_f40:(0.008) 
44:1371:86700:0:14:494:528:455:144:g_d0_f40:144:g_d0_f40:-0.026 
44:1372:86706:14:18:492:530:441:144:g_d0_f40:144:g_d0_f40:(0.008) 
44:1373:86713:18:14:72:457:423:144:g_d0_f40:144:g_d0_f40:  paclitaxel 0.300 -0.074 
44:1374:86734:14:0:421:460:409:144:g_d0_f40:144:g_d0_f40:(0.007) 
44:1375:86741:0:14:494:528:423:144:g_d0_f40:144:g_d0_f40:-0.061 
44:1376:86747:14:19:492:530:409:144:g_d0_f40:144:g_d0_f40:(0.006) 
44:1377:86754:19:13:72:455:390:144:g_d0_f40:144:g_d0_f40:  docetaxel  0.083 0.026 
44:1378:86773:13:0:421:460:377:144:g_d0_f40:144:g_d0_f40:(0.004) 
44:1379:86780:0:13:496:526:390:144:g_d0_f40:144:g_d0_f40:0.026 
44:1380:86785:13:19:492:530:377:144:g_d0_f40:144:g_d0_f40:(0.006) 
44:1381:86792:19:14:72:457:358:144:g_d0_f40:144:g_d0_f40:  etoposide 0.210 -0.005 
44:1382:86812:14:0:421:460:344:144:g_d0_f40:144:g_d0_f40:(0.010) 
44:1383:86819:0:14:496:526:358:144:g_d0_f40:144:g_d0_f40:0.004 
44:1384:86824:14:19:492:530:344:144:g_d0_f40:144:g_d0_f40:(0.007) 
44:1385:86831:19:13:72:455:325:144:g_d0_f40:144:g_d0_f40:  gemcitabine 0.100 0.007 
44:1386:86852:13:0:421:460:312:144:g_d0_f40:144:g_d0_f40:(0.003) 
44:1387:86859:0:14:496:526:326:144:g_d0_f40:144:g_d0_f40:0.008 
44:1388:86864:14:19:492:530:312:144:g_d0_f40:144:g_d0_f40:(0.004) 
44:1389:86871:19:24:72:519:293:144:g_d0_f40:144:g_d0_f40:Number of Observations (weeks) 48 96 72 
44:1390:86907:24:230:72:173:269:81:g_d0_f40:81:g_d0_f40:Notes: See notes to Table 3 
45:1391:86935:230:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
45:1392:86935:0:18:72:503:709:144:g_d0_f42:144:g_d0_f42:Table 6. Change in the Share of Patients Dying within 3, 6, 9 or 12 Months of Diagnosis  
45:1393:87024:18:16:72:75:691:144:g_d0_f42:144:g_d0_f42: 
45:1394:87024:16:0:72:75:675:144:g_d0_f42:144:g_d0_f42: 
45:1395:87024:0:14:334:367:691:144:g_d0_f42:144:g_d0_f42:Mean  
45:1396:87029:14:0:314:384:677:144:g_d0_f42:144:g_d0_f42:Before Jan/05 
45:1397:87042:0:14:422:462:691:144:g_d0_f42:144:g_d0_f42:Feb/04  
45:1398:87049:14:0:418:466:677:144:g_d0_f43:144:g_d0_f42:–Nov/05  
45:1399:87057:0:14:493:533:691:144:g_d0_f42:144:g_d0_f42:Apr/04  
45:1400:87064:14:18:488:534:677:144:g_d0_f43:144:g_d0_f42:–Sept/05 
45:1401:87072:18:26:72:235:659:144:g_d0_f43:144:g_d0_f42:Share  of  Patients  Dying  within... 
45:1402:87109:26:14:72:457:633:144:g_d0_f42:144:g_d0_f42:  3 months of diagnosis  0.339 -0.009 
45:1403:87142:14:0:421:460:619:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1404:87149:0:14:494:528:633:144:g_d0_f42:144:g_d0_f42:-0.010 
45:1405:87155:14:26:492:530:619:144:g_d0_f42:144:g_d0_f42:(0.005) 
45:1406:87162:26:25:72:186:593:144:g_d0_f42:144:g_d0_f42:  6 months of diagnosis 
45:1407:87183:25:0:72:78:568:144:g_d0_f42:144:g_d0_f42:  
45:1408:87183:0:13:334:457:593:144:g_d0_f42:144:g_d0_f42:0.469 -0.016 
45:1409:87194:13:0:421:460:580:144:g_d0_f42:144:g_d0_f42:(0.002) 
45:1410:87201:0:13:494:528:593:144:g_d0_f42:144:g_d0_f42:-0.016 
45:1411:87207:13:38:492:530:580:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1412:87214:38:26:72:186:542:144:g_d0_f42:144:g_d0_f42:  9 months of diagnosis 
45:1413:87235:26:0:72:78:516:144:g_d0_f42:144:g_d0_f42:  
45:1414:87235:0:14:334:457:542:144:g_d0_f42:144:g_d0_f42:0.527 -0.011 
45:1415:87246:14:0:421:460:528:144:g_d0_f42:144:g_d0_f42:(0.002) 
45:1416:87253:0:14:494:528:542:144:g_d0_f42:144:g_d0_f42:-0.011 
45:1417:87259:14:38:492:530:528:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1418:87266:38:14:72:457:490:144:g_d0_f42:144:g_d0_f42:  1 year of diagnosis 0. 619 -0.001 
45:1419:87296:14:0:421:460:476:144:g_d0_f42:144:g_d0_f42:(0.003) 
45:1420:87303:0:14:494:528:490:144:g_d0_f42:144:g_d0_f42:-0.001 
45:1421:87309:14:26:492:530:476:144:g_d0_f42:144:g_d0_f42:(0.003) 
45:1422:87316:26:24:72:519:450:144:g_d0_f42:144:g_d0_f42:Number of Observations (weeks) 48 96 72 
45:1423:87352:24:13:72:191:426:99:g_d0_f42:99:g_d0_f42:Notes: see notes to Tables 3.  
45:1424:87383:13:15:72:75:413:122:g_d0_f42:122:g_d0_f42: 
45:1425:87383:15:21:72:520:398:144:g_d0_f42:144:g_d0_f42:Table 7. Change in the Share of Patients Dying: Above vs. Below Median Responsive States 
45:1426:87472:21:26:72:503:377:144:g_d0_f42:144:g_d0_f42: Above Median Response Below Median Response 
45:1427:87514:26:14:72:263:351:144:g_d0_f42:144:g_d0_f42: Mean  Feb/04  
45:1428:87526:14:0:219:267:337:144:g_d0_f43:144:g_d0_f42:–Nov/05  
45:1429:87534:0:14:290:330:351:144:g_d0_f42:144:g_d0_f42:Apr/04  
45:1430:87541:14:0:285:331:337:144:g_d0_f43:144:g_d0_f42:–Sept/05 
45:1431:87549:0:14:360:463:351:144:g_d0_f42:144:g_d0_f42:Mean Feb/04  
45:1432:87560:14:0:419:467:337:144:g_d0_f43:144:g_d0_f42:–Nov/05  
45:1433:87568:0:14:490:530:351:144:g_d0_f42:144:g_d0_f42:Apr/04  
45:1434:87575:14:20:485:531:337:144:g_d0_f43:144:g_d0_f42:–Sept/05 
45:1435:87583:20:19:70:231:317:144:g_d0_f43:144:g_d0_f42:Change  in  Share  Dying  within... 
45:1436:87618:19:13:70:126:298:144:g_d0_f42:144:g_d0_f42:  3 months  
45:1437:87626:13:0:70:73:285:144:g_d0_f42:144:g_d0_f42: 
45:1438:87626:0:13:160:258:298:144:g_d0_f42:144:g_d0_f42:0.338 -0.011 
45:1439:87637:13:0:223:261:285:144:g_d0_f42:144:g_d0_f42:(0.006) 
45:1440:87644:0:13:291:325:298:144:g_d0_f42:144:g_d0_f42:-0.023 
45:1441:87650:13:0:289:327:285:144:g_d0_f42:144:g_d0_f42:(0.003) 
45:1442:87657:0:13:360:457:298:144:g_d0_f42:144:g_d0_f42:0.340 0.014 
45:1443:87667:13:0:423:461:285:144:g_d0_f42:144:g_d0_f42:(0.002) 
45:1444:87674:0:13:493:523:298:144:g_d0_f42:144:g_d0_f42:0.014 
45:1445:87679:13:20:488:529:285:144:g_d0_f42:144:g_d0_f42:(0.003)  
45:1446:87686:20:14:70:123:265:144:g_d0_f42:144:g_d0_f42:  6 months 
45:1447:87694:14:0:70:76:251:144:g_d0_f42:144:g_d0_f42:  
45:1448:87694:0:14:160:259:265:144:g_d0_f42:144:g_d0_f42:0.466 -0.015 
45:1449:87705:14:0:223:261:251:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1450:87712:0:14:291:325:265:144:g_d0_f42:144:g_d0_f42:-0.023 
45:1451:87718:14:0:289:327:251:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1452:87725:0:14:360:457:265:144:g_d0_f42:144:g_d0_f42:0.473 0.003 
45:1453:87735:14:0:423:461:251:144:g_d0_f42:144:g_d0_f42:(0.005) 
45:1454:87742:0:14:493:523:265:144:g_d0_f42:144:g_d0_f42:0.006 
45:1455:87747:14:19:489:527:251:144:g_d0_f42:144:g_d0_f42:(0.007) 
45:1456:87754:19:14:70:123:232:144:g_d0_f42:144:g_d0_f42:  9 months 
45:1457:87762:14:0:70:76:218:144:g_d0_f42:144:g_d0_f42:  
45:1458:87762:0:14:160:259:232:144:g_d0_f42:144:g_d0_f42:0.524 -0.008 
45:1459:87773:14:0:223:261:218:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1460:87780:0:14:291:325:232:144:g_d0_f42:144:g_d0_f42:-0.017 
45:1461:87786:14:0:289:327:218:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1462:87793:0:14:360:462:232:144:g_d0_f42:144:g_d0_f42:0.531 -0.0001 
45:1463:87805:14:0:423:461:218:144:g_d0_f42:144:g_d0_f42:(0.006) 
45:1464:87812:0:14:493:523:232:144:g_d0_f42:144:g_d0_f42:0.003 
45:1465:87817:14:19:489:527:218:144:g_d0_f42:144:g_d0_f42:(0.007) 
45:1466:87824:19:14:70:262:199:144:g_d0_f42:144:g_d0_f42:  1 year  0. 615 -0.0001 
45:1467:87844:14:0:223:261:185:144:g_d0_f42:144:g_d0_f42:(0.003) 
45:1468:87851:0:14:291:325:199:144:g_d0_f42:144:g_d0_f42:-0.007 
45:1469:87857:14:0:289:327:185:144:g_d0_f42:144:g_d0_f42:(0.004) 
45:1470:87864:0:14:360:457:199:144:g_d0_f42:144:g_d0_f42:0.623 0.009 
45:1471:87874:14:0:423:461:185:144:g_d0_f42:144:g_d0_f42:(0.007) 
45:1472:87881:0:14:493:523:199:144:g_d0_f42:144:g_d0_f42:0.007 
45:1473:87886:14:19:489:527:185:144:g_d0_f42:144:g_d0_f42:(0.008) 
45:1474:87893:19:17:70:516:166:144:g_d0_f42:144:g_d0_f42:Obs (weeks) 48 96 72 48 96 72 
45:1475:87916:17:12:72:526:149:99:g_d0_f42:99:g_d0_f42:Notes: Means in column 1 and 4 are for the dependent variable for states with above or below median changes in 
45:1476:88027:12:13:72:462:137:99:g_d0_f42:99:g_d0_f42:chemotherapy treatment in the period prior to the reform. See notes to Tables 3 for other details.  
45:1477:88127:13:14:72:75:124:144:g_d0_f42:144:g_d0_f42: 
45:1478:88127:14:71:72:75:110:144:g_d0_f42:144:g_d0_f42: 
46:1479:88127:71:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
46:1480:88127:0:19:72:476:709:144:g_d0_f44:144:g_d0_f44:Table 8: Change in Treatment and Survival: Above vs. Below Median Age Patients 
46:1481:88206:19:22:72:530:690:144:g_d0_f44:144:g_d0_f44: Above Median Age Patients Below Median Age Patients 
46:1482:88256:22:14:72:323:668:144:g_d0_f44:144:g_d0_f44: Mean  Feb/04  
46:1483:88267:14:0:279:327:654:144:g_d0_f45:144:g_d0_f44:–Nov/05  
46:1484:88275:0:14:337:376:668:144:g_d0_f44:144:g_d0_f44:Apr/04  
46:1485:88282:14:0:332:378:654:144:g_d0_f45:144:g_d0_f44:–Sept/05 
46:1486:88290:0:14:393:483:668:144:g_d0_f44:144:g_d0_f44:Mean  Feb/04  
46:1487:88302:14:0:439:487:654:144:g_d0_f45:144:g_d0_f44:–Nov/05  
46:1488:88310:0:14:497:536:668:144:g_d0_f44:144:g_d0_f44:Apr/04  
46:1489:88317:14:20:492:538:654:144:g_d0_f45:144:g_d0_f44:–Sept/05 
46:1490:88325:20:19:70:377:634:144:g_d0_f45:144:g_d0_f44:Share  of  Patients  Receiving  Chemotherapy  Treatment  within... 
46:1491:88391:19:14:70:316:615:144:g_d0_f44:144:g_d0_f44: 1 month of diagnosis  0.119 0.014 
46:1492:88422:14:0:283:321:601:144:g_d0_f44:144:g_d0_f44:(0.002) 
46:1493:88429:0:14:340:370:615:144:g_d0_f44:144:g_d0_f44:0.014 
46:1494:88434:14:0:336:374:601:144:g_d0_f44:144:g_d0_f44:(0.003) 
46:1495:88441:0:14:393:476:615:144:g_d0_f44:144:g_d0_f44:0.210 0.024 
46:1496:88451:14:0:442:480:601:144:g_d0_f44:144:g_d0_f44:(0.003) 
46:1497:88458:0:14:499:529:615:144:g_d0_f44:144:g_d0_f44:0.020 
46:1498:88463:14:19:498:530:601:144:g_d0_f44:144:g_d0_f44:(.003) 
46:1499:88469:19:19:70:235:582:144:g_d0_f44:144:g_d0_f44:Share of Patients Dying  Within... 
46:1500:88501:19:14:70:187:563:144:g_d0_f44:144:g_d0_f44:  3 months of diagnosis  
46:1501:88523:14:0:70:73:549:144:g_d0_f44:144:g_d0_f44: 
46:1502:88523:0:14:233:319:563:144:g_d0_f44:144:g_d0_f44:0.397 -0.023 
46:1503:88534:14:0:283:321:549:144:g_d0_f44:144:g_d0_f44:(0.006) 
46:1504:88541:0:14:338:372:563:144:g_d0_f44:144:g_d0_f44:-0.024 
46:1505:88547:14:0:336:374:549:144:g_d0_f44:144:g_d0_f44:(0.005) 
46:1506:88554:0:14:393:485:563:144:g_d0_f44:144:g_d0_f44:0.285 -0.0059  
46:1507:88567:14:0:439:484:549:144:g_d0_f44:144:g_d0_f44:(0.0035) 
46:1508:88575:0:14:495:538:563:144:g_d0_f44:144:g_d0_f44:-0.0063  
46:1509:88583:14:19:493:537:549:144:g_d0_f44:144:g_d0_f44:(0.0036) 
46:1510:88591:19:14:70:184:530:144:g_d0_f44:144:g_d0_f44:  6 months of diagnosis 
46:1511:88612:14:0:70:76:516:144:g_d0_f44:144:g_d0_f44:  
46:1512:88612:0:14:233:319:530:144:g_d0_f44:144:g_d0_f44:0.530 -0.029 
46:1513:88625:14:0:283:321:516:144:g_d0_f44:144:g_d0_f44:(0.004) 
46:1514:88633:0:14:338:372:530:144:g_d0_f44:144:g_d0_f44:-0.032 
46:1515:88639:14:0:336:374:516:144:g_d0_f44:144:g_d0_f44:(0.005) 
46:1516:88646:0:14:393:479:530:144:g_d0_f44:144:g_d0_f44:0.411 -0.015 
46:1517:88657:14:0:442:481:516:144:g_d0_f44:144:g_d0_f44:(0.002) 
46:1518:88664:0:14:498:532:530:144:g_d0_f44:144:g_d0_f44:-0.020 
46:1519:88670:14:19:493:537:516:144:g_d0_f44:144:g_d0_f44:(0.0023) 
46:1520:88678:19:14:70:184:497:144:g_d0_f44:144:g_d0_f44:  9 months of diagnosis 
46:1521:88699:14:0:70:76:483:144:g_d0_f44:144:g_d0_f44:  
46:1522:88699:0:14:233:322:497:144:g_d0_f44:144:g_d0_f44:0.588 -0.026  
46:1523:88713:14:0:283:321:483:144:g_d0_f44:144:g_d0_f44:(0.003) 
46:1524:88721:0:14:338:372:497:144:g_d0_f44:144:g_d0_f44:-0.031 
46:1525:88727:14:0:336:374:483:144:g_d0_f44:144:g_d0_f44:(0.004) 
46:1526:88734:0:14:393:479:497:144:g_d0_f44:144:g_d0_f44:0.470 -0.012 
46:1527:88745:14:0:441:482:483:144:g_d0_f44:144:g_d0_f44:(0.003)  
46:1528:88752:0:14:498:532:497:144:g_d0_f44:144:g_d0_f44:-0.017 
46:1529:88758:14:20:496:534:483:144:g_d0_f44:144:g_d0_f44:(0.003) 
46:1530:88765:20:13:70:322:463:144:g_d0_f44:144:g_d0_f44:  1 year of diagnosis 0. 675 -0.015  
46:1531:88799:13:0:283:321:450:144:g_d0_f44:144:g_d0_f44:(0.002) 
46:1532:88807:0:13:338:375:463:144:g_d0_f44:144:g_d0_f44:-0.018  
46:1533:88814:13:0:336:374:450:144:g_d0_f44:144:g_d0_f44:(0.003) 
46:1534:88821:0:13:393:479:463:144:g_d0_f44:144:g_d0_f44:0.567 0.002  
46:1535:88832:13:0:442:481:450:144:g_d0_f44:144:g_d0_f44:(0.003) 
46:1536:88839:0:13:498:535:463:144:g_d0_f44:144:g_d0_f44:-0.006  
46:1537:88846:13:20:493:537:450:144:g_d0_f44:144:g_d0_f44:(0.0038) 
46:1538:88854:20:17:70:522:430:144:g_d0_f44:144:g_d0_f44:Observations (weeks) 48 96 72 48 96 72 
46:1539:88888:17:12:72:518:413:99:g_d0_f44:99:g_d0_f44:Notes: Means in column 1 and 4 are for the dependent variable for patients above versus below the median age 
46:1540:88997:12:11:72:499:401:99:g_d0_f44:99:g_d0_f44:patient at diagnosis in the period prior to the reform, Feb-Nov 2004. See notes to Table 3 for other details. 
46:1541:89107:11:13:72:74:390:99:g_d0_f44:99:g_d0_f44: 
46:1542:89107:13:338:72:75:377:144:g_d0_f44:144:g_d0_f44: 
47:1543:89107:338:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
47:1544:89107:0:14:72:517:709:144:g_d0_f46:144:g_d0_f46:Table 9. Change in Treatment and Survival: Counties with a High vs. Low Concentration of 
47:1545:89196:14:19:72:319:695:144:g_d0_f46:144:g_d0_f46:Providers Administering Chemotherapy Treatment 
47:1546:89243:19:26:72:532:676:144:g_d0_f46:144:g_d0_f46: High Concentration Counties Low Concentration Counties 
47:1547:89294:26:14:72:323:650:144:g_d0_f46:144:g_d0_f46: Mean  Feb/04  
47:1548:89306:14:0:279:327:636:144:g_d0_f47:144:g_d0_f46:–Nov/05  
47:1549:89314:0:14:337:376:650:144:g_d0_f46:144:g_d0_f46:Apr/04  
47:1550:89321:14:0:332:378:636:144:g_d0_f47:144:g_d0_f46:–Sept/05 
47:1551:89329:0:14:393:423:650:144:g_d0_f46:144:g_d0_f46:Mean 
47:1552:89334:14:0:389:431:636:144:g_d0_f46:144:g_d0_f46:Pre-Jan  
47:1553:89342:0:14:443:483:650:144:g_d0_f46:144:g_d0_f46:Feb/04  
47:1554:89349:14:0:439:487:636:144:g_d0_f47:144:g_d0_f46:–Nov/05  
47:1555:89357:0:14:497:536:650:144:g_d0_f46:144:g_d0_f46:Apr/04  
47:1556:89364:14:20:492:538:636:144:g_d0_f47:144:g_d0_f46:–Sept/05 
47:1557:89372:20:19:70:284:616:144:g_d0_f46:144:g_d0_f46:Chemotherapy Treatment within 1 month... 
47:1558:89411:19:14:70:322:597:144:g_d0_f46:144:g_d0_f46: Share Receiving Any  0.169 -0.0004 
47:1559:89442:14:0:283:321:583:144:g_d0_f46:144:g_d0_f46:(0.005) 
47:1560:89449:0:14:340:370:597:144:g_d0_f46:144:g_d0_f46:0.001 
47:1561:89454:14:0:336:374:583:144:g_d0_f46:144:g_d0_f46:(0.007) 
47:1562:89461:0:14:393:476:597:144:g_d0_f46:144:g_d0_f46:0.165 0.020 
47:1563:89471:14:0:442:481:583:144:g_d0_f46:144:g_d0_f46:(0.002) 
47:1564:89478:0:14:500:530:597:144:g_d0_f46:144:g_d0_f46:0.019 
47:1565:89483:14:18:496:534:583:144:g_d0_f46:144:g_d0_f46:(0.003) 
47:1566:89490:18:14:70:316:565:144:g_d0_f46:144:g_d0_f46: Percent Change in Services  0.973 0.203 
47:1567:89529:14:0:283:321:551:144:g_d0_f46:144:g_d0_f46:(0.045) 
47:1568:89537:0:14:340:370:565:144:g_d0_f46:144:g_d0_f46:0.185 
47:1569:89542:14:0:336:374:551:144:g_d0_f46:144:g_d0_f46:(0.045) 
47:1570:89549:0:14:396:476:565:144:g_d0_f46:144:g_d0_f46:1.01 0.389 
47:1571:89558:14:0:442:481:551:144:g_d0_f46:144:g_d0_f46:(0.031) 
47:1572:89565:0:14:501:528:565:144:g_d0_f46:144:g_d0_f46:0390 
47:1573:89569:14:26:496:534:551:144:g_d0_f46:144:g_d0_f46:(0.030) 
47:1574:89576:26:19:70:181:525:144:g_d0_f47:144:g_d0_f46:Share  Dying  Within... 
47:1575:89599:19:14:70:319:506:144:g_d0_f46:144:g_d0_f46:  3 months of diagnosis  0.351 -0.017 
47:1576:89634:14:0:283:321:492:144:g_d0_f46:144:g_d0_f46:(0.006) 
47:1577:89642:0:14:338:372:506:144:g_d0_f46:144:g_d0_f46:-0.010 
47:1578:89648:14:0:336:374:492:144:g_d0_f46:144:g_d0_f46:(0.004) 
47:1579:89655:0:14:393:482:506:144:g_d0_f46:144:g_d0_f46:0.337 -0.006  
47:1580:89667:14:14:439:484:492:144:g_d0_f46:144:g_d0_f46:(0.0036) 
47:1581:89675:14:0:458:464:478:144:g_d0_f46:144:g_d0_f46:  
47:1582:89675:0:14:498:535:506:144:g_d0_f46:144:g_d0_f46:-0.008  
47:1583:89682:14:14:496:534:492:144:g_d0_f46:144:g_d0_f46:(0.004) 
47:1584:89689:14:14:513:516:478:144:g_d0_f46:144:g_d0_f46: 
47:1585:89689:14:14:70:184:464:144:g_d0_f46:144:g_d0_f46:  6 months of diagnosis 
47:1586:89710:14:0:70:76:450:144:g_d0_f46:144:g_d0_f46:  
47:1587:89710:0:14:233:322:464:144:g_d0_f46:144:g_d0_f46:0.482 -0.028  
47:1588:89724:14:0:283:321:450:144:g_d0_f46:144:g_d0_f46:(0.008) 
47:1589:89732:0:14:338:375:464:144:g_d0_f46:144:g_d0_f46:-0.022  
47:1590:89739:14:0:336:374:450:144:g_d0_f46:144:g_d0_f46:(0.006) 
47:1591:89746:0:14:393:479:464:144:g_d0_f46:144:g_d0_f46:0.466 -0.012 
47:1592:89757:14:14:442:481:450:144:g_d0_f46:144:g_d0_f46:(0.002) 
47:1593:89764:14:0:458:464:436:144:g_d0_f46:144:g_d0_f46:  
47:1594:89764:0:14:498:532:464:144:g_d0_f46:144:g_d0_f46:-0.014 
47:1595:89770:14:14:496:534:450:144:g_d0_f46:144:g_d0_f46:(0.002) 
47:1596:89777:14:14:513:516:436:144:g_d0_f46:144:g_d0_f46: 
47:1597:89777:14:14:70:184:422:144:g_d0_f46:144:g_d0_f46:  9 months of diagnosis 
47:1598:89798:14:0:70:76:408:144:g_d0_f46:144:g_d0_f46:  
47:1599:89798:0:14:233:322:422:144:g_d0_f46:144:g_d0_f46:0.541 -0.027  
47:1600:89812:14:0:283:321:408:144:g_d0_f46:144:g_d0_f46:(0.008) 
47:1601:89820:0:14:338:372:422:144:g_d0_f46:144:g_d0_f46:-0.019 
47:1602:89826:14:0:336:374:408:144:g_d0_f46:144:g_d0_f46:(0.005) 
47:1603:89833:0:14:393:479:422:144:g_d0_f46:144:g_d0_f46:0.524 -0.004 
47:1604:89844:14:14:442:481:408:144:g_d0_f46:144:g_d0_f46:(0.003) 
47:1605:89851:14:0:458:464:394:144:g_d0_f46:144:g_d0_f46:  
47:1606:89851:0:14:498:532:422:144:g_d0_f46:144:g_d0_f46:-0.007 
47:1607:89857:14:14:496:534:408:144:g_d0_f46:144:g_d0_f46:(0.002) 
47:1608:89864:14:15:513:516:394:144:g_d0_f46:144:g_d0_f46: 
47:1609:89864:15:13:70:322:379:144:g_d0_f46:144:g_d0_f46:  1 year of diagnosis 0. 635 -0.008  
47:1610:89896:13:0:283:321:366:144:g_d0_f46:144:g_d0_f46:(0.008) 
47:1611:89903:0:13:337:373:379:144:g_d0_f46:144:g_d0_f46:0.0003 
47:1612:89909:13:0:336:374:366:144:g_d0_f46:144:g_d0_f46:(0.006) 
47:1613:89916:0:13:393:479:379:144:g_d0_f46:144:g_d0_f46:0.616 0.006  
47:1614:89927:13:14:442:481:366:144:g_d0_f46:144:g_d0_f46:(0.005) 
47:1615:89934:14:0:458:464:352:144:g_d0_f46:144:g_d0_f46:  
47:1616:89934:0:13:497:536:379:144:g_d0_f46:144:g_d0_f46:0.0001  
47:1617:89941:13:14:496:534:366:144:g_d0_f46:144:g_d0_f46:(0.002) 
47:1618:89948:14:15:513:516:352:144:g_d0_f46:144:g_d0_f46: 
47:1619:89948:15:17:70:522:337:144:g_d0_f46:144:g_d0_f46:Observations (weeks) 48 96 72 48 96 72 
47:1620:89980:17:11:72:492:320:99:g_d0_f46:99:g_d0_f46:Notes: Means in column 1 and 3 are for the dependent variable for patients in counties with low vs. high 
47:1621:90085:11:12:72:526:309:99:g_d0_f46:99:g_d0_f46:concentration in the period prior to the reform, Feb-Nov 2004. The mean for service counts is without logs. High 
47:1622:90198:12:0:72:440:297:99:g_d0_f46:99:g_d0_f46:concentration is defined as an HHI greater than 0.25. See notes to Table 3 for other details.  
48:1623:90293:0:34:90:173:671:296:g_d0_f9:296:g_d0_f9:Appendix
48:1624:90301:34:26:90:248:637:206:g_d0_f9:206:g_d0_f9:Proof of Proposition 1
48:1625:90323:26:18:90:522:611:143:g_d0_f9:143:g_d0_f3:Proof.Letsjm=qjm/⌘jthe change in the share of patients treated by physicianjin
48:1626:90401:18:34:90:473:593:143:g_d0_f3:143:g_d0_f3:response to a change inm.Thenfor↵⇡0, equation 3 can be rewritten as
48:1627:90468:34:0:119:145:559:143:g_d0_f10:143:g_d0_f3:sjm⇠=
48:1628:90473:0:17:149:201:567:143:g_d0_f10:143:g_d0_f13:V⇡+V⇡⇡⇡
48:1629:90480:17:0:163:187:550:143:g_d0_f13:64:g_d0_f14:⌘jeqq
48:1630:90485:0:38:202:522:559:143:g_d0_f10:143:g_d0_f3:.(6)
48:1631:90489:38:18:107:521:521:143:g_d0_f3:143:g_d0_f3:Denote the inverse of the change in the share of patients treated ash(⌘j)=||1sjm||=
48:1632:90572:18:17:90:522:503:143:g_d0_f13:143:g_d0_f3:⌘jwhere⌘||eqqV⇡+V⇡⇡⇡||.Themarketlevelmeasureofhis then given by the weighed
48:1633:90649:17:33:89:254:486:143:g_d0_f3:143:g_d0_f3:averages of the individualh(⌘j):
48:1634:90681:33:33:119:522:453:143:g_d0_f10:143:g_d0_f3:Hm=⌃Jj=1⌘jh(⌘j).(7)
48:1635:90700:33:18:107:521:420:143:g_d0_f3:143:g_d0_f3:An internal solution for equation 2 implies thatis invariant with respect to⌘,
48:1636:90779:18:33:90:224:402:143:g_d0_f3:143:g_d0_f3:soHmcan be rewritten as
48:1637:90802:33:32:119:522:369:143:g_d0_f10:143:g_d0_f3:Hm=⌃Jj=1⌘j⌘j=⌃Jj=1⌘j⌘j.(8)
48:1638:90830:32:18:90:522:337:143:g_d0_f3:143:g_d0_f3:So the change in the share of patients treated in a market m is equivalent to a scaled
48:1639:90916:18:18:90:522:319:143:g_d0_f3:143:g_d0_f3:version of the Herfindahl-Hirschman Index (HHI). And since HHI belongs to the
48:1640:90993:18:18:90:522:301:143:g_d0_f3:143:g_d0_f3:family of “allowable” concentration indices as described in Encaoua and Jacquemin
48:1641:91074:18:18:90:521:283:143:g_d0_f3:143:g_d0_f3:(1980),Hmwill be positively correlated to any other such allowable concentration
48:1642:91154:18:18:90:247:265:143:g_d0_f3:143:g_d0_f3:index (e.g. the entropy index).
48:1643:91185:18:18:107:521:247:143:g_d0_f3:143:g_d0_f3:Then sinceHmis positively correlated to market concentration, its inverse (i.e.
48:1644:91264:18:18:89:521:229:143:g_d0_f3:143:g_d0_f3:the magnitude of the change in the share of patients treated in a market) will be
48:1645:91345:18:39:89:402:211:143:g_d0_f3:143:g_d0_f3:negatively correlated with measures of market concentration.
48:1646:91405:39:26:90:248:172:206:g_d0_f9:206:g_d0_f9:Proof of Proposition 2
48:1647:91427:26:18:90:522:146:143:g_d0_f9:143:g_d0_f3:Proof.The change in patient welfare generated by a physicianj’s response to a
48:1648:91504:18:17:89:527:128:143:g_d0_f3:143:g_d0_f3:change in profit marginmis given byb(qj/⌘j)qjm.Themagnitudeofthemarketlevel
48:1649:91579:17:0:90:526:111:143:g_d0_f3:143:g_d0_f3:change in patient welfare can thus be written asWm=⌃Jj=1⌘j||b(qj/⌘j)qjm||,which
49:1650:91658:0:33:90:273:671:143:g_d0_f3:143:g_d0_f3:for small↵⇡0canberewrittenas
49:1651:91686:33:33:119:522:638:143:g_d0_f10:143:g_d0_f3:Wm⇠=⌃Jj=1⌘jh(⌘j)whereh(⌘j)=b(qj/⌘j)||V⇡+V⇡⇡⇡eqq||.(9)
49:1652:91739:33:33:107:510:605:143:g_d0_f3:143:g_d0_f3:Encaoua and Jacquemin (1980) show that for a concentration index defined as
49:1653:91814:33:32:119:522:572:143:g_d0_f13:143:g_d0_f3:⇣(↵1,0,↵N)=⌃Ni=1↵ig(↵i),(10)
49:1654:91842:32:18:90:521:540:143:g_d0_f3:143:g_d0_f3:where the↵isrepresentsthemarketshareoffirmi,ifg(↵) is any arbitrary function
49:1655:91918:18:18:90:528:522:143:g_d0_f3:143:g_d0_f3:that is weakly increasing in↵,if↵g(↵)isconvexin↵,itbelongstoafamilyof
49:1656:91987:18:18:89:521:504:143:g_d0_f3:143:g_d0_f3:“allowable” concentration indices.  Such allowable indices (which include HHI and
49:1657:92068:18:18:89:521:486:143:g_d0_f3:143:g_d0_f3:the entropy index) satisfies the following properties: it is invariant to permutations of
49:1658:92157:18:18:89:525:468:143:g_d0_f3:143:g_d0_f3:market shares between firmsi,itsatisfiestheLorentzconditionthatameanpressuring
49:1659:92235:18:18:89:525:450:143:g_d0_f3:143:g_d0_f3:spread increases",andtheconcentrationofsymmetricfirmsdecreasesinthenumber
49:1660:92308:18:18:89:525:432:143:g_d0_f3:143:g_d0_f3:of firms. Thus it is su-cient to show thath(⌘)isincreasingin⌘and⌘h(⌘)isconvex
49:1661:92385:18:18:90:240:414:143:g_d0_f3:143:g_d0_f3:in⌘to prove the proposition.
49:1662:92413:18:18:107:521:396:143:g_d0_f3:143:g_d0_f3:To showh(⌘)isweaklyincreasingin⌘,wetakethederivativeofhwith respect
49:1663:92480:18:28:90:152:378:143:g_d0_f3:143:g_d0_f3:to⌘and get
49:1664:92490:28:16:120:133:350:143:g_d0_f10:143:g_d0_f10:dh
49:1665:92492:16:0:120:132:334:143:g_d0_f10:143:g_d0_f13:d⌘
49:1666:92494:0:0:137:159:342:143:g_d0_f3:143:g_d0_f11:=-
49:1667:92496:0:17:161:169:351:143:g_d0_f10:64:g_d0_f14:qj
49:1668:92498:17:0:160:170:334:143:g_d0_f13:64:g_d0_f5:⌘2
49:1669:92500:0:0:172:187:342:143:g_d0_f10:143:g_d0_f12:b0||
49:1670:92504:0:17:188:239:351:143:g_d0_f10:143:g_d0_f13:V⇡+V⇡⇡⇡
49:1671:92511:17:0:207:220:334:143:g_d0_f10:64:g_d0_f14:eqq
49:1672:92514:0:36:241:522:342:143:g_d0_f12:143:g_d0_f3:||.(11)
49:1673:92521:36:18:89:481:306:143:g_d0_f3:143:g_d0_f3:Then sinceb00, equation 11 is positive andh(⌘)isweaklyincreasingin⌘.
49:1674:92590:18:18:107:526:288:143:g_d0_f3:143:g_d0_f3:To show convexity of⌘h(⌘)wetakethesecondderivativeandget(aftersome
49:1675:92656:18:28:90:239:270:143:g_d0_f3:143:g_d0_f3:simplification) the expression
49:1676:92686:28:16:120:153:242:143:g_d0_f10:143:g_d0_f3:d2(⌘h)
49:1677:92692:16:0:128:144:226:143:g_d0_f10:64:g_d0_f5:d⌘2
49:1678:92695:0:0:157:166:234:143:g_d0_f3:143:g_d0_f3:=
49:1679:92696:0:16:171:194:242:143:g_d0_f3:64:g_d0_f5:(qj)2
49:1680:92701:16:0:177:188:226:143:g_d0_f13:64:g_d0_f5:⌘3
49:1681:92703:0:0:196:213:234:143:g_d0_f10:143:g_d0_f12:b00||
49:1682:92708:0:16:214:265:242:143:g_d0_f10:143:g_d0_f13:V⇡+V⇡⇡⇡
49:1683:92715:16:0:233:246:226:143:g_d0_f10:64:g_d0_f14:eqq
49:1684:92718:0:40:267:522:234:143:g_d0_f12:143:g_d0_f3:||.(12)
49:1685:92725:40:0:89:242:194:143:g_d0_f3:64:g_d0_f14:Since by assumptionb00>0,d
49:1686:92751:0:12:243:262:202:36:g_d0_f50:64:g_d0_f5:2(⌘h)
49:1687:92756:12:35:244:289:190:64:g_d0_f14:143:g_d0_f3:d⌘2>0.
49:1688:92762:35:26:90:216:155:206:g_d0_f9:206:g_d0_f9:Two-Payer Model
49:1689:92777:26:18:90:522:129:143:g_d0_f3:143:g_d0_f3:In this section, we analyze the model presented in the paper, with the addition of a
49:1690:92861:18:0:90:522:111:143:g_d0_f3:143:g_d0_f3:second, private payer. Here we show that the two propositions in the paper hold in a
50:1691:92945:0:18:90:522:671:143:g_d0_f3:143:g_d0_f3:two payer model, and generate two addition predictions regarding how the share for
50:1692:93027:18:18:90:425:653:143:g_d0_f3:143:g_d0_f3:public vs. private patients a↵ects physician response to a fee cut.
50:1693:93094:18:18:107:521:635:143:g_d0_f3:143:g_d0_f3:In addition the assumptions of the main model, we incorporate a second payer for
50:1694:93174:18:18:90:522:617:143:g_d0_f3:143:g_d0_f3:medical care. In each marketk,forpatientsoftypeb,afraction-are public (i.e.
50:1695:93249:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:Medicare) patients while the remaining (1--) are private payers. Notationally, we
50:1696:93330:18:18:90:521:581:143:g_d0_f3:143:g_d0_f3:denote the number of public patients treated byqand the number of private payer
50:1697:93409:18:18:89:526:563:143:g_d0_f3:143:g_d0_f3:patients treated byq0.Similarlytheprofitmarginfortreatingeachtypeofpatientis
50:1698:93485:18:18:90:266:545:143:g_d0_f3:143:g_d0_f3:denoted bymandm0respectively.
50:1699:93514:18:34:107:356:527:143:g_d0_f3:143:g_d0_f3:Physician utility function can then be written as
50:1700:93563:34:0:119:279:493:143:g_d0_f10:143:g_d0_f13:U(q)=V(⇡)-e(q+q0)+↵⌘[-
50:1701:93585:0:27:282:311:509:143:g_d0_f15:64:g_d0_f16:Zq/⌘-
50:1702:93590:27:0:288:292:482:64:g_d0_f5:64:g_d0_f5:0
50:1703:93591:0:0:314:398:493:143:g_d0_f10:143:g_d0_f3:b(x)dx+(1--)
50:1704:93603:0:27:400:449:509:143:g_d0_f15:64:g_d0_f5:Zq0/⌘(1--)
50:1705:93613:27:0:407:411:482:64:g_d0_f5:64:g_d0_f5:0
50:1706:93614:0:36:452:522:493:143:g_d0_f10:143:g_d0_f3:b(x)dx],(13)
50:1707:93626:36:18:89:521:457:143:g_d0_f3:143:g_d0_f3:where⇡=mq+m0q0and↵represents the weight physicians place on patient benefit.
50:1708:93702:18:27:90:363:439:143:g_d0_f3:143:g_d0_f3:The FOCs for utility maximization are then given by
50:1709:93753:27:21:154:522:412:143:g_d0_f10:143:g_d0_f3:mV⇡-eq+↵b(q/⌘-)=0(14)
50:1710:93774:21:30:119:522:391:143:g_d0_f10:143:g_d0_f3:m0V⇡-eq+↵b(q0/⌘(1--))  =  0.(15)
50:1711:93806:30:18:107:526:361:143:g_d0_f3:143:g_d0_f3:As before concern for patient welfare (↵b)pushesphysicianstowardsproviding
50:1712:93880:18:18:90:526:343:143:g_d0_f3:143:g_d0_f3:what, from the patient’s perspective, is the optimal level of careqP,butingeneral
50:1713:93961:18:18:89:521:325:143:g_d0_f3:143:g_d0_f3:physicians may either under or over provide care relative to this optimum: in the
50:1714:94042:18:18:89:207:307:143:g_d0_f3:143:g_d0_f3:limit↵!1,q⇤!qP.
50:1715:94057:18:18:107:527:289:143:g_d0_f3:143:g_d0_f3:To determine physician response inqto a change in profit marginm,wetake
50:1716:94128:18:18:89:521:271:143:g_d0_f3:143:g_d0_f3:the derivative of equation 14 with respect to m. Rearranging, we get the following
50:1717:94210:18:32:89:152:253:143:g_d0_f3:143:g_d0_f3:relationship:
50:1718:94223:32:0:119:144:221:143:g_d0_f10:143:g_d0_f3:qm=
50:1719:94226:0:16:149:307:229:143:g_d0_f10:143:g_d0_f3:V⇡+V⇡⇡⇡+q0m(V⇡⇡mm0-eqq)
50:1720:94249:16:0:203:252:213:143:g_d0_f10:64:g_d0_f14:eqq+↵⌘-bq
50:1721:94258:0:38:501:522:221:143:g_d0_f3:143:g_d0_f3:(16)
50:1722:94262:38:18:107:521:183:143:g_d0_f3:143:g_d0_f3:As beforeqmcan be positive or negative. That is, it cannot be determined ex-ante
50:1723:94342:18:18:90:522:165:143:g_d0_f3:143:g_d0_f3:whether an increase in profitability leads to an increase or decrease in provision of
50:1724:94427:18:18:90:521:147:143:g_d0_f3:143:g_d0_f3:the service experiencing a price cut. But nowqmis driven by the tradeo↵between
50:1725:94505:18:18:89:522:129:143:g_d0_f3:143:g_d0_f3:decreasing marginal returns (the substitution e↵ect) and the increasing marginal re-
50:1726:94589:18:0:89:521:111:143:g_d0_f3:143:g_d0_f3:turns to income (the income e↵ect), as well as “cross-service e↵ects” (i.e. changes in
51:1727:94675:0:18:90:359:671:143:g_d0_f3:143:g_d0_f3:the marginal cost of e↵ort ofqdue to changes inq0).
51:1728:94726:18:18:107:521:653:143:g_d0_f3:143:g_d0_f3:Note that in the case whereq0m⇡0, equation 16 is identical to equation 3, with
51:1729:94804:18:18:89:521:635:143:g_d0_f13:143:g_d0_f3:⌘-, the Medicare market share, taking taking the place of overall market share⌘.
51:1730:94884:18:18:89:522:617:143:g_d0_f3:143:g_d0_f3:This is the case described in McGuire and Pauly (1991): “When income e↵ects are
51:1731:94963:18:18:89:521:599:143:g_d0_f3:143:g_d0_f3:absent and either the marginal utility of leisure is unchanged... we get a surprising
51:1732:95048:18:18:89:521:581:143:g_d0_f3:143:g_d0_f3:conclusing: there will be no e↵ects” on the quantity of service provided to the private
51:1733:95135:18:18:89:521:563:143:g_d0_f3:143:g_d0_f3:payer in response to a change in public payer margins. In such a case the ”bite of
51:1734:95217:18:18:89:525:545:143:g_d0_f3:143:g_d0_f3:apricecutwilldeclinewithmarketshare”. Thatisdoctorsinmarketswithhigher
51:1735:95287:18:18:89:521:527:143:g_d0_f3:143:g_d0_f3:share of Medicare patients will be more a↵ected by the price cut than those in low
51:1736:95369:18:18:89:254:509:143:g_d0_f3:143:g_d0_f3:Medicare patient share markets.
51:1737:95400:18:31:107:521:491:143:g_d0_f3:143:g_d0_f3:In this case, in addition to proposition 1 and 2, and we get the following corollaries:
51:1738:95487:31:30:89:395:460:143:g_d0_f9:143:g_d0_f23:Corollary 3If Proposition 3 holds,Hkmis increasing in-.
51:1739:95542:30:0:90:242:430:143:g_d0_f9:64:g_d0_f14:Proof.Sinced⌘d-=dd-=0,dH
51:1740:95567:0:12:242:249:438:36:g_d0_f48:36:g_d0_f48:km
51:1741:95569:12:0:235:281:426:64:g_d0_f14:143:g_d0_f4:d-=⌃
51:1742:95574:0:7:281:286:434:64:g_d0_f14:64:g_d0_f14:J
51:1743:95575:7:28:281:338:427:64:g_d0_f14:143:g_d0_f3:j=1⌘j⌘j>0
51:1744:95584:28:31:90:396:399:143:g_d0_f9:143:g_d0_f23:Corollary 4If Proposition 4 holds,Wkmis increasing in-.
51:1745:95639:31:0:90:144:368:143:g_d0_f9:64:g_d0_f14:Proof.dW
51:1746:95647:0:12:146:152:376:36:g_d0_f48:36:g_d0_f48:km
51:1747:95649:12:0:135:181:364:64:g_d0_f14:143:g_d0_f4:d-k=⌃
51:1748:95654:0:7:177:182:372:64:g_d0_f14:64:g_d0_f14:J
51:1749:95655:7:0:177:197:365:64:g_d0_f14:143:g_d0_f3:j=1(
51:1750:95659:0:9:198:212:373:64:g_d0_f22:36:g_d0_f48:-qj
51:1751:95662:9:0:201:223:364:64:g_d0_f16:143:g_d0_f10:-2)b
51:1752:95666:0:8:223:344:372:64:g_d0_f22:64:g_d0_f5:0||V⇡+V⇡⇡⇡+q0m(V⇡⇡mm0-eqq)
51:1753:95692:8:0:283:396:364:64:g_d0_f14:143:g_d0_f10:eqq||.Sinceb
51:1754:95704:0:8:396:449:372:64:g_d0_f22:36:g_d0_f48:0<0,dWkm
51:1755:95712:8:32:432:472:364:64:g_d0_f14:143:g_d0_f3:d-k<0
51:1756:95717:32:18:90:522:332:143:g_d0_f3:143:g_d0_f3:These corollaries simply state that when the the share of public patients is larger, a
51:1757:95803:18:18:90:489:314:143:g_d0_f3:143:g_d0_f3:cut in public patient margins will have a larger impact on physician behavior.
51:1758:95881:18:18:107:522:296:143:g_d0_f3:143:g_d0_f3:In the case where there are significant “cross service e↵ects” (i.e.||q0m||>>0),
51:1759:95961:18:18:89:521:278:143:g_d0_f3:143:g_d0_f3:the expressions that describe physician response are quite complex, and will depend
51:1760:96044:18:18:89:521:260:143:g_d0_f3:143:g_d0_f3:on the specific values of the various parameters. In such a case, while proposition 1
51:1761:96129:18:18:89:521:242:143:g_d0_f3:143:g_d0_f3:and 2 hold, the two corollaries need not, and will depend on the specific form of the
51:1762:96214:18:17:89:336:224:143:g_d0_f3:143:g_d0_f3:utility function, as well as the parameter values.
51:1763:96264:17:18:107:521:207:143:g_d0_f3:143:g_d0_f3:While the predictions regarding share Medicare patient share and physician re-
51:1764:96342:18:18:89:521:189:143:g_d0_f3:143:g_d0_f3:sponse are straightforward, data on the share of Medicare patients vs. private payer
51:1765:96426:18:18:89:521:171:143:g_d0_f3:143:g_d0_f3:patients is largely unavailable, and so we were unable to empirically test these addi-
51:1766:96512:18:114:89:251:153:143:g_d0_f3:143:g_d0_f3:tional predictions in this paper.
52:1767:96545:114:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
52:1768:96545:0:295:483:486:709:122:g_d0_f29:122:g_d0_f29: 
52:1769:96545:295:321:72:75:414:122:g_d0_f29:122:g_d0_f29: 
52:1770:96545:321:0:474:477:93:122:g_d0_f29:122:g_d0_f29: 
52:1771:96561:0:0:110:456:172:45:g_d0_f51:45:g_d0_f51:-12-9-6-3036912-12-9-6-3036912
52:1772:96591:0:85:146:442:338:88:g_d0_f51:88:g_d0_f51:App Fig 2a. All SettingsApp Fig 2b. Excluding Carboplatin
52:1773:96648:85:109:132:418:253:88:g_d0_f51:88:g_d0_f51:App Fig 2c. Physician's OfficeApp Fig 2d. Outpatient
52:1774:96700:109:14:227:368:144:17:g_d0_f51:17:g_d0_f51:Reg-adjusted DifferenceLower Bound 95% CI
52:1775:96741:14:0:227:265:130:17:g_d0_f51:17:g_d0_f51:Upper Bound 95% CI
52:1776:96794:0:49:223:335:160:63:g_d0_f51:63:g_d0_f51:Month Relative to January 2005
52:1777:96824:49:0:94:156:111:63:g_d0_f51:63:g_d0_f51:Graphs by setting
52:1778:96841:0:11:132:418:364:122:g_d0_f51:122:g_d0_f51:Change in the Share Given Chemotherapy Within 90 Days
52:1779:96894:11:0:83:467:353:122:g_d0_f51:122:g_d0_f51:By Month of Diagnosis Relative to the January 2005 ASP Implementation Date
52:1780:97003:0:0:104:191:579:36:g_d0_f51:36:g_d0_f51:-40-2002040time
52:1781:97018:0:102:143:231:681:71:g_d0_f51:71:g_d0_f51:App Fig 1a. All Settings
52:1782:97079:102:0:296:383:579:36:g_d0_f51:36:g_d0_f51:-40-2002040time
52:1783:97094:0:232:316:443:681:71:g_d0_f51:71:g_d0_f51:App Fig 1b. Excluding Carboplatin
52:1784:97162:232:0:104:191:449:36:g_d0_f51:36:g_d0_f51:-40-2002040time
52:1785:97177:0:102:131:242:551:71:g_d0_f51:71:g_d0_f51:App Fig 1c. Physician's Office
52:1786:97241:102:0:296:383:449:36:g_d0_f51:36:g_d0_f51:-40-2002040time
52:1787:97256:0:0:336:420:551:71:g_d0_f51:71:g_d0_f51:App Fig 1d. Outpatient
52:1788:97278:0:660:117:428:699:122:g_d0_f51:122:g_d0_f51:Appendix Figure 1: F-statistics Testing for a Break in Treatment
53:1789:97342:660:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
53:1790:97342:0:30:72:479:424:81:g_d0_f52:122:g_d0_f52:  
53:1791:97342:30:11:72:539:394:99:g_d0_f52:99:g_d0_f52:Note: There is a small discontinuity we cannot explain at about 365 days in both the cohorts diagnosed in 
53:1792:97448:11:23:72:533:383:99:g_d0_f52:99:g_d0_f52:the pre and post periods. Since it is of similar magnitude across cohorts, it should not affect our results.  
53:1793:97558:23:25:72:74:360:122:g_d0_f27:122:g_d0_f27: 
53:1794:97558:25:26:72:74:335:122:g_d0_f27:122:g_d0_f27: 
53:1795:97558:26:25:72:74:309:122:g_d0_f27:122:g_d0_f27: 
53:1796:97558:25:0:72:74:284:122:g_d0_f27:122:g_d0_f27: 
53:1797:97578:0:8:109:463:475:63:g_d0_f53:63:g_d0_f53:0100200300400500600
53:1798:97597:8:20:275:293:467:63:g_d0_f53:63:g_d0_f53:Days
53:1799:97601:20:0:263:347:447:63:g_d0_f53:63:g_d0_f53:prepost
53:1800:97608:0:11:154:411:695:122:g_d0_f53:122:g_d0_f53:App Fig 3. Kaplan Meier Unadjusted Survival Curves
53:1801:97658:11:645:119:447:684:122:g_d0_f53:122:g_d0_f53:Comparing Those Diagnosed 11 Months Pre versus Post Jan 2005
54:1802:97718:645:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
54:1803:97718:0:11:495:498:410:144:g_d0_f54:144:g_d0_f54: 
54:1804:97718:11:313:72:75:399:144:g_d0_f54:144:g_d0_f54: 
54:1805:97718:313:0:495:498:86:144:g_d0_f29:144:g_d0_f29: 
54:1806:97748:0:0:113:475:492:50:g_d0_f55:50:g_d0_f55:-12-9-6-3036912-12-9-6-3036912
54:1807:97778:0:89:150:460:666:97:g_d0_f55:97:g_d0_f55:App Fig 4a. All SettingsApp Fig 4b. Excluding Carboplatin
54:1808:97835:89:114:136:436:577:97:g_d0_f55:97:g_d0_f55:App Fig 4c. Physician's OfficeApp Fig 4d. Outpatient
54:1809:97887:114:15:236:383:463:18:g_d0_f55:18:g_d0_f55:Reg-adjusted DifferenceLower Bound 95% CI
54:1810:97928:15:0:236:276:448:18:g_d0_f55:18:g_d0_f55:Upper Bound 95% CI
54:1811:97981:0:52:231:349:479:69:g_d0_f55:69:g_d0_f55:Month Relative to January 2005
54:1812:98011:52:0:96:161:427:69:g_d0_f55:69:g_d0_f55:Graphs by setting
54:1813:98028:0:12:98:473:694:135:g_d0_f55:135:g_d0_f55:Change in Share Given Chemotherapy in States with High Paclitaxel Use
54:1814:98097:12:513:144:428:682:135:g_d0_f55:135:g_d0_f55:Relative to the January 2005 ASP Implementation Date
54:1815:98179:513:0:113:475:169:50:g_d0_f55:50:g_d0_f55:-12-9-6-3036912-12-9-6-3036912
54:1816:98209:0:89:150:459:342:97:g_d0_f55:97:g_d0_f55:App Fig 4e. All SettingsApp Fig 4f. Excluding Carboplatin
54:1817:98266:89:114:136:436:253:97:g_d0_f55:97:g_d0_f55:App Fig 4g. Physician's OfficeApp Fig 4h. Outpatient
54:1818:98318:114:15:236:383:139:18:g_d0_f55:18:g_d0_f55:Reg-adjusted DifferenceLower Bound 95% CI
54:1819:98359:15:0:236:276:124:18:g_d0_f55:18:g_d0_f55:Upper Bound 95% CI
54:1820:98412:0:52:231:349:156:69:g_d0_f55:69:g_d0_f55:Month Relative to January 2005
54:1821:98442:52:0:96:161:104:69:g_d0_f55:69:g_d0_f55:Graphs by setting
54:1822:98459:0:12:99:472:371:135:g_d0_f55:135:g_d0_f55:Change in Share Given Chemotherapy in States with Low Paclitaxel Use
54:1823:98527:12:320:144:428:359:135:g_d0_f55:135:g_d0_f55:Relative to the January 2005 ASP Implementation Date
55:1824:98579:320:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
55:1825:98579:0:322:495:498:410:122:g_d0_f54:122:g_d0_f54: 
55:1826:98579:322:0:495:498:88:122:g_d0_f54:122:g_d0_f54: 
55:1827:98609:0:0:112:475:492:50:g_d0_f56:50:g_d0_f56:-12-9-6-3036912-12-9-6-3036912
55:1828:98639:0:89:124:462:666:97:g_d0_f56:97:g_d0_f56:App Fig 5a. Death Within 3 MonthsApp Fig 5b. Death Within 6 Months
55:1829:98705:89:116:124:465:577:97:g_d0_f56:97:g_d0_f56:App Fig 5c. Death Within 9 MonthsApp Fig 5d. Death Within 12 Months
55:1830:98772:116:15:191:425:461:69:g_d0_f56:69:g_d0_f56:Reg-adjusted DifferenceLower Bound 95% CI
55:1831:98813:15:0:191:270:446:69:g_d0_f56:69:g_d0_f56:Upper Bound 95% CI
55:1832:98866:0:52:238:340:479:69:g_d0_f56:69:g_d0_f56:Month Relative to Jan 2005
55:1833:98892:52:0:95:159:427:69:g_d0_f56:69:g_d0_f56:Graphs by period
55:1834:98908:0:12:79:492:694:135:g_d0_f56:135:g_d0_f56:Change in Share Dying by Month of Diagnosis in States with High Paclitaxel Use
55:1835:98986:12:512:144:428:682:135:g_d0_f56:135:g_d0_f56:Relative to the January 2005 ASP Implementation Date
55:1836:99068:512:0:112:475:170:50:g_d0_f56:50:g_d0_f56:-12-9-6-3036912-12-9-6-3036912
55:1837:99098:0:89:124:461:344:97:g_d0_f56:97:g_d0_f56:App Fig 5e. Death Within 3 MonthsApp Fig 5f. Death Within 6 Months
55:1838:99164:89:116:124:465:255:97:g_d0_f56:97:g_d0_f56:App Fig 5g. Death Within 9 MonthsApp Fig 5h. Death Within 12 Months
55:1839:99231:116:14:191:425:139:69:g_d0_f56:69:g_d0_f56:Reg-adjusted DifferenceLower Bound 95% CI
55:1840:99272:14:0:191:270:125:69:g_d0_f56:69:g_d0_f56:Upper Bound 95% CI
55:1841:99325:0:52:238:340:158:69:g_d0_f56:69:g_d0_f56:Month Relative to Jan 2005
55:1842:99351:52:0:95:159:106:69:g_d0_f56:69:g_d0_f56:Graphs by period
55:1843:99367:0:12:80:491:373:135:g_d0_f56:135:g_d0_f56:Change in Share Dying by Month of Diagnosis in States with Low Paclitaxel Use
55:1844:99444:12:322:142:429:361:135:g_d0_f56:135:g_d0_f56:Relative to the January 2005 ASP  Implementation Date
56:1845:99497:322:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
56:1846:99497:0:316:495:498:410:122:g_d0_f54:122:g_d0_f54: 
56:1847:99497:316:0:495:498:94:122:g_d0_f54:122:g_d0_f54: 
56:1848:99527:0:0:113:475:492:50:g_d0_f28:50:g_d0_f28:-12-9-6-3036912-12-9-6-3036912
56:1849:99557:0:89:150:460:666:97:g_d0_f28:97:g_d0_f28:App Fig 6a. All SettingsApp Fig 6b. Excluding Carboplatin
56:1850:99614:89:114:136:436:577:97:g_d0_f28:97:g_d0_f28:App Fig 6c. Physician's OfficeApp Fig 6d. Outpatient
56:1851:99666:114:15:236:383:463:18:g_d0_f28:18:g_d0_f28:Reg-adjusted DifferenceLower Bound 95% CI
56:1852:99707:15:0:236:276:448:18:g_d0_f28:18:g_d0_f28:Upper Bound 95% CI
56:1853:99760:0:52:231:349:479:69:g_d0_f28:69:g_d0_f28:Month Relative to January 2005
56:1854:99790:52:0:96:161:427:69:g_d0_f28:69:g_d0_f28:Graphs by setting
56:1855:99807:0:12:92:478:694:135:g_d0_f28:135:g_d0_f28:Change in Share Given Chemotherapy Among Above Median Age Patients
56:1856:99873:12:506:144:428:682:135:g_d0_f28:135:g_d0_f28:Relative to the January 2005 ASP Implementation Date
56:1857:99955:506:0:112:475:176:50:g_d0_f28:50:g_d0_f28:-12-9-6-3036912-12-9-6-3036912
56:1858:99985:0:89:149:459:350:97:g_d0_f28:97:g_d0_f28:App Fig 6e. All SettingsApp Fig 6f. Excluding Carboplatin
56:1859:100042:89:114:135:436:261:97:g_d0_f28:97:g_d0_f28:App Fig 6g. Physician's OfficeApp Fig 6h. Outpatient
56:1860:100094:114:15:235:383:147:18:g_d0_f28:18:g_d0_f28:Reg-adjusted DifferenceLower Bound 95% CI
56:1861:100135:15:0:235:275:132:18:g_d0_f28:18:g_d0_f28:Upper Bound 95% CI
56:1862:100188:0:51:231:349:163:69:g_d0_f28:69:g_d0_f28:Month Relative to January 2005
56:1863:100218:51:0:95:160:112:69:g_d0_f28:69:g_d0_f28:Graphs by setting
56:1864:100235:0:11:83:487:378:135:g_d0_f28:135:g_d0_f28:Change in the Share Given Chemotherapy Among Below Median Age Patients
56:1865:100305:11:328:142:429:367:135:g_d0_f28:135:g_d0_f28:Relative to the January 2005 ASP  Implementation Date
57:1866:100358:328:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
57:1867:100358:0:16:495:498:410:122:g_d0_f54:122:g_d0_f54: 
57:1868:100358:16:318:72:75:394:122:g_d0_f54:122:g_d0_f54: 
57:1869:100358:318:0:495:498:76:122:g_d0_f54:122:g_d0_f54: 
57:1870:100388:0:0:113:475:492:50:g_d0_f31:50:g_d0_f31:-12-9-6-3036912-12-9-6-3036912
57:1871:100418:0:89:124:462:666:97:g_d0_f31:97:g_d0_f31:App Fig 7a. Death Within 3 MonthsApp Fig 7b. Death Within 6 Months
57:1872:100484:89:116:125:465:577:97:g_d0_f31:97:g_d0_f31:App Fig 7c. Death Within 9 MonthsApp Fig 7d. Death Within 12 Months
57:1873:100551:116:15:191:425:461:69:g_d0_f31:69:g_d0_f31:Reg-adjusted DifferenceLower Bound 95% CI
57:1874:100592:15:0:191:270:446:69:g_d0_f31:69:g_d0_f31:Upper Bound 95% CI
57:1875:100645:0:52:238:340:479:69:g_d0_f31:69:g_d0_f31:Month Relative to Jan 2005
57:1876:100671:52:0:96:160:427:69:g_d0_f31:69:g_d0_f31:Graphs by period
57:1877:100687:0:12:133:439:694:135:g_d0_f31:135:g_d0_f31:Change in Share Dying Among Above Median Age Patients
57:1878:100740:12:524:144:428:682:135:g_d0_f31:135:g_d0_f31:Relative to the January 2005 ASP Implementation Date
57:1879:100822:524:0:113:475:158:50:g_d0_f31:50:g_d0_f31:-12-9-6-3036912-12-9-6-3036912
57:1880:100852:0:90:124:461:332:97:g_d0_f31:97:g_d0_f31:App Fig 7e. Death Within 3 MonthsApp Fig 7f. Death Within 6 Months
57:1881:100918:90:115:124:465:242:97:g_d0_f31:97:g_d0_f31:App Fig 7g. Death Within 9 MonthsApp Fig 7h. Death Within 12 Months
57:1882:100985:115:15:191:425:127:69:g_d0_f31:69:g_d0_f31:Reg-adjusted DifferenceLower Bound 95% CI
57:1883:101026:15:0:191:270:112:69:g_d0_f31:69:g_d0_f31:Upper Bound 95% CI
57:1884:101079:0:52:238:340:145:69:g_d0_f31:69:g_d0_f31:Month Relative to Jan 2005
57:1885:101105:52:0:96:160:93:69:g_d0_f31:69:g_d0_f31:Graphs by period
57:1886:101121:0:12:134:439:360:135:g_d0_f31:135:g_d0_f31:Change in Share Dying Among Below Median Age Patients
57:1887:101174:12:309:142:429:348:135:g_d0_f31:135:g_d0_f31:Relative to the  January 2005 ASP Implementation Date
58:1888:101227:309:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
58:1889:101227:0:316:495:498:410:122:g_d0_f54:122:g_d0_f54: 
58:1890:101227:316:0:495:498:94:122:g_d0_f54:122:g_d0_f54: 
58:1891:101249:0:0:113:475:492:50:g_d0_f57:50:g_d0_f57:-12-9-6-3036912-12-9-6-3036912
58:1892:101279:0:89:150:460:666:97:g_d0_f57:97:g_d0_f57:App Fig 8a. All SettingsApp Fig 8b. Excluding Carboplatin
58:1893:101336:89:114:136:436:577:97:g_d0_f57:97:g_d0_f57:App Fig 8c. Physician's OfficeApp Fig 8d. Outpatient
58:1894:101388:114:15:236:383:463:18:g_d0_f57:18:g_d0_f57:Reg-adjusted DifferenceLower Bound 95% CI
58:1895:101429:15:0:236:276:448:18:g_d0_f57:18:g_d0_f57:Upper Bound 95% CI
58:1896:101482:0:52:231:349:479:69:g_d0_f57:69:g_d0_f57:Month Relative to January 2005
58:1897:101512:52:0:96:161:427:69:g_d0_f57:69:g_d0_f57:Graphs by setting
58:1898:101529:0:12:103:469:694:135:g_d0_f57:135:g_d0_f57:Percent Change in Chemotherapy Service Count in High Concentration
58:1899:101595:12:506:119:452:682:135:g_d0_f57:135:g_d0_f57:Counties Relative to the January 2005 ASP Implementation Date
58:1900:101674:506:0:113:475:176:50:g_d0_f57:50:g_d0_f57:-12-9-6-3036912-12-9-6-3036912
58:1901:101704:0:89:150:458:350:97:g_d0_f57:97:g_d0_f57:App Fig 8e. All SettingsApp Fig 8f. Excluding Carboplatin
58:1902:101761:89:114:136:436:261:97:g_d0_f57:97:g_d0_f57:App Fig 8g. Physician's OfficeApp Fig 8h. Outpatient
58:1903:101813:114:15:236:383:147:18:g_d0_f57:18:g_d0_f57:Reg-adjusted DifferenceLower Bound 95% CI
58:1904:101854:15:0:236:276:132:18:g_d0_f57:18:g_d0_f57:Upper Bound 95% CI
58:1905:101907:0:51:231:349:163:69:g_d0_f57:69:g_d0_f57:Month Relative to January 2005
58:1906:101937:51:0:96:161:112:69:g_d0_f57:69:g_d0_f57:Graphs by setting
58:1907:101954:0:11:104:467:378:135:g_d0_f57:135:g_d0_f57:Percent Change in Chemotherapy Service Count in Low Concentration
58:1908:102019:11:328:119:452:367:135:g_d0_f57:135:g_d0_f57:Counties Relative to the January 2005 ASP Implementation Date
59:1909:102080:328:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
59:1910:102080:0:322:495:497:410:122:g_d0_f27:122:g_d0_f27: 
59:1911:102080:322:0:495:497:88:122:g_d0_f27:122:g_d0_f27: 
59:1912:102096:0:0:113:475:492:50:g_d0_f28:50:g_d0_f28:-12-9-6-3036912-12-9-6-3036912
59:1913:102126:0:89:150:460:666:97:g_d0_f28:97:g_d0_f28:App Fig 9a. All SettingsApp Fig 9b. Excluding Carboplatin
59:1914:102183:89:114:136:436:577:97:g_d0_f28:97:g_d0_f28:App Fig 9c. Physician's OfficeApp Fig 9d. Outpatient
59:1915:102235:114:15:236:383:463:18:g_d0_f28:18:g_d0_f28:Reg-adjusted DifferenceLower Bound 95% CI
59:1916:102276:15:0:236:276:448:18:g_d0_f28:18:g_d0_f28:Upper Bound 95% CI
59:1917:102329:0:52:231:349:479:69:g_d0_f28:69:g_d0_f28:Month Relative to January 2005
59:1918:102359:52:0:96:161:427:69:g_d0_f28:69:g_d0_f28:Graphs by setting
59:1919:102376:0:12:108:463:694:135:g_d0_f28:135:g_d0_f28:Change in Share Given Chemotherapy in Above Median Patients Per
59:1920:102439:12:512:99:473:682:135:g_d0_f28:135:g_d0_f28:Doctor Counties Relative to the January  2005 ASP Implementation Date
59:1921:102538:512:0:113:475:170:50:g_d0_f28:50:g_d0_f28:-12-9-6-3036912-12-9-6-3036912
59:1922:102568:0:89:150:459:344:97:g_d0_f28:97:g_d0_f28:App Fig 9e. All SettingsApp Fig 9f. Excluding Carboplatin
59:1923:102625:89:114:136:436:255:97:g_d0_f28:97:g_d0_f28:App Fig 9g. Physician's OfficeApp Fig 9h. Outpatient
59:1924:102677:114:15:236:383:141:18:g_d0_f28:18:g_d0_f28:Reg-adjusted DifferenceLower Bound 95% CI
59:1925:102718:15:0:236:276:126:18:g_d0_f28:18:g_d0_f28:Upper Bound 95% CI
59:1926:102771:0:51:231:349:157:69:g_d0_f28:69:g_d0_f28:Month Relative to January 2005
59:1927:102801:51:0:96:161:106:69:g_d0_f28:69:g_d0_f28:Graphs by setting
59:1928:102818:0:11:109:463:372:135:g_d0_f28:135:g_d0_f28:Change in Share Given Chemotherapy in Below Median Patients Per
59:1929:102881:11:322:99:473:361:135:g_d0_f28:135:g_d0_f28:Doctor Counties Relative to the January 2005  ASP Implementation Date
60:1930:102950:322:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
60:1931:102950:0:322:495:497:410:122:g_d0_f27:122:g_d0_f27: 
60:1932:102950:322:0:495:497:88:122:g_d0_f27:122:g_d0_f27: 
60:1933:102968:0:0:112:475:492:50:g_d0_f58:50:g_d0_f58:-12-9-6-3036912-12-9-6-3036912
60:1934:102998:0:89:147:463:666:97:g_d0_f58:97:g_d0_f58:App Fig 10a. All SettingsApp Fig 10b. Excluding Carboplatin
60:1935:103057:89:114:133:438:577:97:g_d0_f58:97:g_d0_f58:App Fig 10c. Physician's OfficeApp Fig 10d. Outpatient
60:1936:103111:114:15:235:383:463:18:g_d0_f58:18:g_d0_f58:Reg-adjusted DifferenceLower Bound 95% CI
60:1937:103152:15:0:235:275:448:18:g_d0_f58:18:g_d0_f58:Upper Bound 95% CI
60:1938:103205:0:52:231:349:479:69:g_d0_f58:69:g_d0_f58:Month Relative to January 2005
60:1939:103235:52:0:95:160:427:69:g_d0_f58:69:g_d0_f58:Graphs by setting
60:1940:103252:0:12:82:489:694:135:g_d0_f58:135:g_d0_f58:Percent Change in Chemotherapy Service Count in Above Median Patients Per
60:1941:103325:12:512:100:470:682:135:g_d0_f58:135:g_d0_f58:Doctor Counties Relative to the January 2005 ASP Implementation Date
60:1942:103411:512:0:112:475:170:50:g_d0_f58:50:g_d0_f58:-12-9-6-3036912-12-9-6-3036912
60:1943:103441:0:89:147:462:344:97:g_d0_f58:97:g_d0_f58:App Fig 10e. All SettingsApp Fig 10f. Excluding Carboplatin
60:1944:103500:89:114:132:438:255:97:g_d0_f58:97:g_d0_f58:App Fig 10g. Physician's OfficeApp Fig 10h. Outpatient
60:1945:103554:114:15:235:383:141:18:g_d0_f58:18:g_d0_f58:Reg-adjusted DifferenceLower Bound 95% CI
60:1946:103595:15:0:235:275:126:18:g_d0_f58:18:g_d0_f58:Upper Bound 95% CI
60:1947:103648:0:51:231:349:157:69:g_d0_f58:69:g_d0_f58:Month Relative to January 2005
60:1948:103678:51:0:95:160:106:69:g_d0_f58:69:g_d0_f58:Graphs by setting
60:1949:103695:0:11:82:487:372:135:g_d0_f58:135:g_d0_f58:Percent Change in Chemotherapy Service Count in Below Median Patients Per
60:1950:103768:11:322:100:470:361:135:g_d0_f58:135:g_d0_f58:Doctor Counties Relative to the January 2005 ASP Implementation Date
61:1951:103836:322:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
61:1952:103836:0:322:495:497:410:122:g_d0_f27:122:g_d0_f27: 
61:1953:103836:322:0:495:642:88:122:g_d0_f54:122:g_d0_f54:  
61:1954:103852:0:0:113:475:492:50:g_d0_f59:50:g_d0_f59:-12-9-6-3036912-12-9-6-3036912
61:1955:103882:0:89:121:465:666:97:g_d0_f59:97:g_d0_f59:App Fig 11a. Death Within 3 MonthsApp Fig 11b. Death Within 6 Months
61:1956:103950:89:116:122:468:577:97:g_d0_f59:97:g_d0_f59:App Fig 11c. Death Within 9 MonthsApp Fig 11d. Death Within 12 Months
61:1957:104019:116:15:191:425:461:69:g_d0_f59:69:g_d0_f59:Reg-adjusted DifferenceLower Bound 95% CI
61:1958:104060:15:0:191:270:446:69:g_d0_f59:69:g_d0_f59:Upper Bound 95% CI
61:1959:104113:0:52:238:340:479:69:g_d0_f59:69:g_d0_f59:Month Relative to Jan 2005
61:1960:104139:52:0:96:160:427:69:g_d0_f59:69:g_d0_f59:Graphs by period
61:1961:104155:0:12:148:423:694:135:g_d0_f59:135:g_d0_f59:Change in Share Dying in Above Median Patients Per
61:1962:104205:12:512:99:473:682:135:g_d0_f59:135:g_d0_f59:Doctor Counties Relative to the  January 2005 ASP Implementation Date
61:1963:104304:512:0:113:475:170:50:g_d0_f59:50:g_d0_f59:-12-9-6-3036912-12-9-6-3036912
61:1964:104334:0:89:122:464:344:97:g_d0_f59:97:g_d0_f59:App Fig 11e. Death Within 3 MonthsApp Fig 11f. Death Within 6 Months
61:1965:104402:89:116:122:468:255:97:g_d0_f59:97:g_d0_f59:App Fig 11g. Death Within 9 MonthsApp Fig 11h. Death Within 12 Months
61:1966:104471:116:14:191:425:139:69:g_d0_f59:69:g_d0_f59:Reg-adjusted DifferenceLower Bound 95% CI
61:1967:104512:14:0:191:270:125:69:g_d0_f59:69:g_d0_f59:Upper Bound 95% CI
61:1968:104565:0:51:238:340:157:69:g_d0_f59:69:g_d0_f59:Month Relative to Jan 2005
61:1969:104591:51:0:96:160:106:69:g_d0_f59:69:g_d0_f59:Graphs by period
61:1970:104607:0:11:149:423:372:135:g_d0_f59:135:g_d0_f59:Change in Share Dying in Below Median Patients Per
61:1971:104657:11:322:100:470:361:135:g_d0_f59:135:g_d0_f59:Doctor Counties Relative to the January 2005 ASP Implementation Date
62:1972:104725:322:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
62:1973:104725:0:21:72:498:710:122:g_d0_f60:122:g_d0_f60:Appendix Table1. Discontinuity in Observable Characteristics of Patients, Pre and Post Reform  
62:1974:104820:21:12:179:366:689:122:g_d0_f60:122:g_d0_f60: Mean Before 
62:1975:104832:12:0:320:352:677:122:g_d0_f60:122:g_d0_f60:Jan/05 
62:1976:104838:0:12:403:439:689:122:g_d0_f60:122:g_d0_f60:Feb/04  
62:1977:104845:12:0:399:444:677:122:g_d0_f61:122:g_d0_f60:–Nov/05  
62:1978:104853:0:12:487:524:689:122:g_d0_f60:122:g_d0_f60:Apr/04  
62:1979:104860:12:25:483:525:677:122:g_d0_f61:122:g_d0_f60:–Sept/05 
62:1980:104868:25:13:72:437:652:122:g_d0_f60:122:g_d0_f60:Log Age at Diagnosis  74.1  0.0096 
62:1981:104900:13:0:400:440:639:122:g_d0_f60:122:g_d0_f60:(0.0008) 
62:1982:104908:0:13:489:520:652:122:g_d0_f60:122:g_d0_f60: 0.010 
62:1983:104913:13:25:487:522:639:122:g_d0_f60:122:g_d0_f60:(0.001) 
62:1984:104920:25:12:72:447:614:122:g_d0_f60:122:g_d0_f60:Share Male  0.516 -2.76X10-18 
62:1985:104947:12:0:391:449:602:122:g_d0_f60:122:g_d0_f60:(5.47X10-17) 
62:1986:104959:0:12:477:532:614:122:g_d0_f60:122:g_d0_f60:-7.78X10-18 
62:1987:104970:12:25:476:533:602:122:g_d0_f60:122:g_d0_f60:(3.56X10-17) 
62:1988:104982:25:12:72:211:577:122:g_d0_f60:122:g_d0_f60:Distribution by Race/ethnicity  
62:1989:105013:12:0:72:110:565:122:g_d0_f60:122:g_d0_f60:  White  
62:1990:105021:0:12:322:439:577:122:g_d0_f60:122:g_d0_f60:0.875 -0.0030 
62:1991:105033:12:0:400:440:565:122:g_d0_f60:122:g_d0_f60:(0.0032) 
62:1992:105041:0:12:486:523:577:122:g_d0_f60:122:g_d0_f60:-0.0010 
62:1993:105048:12:25:484:525:565:122:g_d0_f60:122:g_d0_f60:(0.0024) 
62:1994:105056:25:13:72:437:540:122:g_d0_f60:122:g_d0_f60:  African-American 0.091 0.0026 
62:1995:105085:13:0:400:440:527:122:g_d0_f60:122:g_d0_f60:(0.0031) 
62:1996:105093:0:13:488:521:540:122:g_d0_f60:122:g_d0_f60:0.0013 
62:1997:105099:13:24:484:525:527:122:g_d0_f60:122:g_d0_f60:(0.0023) 
62:1998:105107:24:13:72:437:503:122:g_d0_f60:122:g_d0_f60:  Asian 0.0108 0.0010 
62:1999:105126:13:0:400:440:490:122:g_d0_f60:122:g_d0_f60:(0.0062) 
62:2000:105134:0:13:488:521:503:122:g_d0_f60:122:g_d0_f60:0.0003 
62:2001:105140:13:24:484:525:490:122:g_d0_f60:122:g_d0_f60:(0.0007) 
62:2002:105148:24:13:72:436:466:122:g_d0_f60:122:g_d0_f60:  Other/Unknown 0.009 -.0007 
62:2003:105174:13:0:400:440:453:122:g_d0_f60:122:g_d0_f60:(0.0003) 
62:2004:105182:0:13:486:523:466:122:g_d0_f60:122:g_d0_f60:-.00082 
62:2005:105189:13:25:481:527:453:122:g_d0_f60:122:g_d0_f60:(0.00046) 
62:2006:105198:25:12:72:437:428:122:g_d0_f60:122:g_d0_f60:  Hispanic   0.0103 0.0002 
62:2007:105221:12:0:400:440:416:122:g_d0_f60:122:g_d0_f60:(0.0004) 
62:2008:105229:0:12:486:522:428:122:g_d0_f60:122:g_d0_f60: 0.0008 
62:2009:105235:12:25:484:525:416:122:g_d0_f60:122:g_d0_f60:(0.0005) 
62:2010:105243:25:12:72:439:391:122:g_d0_f60:122:g_d0_f60: Native American 0.0038 -0.0002 
62:2011:105271:12:0:400:440:379:122:g_d0_f60:122:g_d0_f60:(0.0004) 
62:2012:105279:0:12:483:526:391:122:g_d0_f60:122:g_d0_f60:-0.00082 
62:2013:105287:12:25:481:527:379:122:g_d0_f60:122:g_d0_f60:(0.00034) 
62:2014:105296:25:13:72:178:354:122:g_d0_f60:122:g_d0_f60:Metastatic at Diagnosis 
62:2015:105319:13:0:72:75:341:122:g_d0_f60:122:g_d0_f60: 
62:2016:105319:0:13:322:447:354:122:g_d0_f60:122:g_d0_f60:0.289 -9.86X10-18 
62:2017:105335:13:0:391:449:341:122:g_d0_f60:122:g_d0_f60:(2.09X10-17) 
62:2018:105347:0:13:479:530:354:122:g_d0_f60:122:g_d0_f60:1.12X10-18 
62:2019:105357:13:24:476:533:341:122:g_d0_f60:122:g_d0_f60:(3.04X10-17) 
62:2020:105369:24:13:72:436:317:122:g_d0_f60:122:g_d0_f60:Deyo-Charlson Score  1.06 -0.006 
62:2021:105399:13:0:402:440:304:122:g_d0_f60:122:g_d0_f60:(0.010)  
62:2022:105407:0:13:489:520:317:122:g_d0_f60:122:g_d0_f60:-0.016 
62:2023:105413:13:24:487:522:304:122:g_d0_f60:122:g_d0_f60:(0.013) 
62:2024:105420:24:12:72:511:280:122:g_d0_f60:122:g_d0_f60:Number of Observations (weeks) 48 96 72 
62:2025:105456:12:10:72:528:268:81:g_d0_f60:81:g_d0_f60:Notes: Means in column 1 are for the dependent variable for the period before ASP implementation. All cells in columns 2 - 3 
62:2026:105581:10:11:72:538:258:81:g_d0_f60:81:g_d0_f60:present estimates from separate time-series regressions. Estimates are the coefficients on an indicator for the period that the ASP 
62:2027:105713:11:10:72:542:247:81:g_d0_f60:81:g_d0_f60:payment scheme was in effect. Regressions control for other mean patient characteristics (see Table 1), i.e. except the one used as 
62:2028:105845:10:10:72:527:237:81:g_d0_f60:81:g_d0_f60:the dependent variable or any race variables when any race category is a dependent variable, and relative-week trends that are 
62:2029:105972:10:11:72:533:227:81:g_d0_f60:81:g_d0_f60:allowed to differ on either side of the payment change. Newey-West standard errors allowing for autocorrelation up to 52-week 
62:2030:106098:11:12:72:182:216:81:g_d0_f60:81:g_d0_f60:lags are given in parentheses.  
62:2031:106130:12:24:72:75:204:122:g_d0_f62:122:g_d0_f62: 
62:2032:106130:24:25:72:75:180:122:g_d0_f62:122:g_d0_f62: 
62:2033:106130:25:25:72:75:155:122:g_d0_f62:122:g_d0_f62: 
62:2034:106130:25:24:72:75:130:122:g_d0_f62:122:g_d0_f62: 
62:2035:106130:24:25:72:75:106:122:g_d0_f62:122:g_d0_f62: 
62:2036:106130:25:42:72:75:81:122:g_d0_f62:122:g_d0_f62: 
63:2037:106130:42:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
63:2038:106130:0:13:72:539:710:122:g_d0_f63:122:g_d0_f63:Appendix Table 2. Specification Checks of Reform-related changes in Chemotherapy Treatment within 1 
63:2039:106230:13:20:72:166:697:122:g_d0_f63:122:g_d0_f63:months of Diagnosis 
63:2040:106250:20:13:72:540:677:122:g_d0_f62:122:g_d0_f63: Relative month trends Calendar month fixed effects 
63:2041:106299:13:13:72:310:664:122:g_d0_f63:122:g_d0_f63: Feb/04 
63:2042:106305:13:0:273:314:651:122:g_d0_f64:122:g_d0_f62:–Nov/05 
63:2043:106312:0:13:349:383:664:122:g_d0_f63:122:g_d0_f63:Apr/04 
63:2044:106318:13:0:345:387:651:122:g_d0_f64:122:g_d0_f62:–Sept/05 
63:2045:106326:0:13:421:455:664:122:g_d0_f63:122:g_d0_f63:Feb/04 
63:2046:106332:13:0:417:459:651:122:g_d0_f64:122:g_d0_f62:–Nov/05 
63:2047:106339:0:13:493:527:664:122:g_d0_f63:122:g_d0_f63:Apr/04 
63:2048:106345:13:13:489:531:651:122:g_d0_f64:122:g_d0_f62:–Sept/05 
63:2049:106353:13:13:72:310:638:122:g_d0_f63:122:g_d0_f63:  within 1 month of Diagnosis  0.0150 
63:2050:106389:13:0:276:311:625:122:g_d0_f63:122:g_d0_f63:(0.003) 
63:2051:106396:0:13:349:382:638:122:g_d0_f63:122:g_d0_f63:0.0134 
63:2052:106402:13:0:348:383:625:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2053:106409:0:13:421:455:638:122:g_d0_f63:122:g_d0_f63:0.0175 
63:2054:106415:13:0:421:456:625:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2055:106422:0:13:497:524:638:122:g_d0_f63:122:g_d0_f63:.0183 
63:2056:106427:13:13:493:528:625:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2057:106434:13:12:509:512:612:122:g_d0_f63:122:g_d0_f63: 
63:2058:106434:12:13:72:181:600:122:g_d0_f63:122:g_d0_f63:  excluding carboplatin   
63:2059:106459:13:0:72:77:587:122:g_d0_f63:122:g_d0_f62:  
63:2060:106459:0:13:277:310:600:122:g_d0_f63:122:g_d0_f63:0.0140 
63:2061:106465:13:0:276:311:587:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2062:106472:0:13:352:380:600:122:g_d0_f63:122:g_d0_f63:.0121 
63:2063:106477:13:0:348:383:587:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2064:106484:0:13:424:452:600:122:g_d0_f63:122:g_d0_f63:.0126 
63:2065:106489:13:0:421:456:587:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2066:106496:0:13:497:524:600:122:g_d0_f63:122:g_d0_f63:.0126 
63:2067:106501:13:12:493:528:587:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2068:106508:12:13:509:512:575:122:g_d0_f63:122:g_d0_f63: 
63:2069:106508:13:13:72:183:562:122:g_d0_f63:122:g_d0_f63:  in  a  Physician’s  Office   
63:2070:106538:13:0:72:77:549:122:g_d0_f63:122:g_d0_f62:  
63:2071:106538:0:13:277:310:562:122:g_d0_f63:122:g_d0_f63:0.0166 
63:2072:106544:13:0:276:311:549:122:g_d0_f63:122:g_d0_f63:(0.003) 
63:2073:106551:0:13:349:382:562:122:g_d0_f63:122:g_d0_f63:0.0154 
63:2074:106557:13:0:348:383:549:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2075:106564:0:13:421:455:562:122:g_d0_f63:122:g_d0_f63:0.0181 
63:2076:106570:13:0:421:456:549:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2077:106577:0:13:497:524:562:122:g_d0_f63:122:g_d0_f63:0.017 
63:2078:106582:13:12:493:528:549:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2079:106589:12:13:509:512:537:122:g_d0_f63:122:g_d0_f63: 
63:2080:106589:13:13:72:309:524:122:g_d0_f63:122:g_d0_f63:  in an outpatient hospital clinic -0.001 
63:2081:106629:13:0:276:311:511:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2082:106636:0:13:350:382:524:122:g_d0_f63:122:g_d0_f63:-0.001 
63:2083:106642:13:0:348:383:511:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2084:106649:0:13:424:452:524:122:g_d0_f63:122:g_d0_f63:0.002 
63:2085:106654:13:0:421:456:511:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2086:106661:0:13:497:524:524:122:g_d0_f63:122:g_d0_f63:0.002 
63:2087:106666:13:12:493:528:511:122:g_d0_f63:122:g_d0_f63:(0.001) 
63:2088:106673:12:13:509:512:499:122:g_d0_f63:122:g_d0_f63: 
63:2089:106673:13:11:72:517:486:122:g_d0_f63:122:g_d0_f63:Number of Observations (weeks) 96 72 96 72 
63:2090:106711:11:11:72:518:475:81:g_d0_f63:81:g_d0_f63:Notes: Each cell is based on a separate regression. Estimates are the coefficients on an indicator for the period that the ASP 
63:2091:106838:11:10:72:521:464:81:g_d0_f63:81:g_d0_f63:payment scheme was in effect. Regressions control for other mean patient characteristics (see Table 1). Columns (1) and (2) 
63:2092:106962:10:10:72:523:454:81:g_d0_f63:81:g_d0_f63:include relative-month trends that are allowed to differ on either side of the payment change and columns (3) and (4) include 
63:2093:107088:10:11:72:503:444:81:g_d0_f63:81:g_d0_f63:calendar month fixed effects. Newey-West standard errors allowing for autocorrelation up to 52-week lags are given in 
63:2094:107206:11:12:72:121:433:81:g_d0_f63:81:g_d0_f63:parentheses.  
63:2095:107220:12:24:72:75:421:122:g_d0_f62:122:g_d0_f62: 
63:2096:107220:24:13:72:528:397:122:g_d0_f63:122:g_d0_f63:Appendix Table 3. Specification Check of Percent Change in Chemotherapy Treatment Service Counts 
63:2097:107315:13:20:72:386:384:122:g_d0_f63:122:g_d0_f62:Within 1 Month of Diagnosis After the January 2005 Payment Change 
63:2098:107380:20:13:72:250:364:122:g_d0_f62:122:g_d0_f63:  
63:2099:107380:13:0:234:262:351:122:g_d0_f63:122:g_d0_f63:Mean 
63:2100:107384:0:13:298:530:364:122:g_d0_f63:122:g_d0_f63:Relative month trends Calendar month fixed 
63:2101:107426:13:13:464:496:351:122:g_d0_f63:122:g_d0_f63:effects 
63:2102:107433:13:13:479:482:338:122:g_d0_f63:122:g_d0_f63: 
63:2103:107433:13:12:72:328:325:122:g_d0_f63:122:g_d0_f63: within 1 month  1.00 0.342 
63:2104:107457:12:0:297:332:313:122:g_d0_f63:122:g_d0_f63:(0.047) 
63:2105:107464:0:12:368:393:325:122:g_d0_f63:122:g_d0_f63:0328 
63:2106:107468:12:0:363:398:313:122:g_d0_f63:122:g_d0_f63:(0.046) 
63:2107:107475:0:12:433:461:325:122:g_d0_f63:122:g_d0_f63:0.445 
63:2108:107480:12:0:430:465:313:122:g_d0_f63:122:g_d0_f63:(0.009) 
63:2109:107487:0:12:502:524:325:122:g_d0_f63:122:g_d0_f63:.439 
63:2110:107491:12:13:496:531:313:122:g_d0_f63:122:g_d0_f63:(0.013) 
63:2111:107498:13:13:512:515:300:122:g_d0_f63:122:g_d0_f63: 
63:2112:107498:13:13:72:181:287:122:g_d0_f63:122:g_d0_f63:  excluding carboplatin   
63:2113:107523:13:0:72:77:274:122:g_d0_f63:122:g_d0_f62:  
63:2114:107523:0:12:234:328:287:122:g_d0_f63:122:g_d0_f63:0.304 0.206 
63:2115:107533:12:0:297:332:275:122:g_d0_f63:122:g_d0_f63:(0.024) 
63:2116:107540:0:12:367:395:287:122:g_d0_f63:122:g_d0_f63:0.208 
63:2117:107545:12:0:363:398:275:122:g_d0_f63:122:g_d0_f63:(0.022) 
63:2118:107552:0:12:435:460:287:122:g_d0_f63:122:g_d0_f63:0238 
63:2119:107556:12:0:430:465:275:122:g_d0_f63:122:g_d0_f63:(0.006) 
63:2120:107563:0:12:500:527:287:122:g_d0_f63:122:g_d0_f63:0.214 
63:2121:107568:12:13:496:531:275:122:g_d0_f63:122:g_d0_f63:(0.007) 
63:2122:107575:13:13:512:515:262:122:g_d0_f63:122:g_d0_f63: 
63:2123:107575:13:13:72:183:249:122:g_d0_f63:122:g_d0_f63:  in  a  Physician’s  Office   
63:2124:107605:13:0:72:77:236:122:g_d0_f63:122:g_d0_f62:  
63:2125:107605:0:12:234:328:249:122:g_d0_f63:122:g_d0_f63:0.916 0.350 
63:2126:107615:12:0:297:332:237:122:g_d0_f63:122:g_d0_f63:(0.048) 
63:2127:107622:0:12:367:395:249:122:g_d0_f63:122:g_d0_f63:0.338 
63:2128:107627:12:13:363:398:237:122:g_d0_f63:122:g_d0_f63:(0.048) 
63:2129:107634:13:0:379:382:224:122:g_d0_f63:122:g_d0_f63: 
63:2130:107634:0:12:433:461:249:122:g_d0_f63:122:g_d0_f63:0.445 
63:2131:107639:12:0:431:463:237:122:g_d0_f63:122:g_d0_f63:(0.009 
63:2132:107645:0:12:500:527:249:122:g_d0_f63:122:g_d0_f63:0.435 
63:2133:107650:12:13:496:531:237:122:g_d0_f63:122:g_d0_f63:(0.014) 
63:2134:107657:13:13:512:515:224:122:g_d0_f63:122:g_d0_f63: 
63:2135:107657:13:12:72:186:211:122:g_d0_f63:122:g_d0_f63:  in an outpatient hospital 
63:2136:107685:12:0:72:99:199:122:g_d0_f63:122:g_d0_f62:clinic 
63:2137:107691:0:12:234:328:211:122:g_d0_f63:122:g_d0_f63:0.087 0.013 
63:2138:107701:12:0:297:332:199:122:g_d0_f63:122:g_d0_f63:(0.003) 
63:2139:107708:0:12:367:395:211:122:g_d0_f63:122:g_d0_f63:0.012 
63:2140:107713:12:0:363:398:199:122:g_d0_f63:122:g_d0_f63:(0.005) 
63:2141:107720:0:12:433:461:211:122:g_d0_f63:122:g_d0_f63:0.036 
63:2142:107725:12:0:430:465:199:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2143:107732:0:12:500:527:211:122:g_d0_f63:122:g_d0_f63:0.040 
63:2144:107737:12:13:496:531:199:122:g_d0_f63:122:g_d0_f63:(0.002) 
63:2145:107744:13:13:512:515:186:122:g_d0_f63:122:g_d0_f63: 
63:2146:107744:13:11:72:520:173:122:g_d0_f63:122:g_d0_f63:Number of Obs (weeks) 96 72 96 72 
63:2147:107773:11:11:72:518:162:81:g_d0_f63:81:g_d0_f63:Notes: Each cell is based on a separate regression. Estimates are the coefficients on an indicator for the period that the ASP 
63:2148:107900:11:10:72:537:151:81:g_d0_f63:81:g_d0_f63:payment scheme was in effect. Regressions control for other mean patient characteristics (see Table 1). Means in column (1) are 
63:2149:108028:10:10:72:537:141:81:g_d0_f63:81:g_d0_f63:for the dependent variable for the period before ASP implementation. Columns (2) and (3) include relative-month trends that are 
63:2150:108156:10:11:72:522:131:81:g_d0_f63:81:g_d0_f63:allowed to differ on either side of the payment change and columns (4) and (5) include calendar month fixed effects. Newey-
63:2151:108279:11:11:72:416:120:81:g_d0_f63:81:g_d0_f63:West standard errors allowing for autocorrelation up to 52-week lags are given in parentheses.  
63:2152:108375:11:11:72:74:109:99:g_d0_f63:99:g_d0_f63: 
63:2153:108375:11:12:72:74:98:99:g_d0_f63:99:g_d0_f63: 
63:2154:108375:12:47:72:74:86:99:g_d0_f63:99:g_d0_f63: 
64:2155:108375:47:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
64:2156:108375:0:13:72:540:710:122:g_d0_f65:122:g_d0_f65:Appendix Table 4. Changes in Chemotherapy Treatment Within 3 Months of Diagnosis After the January 
64:2157:108474:13:20:72:322:697:122:g_d0_f65:122:g_d0_f62:2005 Payment Change: February 2004- November 2005 
64:2158:108523:20:13:72:211:677:122:g_d0_f62:122:g_d0_f65:  
64:2159:108523:13:0:195:223:664:122:g_d0_f65:122:g_d0_f65:Mean 
64:2160:108527:0:13:254:320:677:122:g_d0_f65:122:g_d0_f65:Relative week 
64:2161:108540:13:0:271:303:664:122:g_d0_f65:122:g_d0_f65: trends 
64:2162:108546:0:13:355:425:677:122:g_d0_f65:122:g_d0_f65:Relative month 
64:2163:108561:13:0:376:406:664:122:g_d0_f65:122:g_d0_f65:trends 
64:2164:108567:0:13:458:531:677:122:g_d0_f65:122:g_d0_f65:Calendar month 
64:2165:108582:13:13:466:523:664:122:g_d0_f65:122:g_d0_f65:fixed effects 
64:2166:108595:13:13:493:496:651:122:g_d0_f65:122:g_d0_f65: 
64:2167:108595:13:12:72:275:638:122:g_d0_f65:122:g_d0_f65: within 3 months  0.263 0.007 
64:2168:108621:12:0:241:281:626:122:g_d0_f65:122:g_d0_f65:(0.0037) 
64:2169:108629:0:12:299:327:638:122:g_d0_f65:122:g_d0_f65:0.029 
64:2170:108634:12:0:295:330:626:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2171:108641:0:12:351:379:638:122:g_d0_f65:122:g_d0_f65:0.007 
64:2172:108646:12:0:345:385:626:122:g_d0_f65:122:g_d0_f65:(0.0040) 
64:2173:108654:0:12:403:430:638:122:g_d0_f65:122:g_d0_f65:0.029 
64:2174:108659:12:0:399:434:626:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2175:108666:0:12:455:482:638:122:g_d0_f65:122:g_d0_f65:0.031 
64:2176:108671:12:0:451:486:626:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2177:108678:0:12:509:532:638:122:g_d0_f65:122:g_d0_f65:.035 
64:2178:108682:12:13:503:538:626:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2179:108689:13:13:519:522:613:122:g_d0_f65:122:g_d0_f65: 
64:2180:108689:13:13:72:181:600:122:g_d0_f65:122:g_d0_f65:  excluding carboplatin   
64:2181:108714:13:0:72:77:587:122:g_d0_f65:122:g_d0_f62:  
64:2182:108714:0:12:195:275:600:122:g_d0_f65:122:g_d0_f65:0.093 0.015 
64:2183:108724:12:0:244:279:588:122:g_d0_f65:122:g_d0_f65:(0.002) 
64:2184:108731:0:12:299:327:600:122:g_d0_f65:122:g_d0_f65:0.023 
64:2185:108736:12:0:295:330:588:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2186:108743:0:12:351:379:600:122:g_d0_f65:122:g_d0_f65:0.015 
64:2187:108748:12:0:347:382:588:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2188:108755:0:12:403:430:600:122:g_d0_f65:122:g_d0_f65:0.023 
64:2189:108760:12:0:399:434:588:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2190:108767:0:12:455:482:600:122:g_d0_f65:122:g_d0_f65:0.019 
64:2191:108772:12:0:451:486:588:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2192:108779:0:12:507:534:600:122:g_d0_f65:122:g_d0_f65:0.020 
64:2193:108784:12:13:503:538:588:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2194:108791:13:13:72:149:575:122:g_d0_f65:122:g_d0_f66:  in  a  Physician’s  
64:2195:108813:13:13:72:105:562:122:g_d0_f65:122:g_d0_f65:Office  
64:2196:108820:13:0:72:77:549:122:g_d0_f65:122:g_d0_f62:  
64:2197:108820:0:13:195:275:575:122:g_d0_f65:122:g_d0_f65:0.212 0.014 
64:2198:108830:13:0:244:279:562:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2199:108837:0:13:299:327:575:122:g_d0_f65:122:g_d0_f65:0.031 
64:2200:108842:13:12:295:330:562:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2201:108849:12:0:311:314:550:122:g_d0_f65:122:g_d0_f65: 
64:2202:108849:0:13:351:379:575:122:g_d0_f65:122:g_d0_f65:0.014 
64:2203:108854:13:0:347:382:562:122:g_d0_f65:122:g_d0_f65:(0.004) 
64:2204:108861:0:13:403:430:575:122:g_d0_f65:122:g_d0_f65:0.031 
64:2205:108866:13:12:399:434:562:122:g_d0_f65:122:g_d0_f65:(0.003) 
64:2206:108873:12:0:415:418:550:122:g_d0_f65:122:g_d0_f65: 
64:2207:108873:0:13:455:482:575:122:g_d0_f65:122:g_d0_f65:0.031 
64:2208:108878:13:0:451:486:562:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2209:108885:0:13:507:534:575:122:g_d0_f65:122:g_d0_f65:0.035 
64:2210:108890:13:12:503:538:562:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2211:108897:12:13:519:522:550:122:g_d0_f65:122:g_d0_f65: 
64:2212:108897:13:13:72:148:537:122:g_d0_f65:122:g_d0_f65:  in an outpatient 
64:2213:108916:13:0:72:137:524:122:g_d0_f65:122:g_d0_f62:hospital clinic 
64:2214:108931:0:13:195:275:537:122:g_d0_f65:122:g_d0_f65:0.066 -0.007 
64:2215:108943:13:0:244:279:524:122:g_d0_f65:122:g_d0_f65:(0.002) 
64:2216:108951:0:15:301:304:537:122:g_d0_f65:122:g_d0_f65: 
64:2217:108951:15:0:239:239:522:0:g_d0_f65:0:g_d0_f65: 
64:2218:108951:0:13:294:331:537:122:g_d0_f65:122:g_d0_f65:-0.0004 
64:2219:108958:13:0:295:330:524:122:g_d0_f65:122:g_d0_f65:(0.002) 
64:2220:108965:0:13:349:381:537:122:g_d0_f65:122:g_d0_f65:-0.007 
64:2221:108971:13:0:347:382:524:122:g_d0_f65:122:g_d0_f65:(0.002) 
64:2222:108978:0:13:398:435:537:122:g_d0_f65:122:g_d0_f65:-0.0004 
64:2223:108985:13:0:399:434:524:122:g_d0_f65:122:g_d0_f65:(0.002) 
64:2224:108992:0:13:455:482:537:122:g_d0_f65:122:g_d0_f65:0.004 
64:2225:108997:13:0:451:486:524:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2226:109004:0:13:507:534:537:122:g_d0_f65:122:g_d0_f65:0.004 
64:2227:109009:13:12:503:538:524:122:g_d0_f65:122:g_d0_f65:(0.001) 
64:2228:109016:12:13:519:522:512:122:g_d0_f65:122:g_d0_f65: 
64:2229:109016:13:13:78:526:499:122:g_d0_f65:122:g_d0_f65:Quarter prior to reform indicator N Y N Y N Y 
64:2230:109056:13:11:72:527:486:122:g_d0_f65:122:g_d0_f65:Number of Obs (weeks) 96 96 96 96 96 96 
64:2231:109090:11:11:72:528:475:81:g_d0_f65:81:g_d0_f65:Notes: Means in column 1 are for the dependent variable for the period before ASP implementation. All cells in columns 2 - 7 
64:2232:109215:11:10:72:538:464:81:g_d0_f65:81:g_d0_f65:present estimates from separate time-series regressions. Estimates are the coefficients on an indicator for the period that the ASP 
64:2233:109347:10:10:72:529:454:81:g_d0_f65:81:g_d0_f65:payment scheme was in effect. Regressions control for mean patient characteristics (see Table 1). Columns (2) and (3) include 
64:2234:109473:10:11:72:511:444:81:g_d0_f65:81:g_d0_f65:relative-week trends and (4) and (5) relative-month trends that are allowed to differ on either side of the payment change. 
64:2235:109597:11:10:72:524:433:81:g_d0_f65:81:g_d0_f65:Columns (6) and (7) include calendar month fixed effects. Newey-West standard errors allowing for autocorrelation up to 52-
64:2236:109720:10:13:72:204:423:81:g_d0_f65:81:g_d0_f65:week lags are given in parentheses.  
64:2237:109757:13:24:72:75:410:122:g_d0_f62:122:g_d0_f62: 
64:2238:109757:24:25:72:75:386:122:g_d0_f62:122:g_d0_f62: 
64:2239:109757:25:24:72:75:361:122:g_d0_f62:122:g_d0_f62: 
64:2240:109757:24:25:72:75:337:122:g_d0_f62:122:g_d0_f62: 
64:2241:109757:25:24:72:75:312:122:g_d0_f62:122:g_d0_f62: 
64:2242:109757:24:25:72:75:288:122:g_d0_f62:122:g_d0_f62: 
64:2243:109757:25:24:72:75:263:122:g_d0_f62:122:g_d0_f62: 
64:2244:109757:24:25:72:75:239:122:g_d0_f62:122:g_d0_f62: 
64:2245:109757:25:24:72:75:214:122:g_d0_f62:122:g_d0_f62: 
64:2246:109757:24:25:72:75:190:122:g_d0_f62:122:g_d0_f62: 
64:2247:109757:25:25:72:75:165:122:g_d0_f62:122:g_d0_f62: 
64:2248:109757:25:24:72:75:140:122:g_d0_f62:122:g_d0_f62: 
64:2249:109757:24:25:72:75:116:122:g_d0_f62:122:g_d0_f62: 
64:2250:109757:25:52:72:75:91:122:g_d0_f62:122:g_d0_f62: 
65:2251:109757:52:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
65:2252:109757:0:13:72:521:710:122:g_d0_f67:122:g_d0_f67:Appendix Table 5. Specification Checks of Reform-related changes in Chemotherapy Types within 1 
65:2253:109852:13:14:72:314:697:122:g_d0_f67:122:g_d0_f67:months of Diagnosis: February 2004- November 2005 
65:2254:109902:14:13:72:297:683:122:g_d0_f62:122:g_d0_f67: Relative week 
65:2255:109915:13:0:247:280:670:122:g_d0_f67:122:g_d0_f67: trends 
65:2256:109921:0:13:327:539:683:122:g_d0_f67:122:g_d0_f67:Relative month trends Calendar month fixed 
65:2257:109963:13:13:474:506:670:122:g_d0_f67:122:g_d0_f67:effects 
65:2258:109970:13:13:72:314:657:122:g_d0_f68:122:g_d0_f67:Share  of  Chemotherapy  Treated  Patients  Receiving...   
65:2259:110028:13:12:72:75:644:122:g_d0_f67:122:g_d0_f67: 
65:2260:110028:12:13:72:132:632:122:g_d0_f67:122:g_d0_f67:  carboplatin  
65:2261:110042:13:0:72:75:619:122:g_d0_f67:122:g_d0_f67: 
65:2262:110042:0:13:220:251:632:122:g_d0_f67:122:g_d0_f67:-0.039 
65:2263:110048:13:0:218:253:619:122:g_d0_f67:122:g_d0_f67:(0.008) 
65:2264:110055:0:13:276:308:632:122:g_d0_f67:122:g_d0_f67:-0.047 
65:2265:110061:13:0:274:310:619:122:g_d0_f67:122:g_d0_f67:(0.012) 
65:2266:110068:0:13:333:364:632:122:g_d0_f67:122:g_d0_f67:-0.038 
65:2267:110074:13:0:331:366:619:122:g_d0_f67:122:g_d0_f67:(0.008) 
65:2268:110081:0:13:389:421:632:122:g_d0_f67:122:g_d0_f67:-0.046 
65:2269:110087:13:25:388:423:619:122:g_d0_f67:122:g_d0_f67:(0.013) 
65:2270:110094:25:0:404:407:594:122:g_d0_f67:122:g_d0_f67: 
65:2271:110094:0:13:446:477:632:122:g_d0_f67:122:g_d0_f67:-0.019 
65:2272:110100:13:0:444:479:619:122:g_d0_f67:122:g_d0_f67:(0.005) 
65:2273:110107:0:13:503:534:632:122:g_d0_f67:122:g_d0_f67:-0.029 
65:2274:110113:13:25:501:536:619:122:g_d0_f67:122:g_d0_f67:(0.005) 
65:2275:110120:25:12:517:520:594:122:g_d0_f67:122:g_d0_f67: 
65:2276:110120:12:13:72:123:582:122:g_d0_f67:122:g_d0_f67:  paclitaxel 
65:2277:110132:13:0:72:75:569:122:g_d0_f67:122:g_d0_f67: 
65:2278:110132:0:13:220:251:582:122:g_d0_f67:122:g_d0_f67:-0.074 
65:2279:110138:13:0:218:253:569:122:g_d0_f67:122:g_d0_f67:(0.007) 
65:2280:110145:0:13:276:308:582:122:g_d0_f67:122:g_d0_f67:-0.084 
65:2281:110151:13:0:274:310:569:122:g_d0_f67:122:g_d0_f67:(0.010) 
65:2282:110158:0:13:333:364:582:122:g_d0_f67:122:g_d0_f67:-0.073 
65:2283:110164:13:0:331:366:569:122:g_d0_f67:122:g_d0_f67:(0.008) 
65:2284:110171:0:13:389:421:582:122:g_d0_f67:122:g_d0_f67:-0.083 
65:2285:110177:13:24:388:423:569:122:g_d0_f67:122:g_d0_f67:(0.010) 
65:2286:110184:24:0:404:407:545:122:g_d0_f67:122:g_d0_f67: 
65:2287:110184:0:13:446:477:582:122:g_d0_f67:122:g_d0_f67:-0.059 
65:2288:110190:13:0:444:479:569:122:g_d0_f67:122:g_d0_f67:(0.003) 
65:2289:110197:0:13:503:534:582:122:g_d0_f67:122:g_d0_f67:-0.068 
65:2290:110203:13:24:501:536:569:122:g_d0_f67:122:g_d0_f67:(0.002) 
65:2291:110210:24:13:517:520:545:122:g_d0_f67:122:g_d0_f67: 
65:2292:110210:13:13:72:125:532:122:g_d0_f67:122:g_d0_f67:  docetaxel  
65:2293:110222:13:0:72:75:519:122:g_d0_f67:122:g_d0_f67: 
65:2294:110222:0:13:222:249:532:122:g_d0_f67:122:g_d0_f67:0.026 
65:2295:110228:13:0:218:253:519:122:g_d0_f67:122:g_d0_f67:(0.004) 
65:2296:110236:0:13:278:305:532:122:g_d0_f67:122:g_d0_f67:0.036 
65:2297:110242:13:0:274:309:519:122:g_d0_f67:122:g_d0_f67:(0.005) 
65:2298:110250:0:13:335:362:532:122:g_d0_f67:122:g_d0_f67:0.026 
65:2299:110255:13:0:331:366:519:122:g_d0_f67:122:g_d0_f67:(0.004) 
65:2300:110262:0:13:391:419:532:122:g_d0_f67:122:g_d0_f67:0.036 
65:2301:110267:13:12:388:423:519:122:g_d0_f67:122:g_d0_f67:(0.005) 
65:2302:110274:12:0:404:407:507:122:g_d0_f67:122:g_d0_f67: 
65:2303:110274:0:13:448:475:532:122:g_d0_f67:122:g_d0_f67:0.014 
65:2304:110279:13:0:444:479:519:122:g_d0_f67:122:g_d0_f67:(0.002) 
65:2305:110286:0:13:504:532:532:122:g_d0_f67:122:g_d0_f67:0.013 
65:2306:110291:13:12:501:536:519:122:g_d0_f67:122:g_d0_f67:(0.003) 
65:2307:110298:12:13:517:520:507:122:g_d0_f67:122:g_d0_f67: 
65:2308:110298:13:13:72:122:494:122:g_d0_f67:122:g_d0_f67:  etoposide 
65:2309:110309:13:0:72:75:481:122:g_d0_f67:122:g_d0_f67: 
65:2310:110309:0:13:220:251:494:122:g_d0_f67:122:g_d0_f67:-0.005 
65:2311:110316:13:0:218:253:481:122:g_d0_f67:122:g_d0_f67:(0.010) 
65:2312:110324:0:13:276:307:494:122:g_d0_f67:122:g_d0_f67:-0.025 
65:2313:110331:13:0:274:309:481:122:g_d0_f67:122:g_d0_f67:(0.007) 
65:2314:110339:0:13:333:364:494:122:g_d0_f67:122:g_d0_f67:-0.003 
65:2315:110345:13:0:331:366:481:122:g_d0_f67:122:g_d0_f67:(0.010) 
65:2316:110352:0:13:389:421:494:122:g_d0_f67:122:g_d0_f67:-0.023 
65:2317:110358:13:12:388:423:481:122:g_d0_f67:122:g_d0_f67:(0.007) 
65:2318:110365:12:0:404:407:469:122:g_d0_f67:122:g_d0_f67: 
65:2319:110365:0:13:446:477:494:122:g_d0_f67:122:g_d0_f67:-0.004 
65:2320:110371:13:0:444:479:481:122:g_d0_f67:122:g_d0_f67:(0.004) 
65:2321:110378:0:13:503:534:494:122:g_d0_f67:122:g_d0_f67:-0.007 
65:2322:110384:13:12:501:536:481:122:g_d0_f67:122:g_d0_f67:(0.003) 
65:2323:110391:12:13:517:520:469:122:g_d0_f67:122:g_d0_f67: 
65:2324:110391:13:13:72:134:456:122:g_d0_f67:122:g_d0_f67:  gemcitabine 
65:2325:110404:13:0:72:75:443:122:g_d0_f67:122:g_d0_f67: 
65:2326:110404:0:13:222:249:456:122:g_d0_f67:122:g_d0_f67:0.007 
65:2327:110410:13:0:218:253:443:122:g_d0_f67:122:g_d0_f67:(0.003) 
65:2328:110418:0:13:278:305:456:122:g_d0_f67:122:g_d0_f67:0.007 
65:2329:110424:13:0:274:309:443:122:g_d0_f67:122:g_d0_f67:(0.003) 
65:2330:110432:0:13:335:362:456:122:g_d0_f67:122:g_d0_f67:0.007 
65:2331:110437:13:0:331:366:443:122:g_d0_f67:122:g_d0_f67:(0.003) 
65:2332:110444:0:13:391:419:456:122:g_d0_f67:122:g_d0_f67:0.008 
65:2333:110449:13:12:388:423:443:122:g_d0_f67:122:g_d0_f67:(0.004) 
65:2334:110456:12:0:404:407:431:122:g_d0_f67:122:g_d0_f67: 
65:2335:110456:0:13:446:477:456:122:g_d0_f67:122:g_d0_f67:-0.019 
65:2336:110462:13:0:444:479:443:122:g_d0_f67:122:g_d0_f67:(0.002) 
65:2337:110469:0:13:503:534:456:122:g_d0_f67:122:g_d0_f67:-0.014 
65:2338:110475:13:12:501:536:443:122:g_d0_f67:122:g_d0_f67:(0.002) 
65:2339:110482:12:13:517:520:431:122:g_d0_f67:122:g_d0_f67: 
65:2340:110482:13:13:72:176:418:122:g_d0_f67:122:g_d0_f67:Quarter prior to reform 
65:2341:110506:13:0:72:114:405:122:g_d0_f67:122:g_d0_f67:indicator 
65:2342:110515:0:26:230:524:418:122:g_d0_f67:122:g_d0_f67:N Y N Y N Y 
65:2343:110523:26:11:72:525:392:122:g_d0_f67:122:g_d0_f67:Number of Obs (weeks) 96 96 96 96 96 96 
65:2344:110558:11:10:72:518:381:81:g_d0_f67:81:g_d0_f67:Notes: Each cell is based on a separate regression. Estimates are the coefficients on an indicator for the period that the ASP 
65:2345:110685:10:11:72:521:371:81:g_d0_f67:81:g_d0_f67:payment scheme was in effect. Regressions control for other mean patient characteristics (see Table 1). Columns (1) and (2) 
65:2346:110809:11:10:72:540:360:81:g_d0_f67:81:g_d0_f67:include relative-week trends and (3) and (4) relative-month trends that are allowed to differ on either side of the payment change. 
65:2347:110941:10:10:72:535:350:81:g_d0_f67:81:g_d0_f67:Columns (5) and (6) include calendar month fixed effects. Odd columns also include an indicator for the 3 months leading up to 
65:2348:111068:10:13:72:487:340:81:g_d0_f67:81:g_d0_f67:the reform. Newey-West standard errors allowing for autocorrelation up to 52-week lags are given in parentheses.  
65:2349:111182:13:12:72:75:327:122:g_d0_f67:122:g_d0_f67: 
65:2350:111182:12:13:72:75:315:122:g_d0_f67:122:g_d0_f67: 
65:2351:111182:13:13:72:75:302:122:g_d0_f67:122:g_d0_f67: 
65:2352:111182:13:12:72:75:289:122:g_d0_f67:122:g_d0_f67: 
65:2353:111182:12:13:72:75:277:122:g_d0_f67:122:g_d0_f67: 
65:2354:111182:13:13:72:75:264:122:g_d0_f67:122:g_d0_f67: 
65:2355:111182:13:12:72:75:251:122:g_d0_f67:122:g_d0_f67: 
65:2356:111182:12:13:72:75:239:122:g_d0_f67:122:g_d0_f67: 
65:2357:111182:13:12:72:75:226:122:g_d0_f67:122:g_d0_f67: 
65:2358:111182:12:13:72:75:214:122:g_d0_f67:122:g_d0_f67: 
65:2359:111182:13:13:72:75:201:122:g_d0_f67:122:g_d0_f67: 
65:2360:111182:13:12:72:75:188:122:g_d0_f67:122:g_d0_f67: 
65:2361:111182:12:13:72:75:176:122:g_d0_f67:122:g_d0_f67: 
65:2362:111182:13:13:72:75:163:122:g_d0_f67:122:g_d0_f67: 
65:2363:111182:13:12:72:75:150:122:g_d0_f67:122:g_d0_f67: 
65:2364:111182:12:13:72:75:138:122:g_d0_f67:122:g_d0_f67: 
65:2365:111182:13:13:72:75:125:122:g_d0_f67:122:g_d0_f67: 
65:2366:111182:13:12:72:75:112:122:g_d0_f67:122:g_d0_f67: 
65:2367:111182:12:13:72:75:100:122:g_d0_f67:122:g_d0_f67: 
65:2368:111182:13:13:72:75:87:122:g_d0_f67:122:g_d0_f67: 
65:2369:111182:13:35:72:75:74:122:g_d0_f67:122:g_d0_f67: 
66:2370:111182:35:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
66:2371:111182:0:15:72:492:710:122:g_d0_f69:122:g_d0_f69:Appendix Table 6. Specification Checks of Reform-related changes in the Likelihood of Death 
66:2372:111273:15:13:72:541:695:122:g_d0_f62:122:g_d0_f69: Relative month trends Calendar month fixed effects 
66:2373:111321:13:12:72:75:682:122:g_d0_f69:122:g_d0_f69: 
66:2374:111321:12:0:72:174:670:122:g_d0_f70:122:g_d0_f69:Share  Dying  within...   
66:2375:111346:0:12:276:310:682:122:g_d0_f69:122:g_d0_f69:Feb/04 
66:2376:111352:12:0:272:314:670:122:g_d0_f70:122:g_d0_f62:–Nov/05 
66:2377:111359:0:12:351:385:682:122:g_d0_f69:122:g_d0_f69:Apr/04 
66:2378:111365:12:0:347:389:670:122:g_d0_f70:122:g_d0_f62:–Sept/05 
66:2379:111373:0:12:423:456:682:122:g_d0_f69:122:g_d0_f69:Feb/04 
66:2380:111379:12:0:419:460:670:122:g_d0_f70:122:g_d0_f62:–Nov/05 
66:2381:111386:0:12:494:528:682:122:g_d0_f69:122:g_d0_f69:Apr/04 
66:2382:111392:12:13:490:532:670:122:g_d0_f70:122:g_d0_f69:–Sept/05 
66:2383:111400:13:13:509:512:657:122:g_d0_f62:122:g_d0_f62: 
66:2384:111400:13:12:72:309:644:122:g_d0_f69:122:g_d0_f69:  3 months of diagnosis  -0.009 
66:2385:111430:12:0:275:310:632:122:g_d0_f69:122:g_d0_f69:(0.004) 
66:2386:111437:0:12:352:384:644:122:g_d0_f69:122:g_d0_f69:-0.010 
66:2387:111443:12:25:351:386:632:122:g_d0_f69:122:g_d0_f69:(0.005) 
66:2388:111450:25:0:367:370:607:122:g_d0_f69:122:g_d0_f69: 
66:2389:111450:0:12:424:455:644:122:g_d0_f69:122:g_d0_f69:-0.012 
66:2390:111456:12:0:422:457:632:122:g_d0_f69:122:g_d0_f69:(0.002) 
66:2391:111463:0:12:495:527:644:122:g_d0_f69:122:g_d0_f69:-0.011 
66:2392:111469:12:25:493:528:632:122:g_d0_f69:122:g_d0_f69:(0.002) 
66:2393:111476:25:13:509:512:607:122:g_d0_f69:122:g_d0_f69: 
66:2394:111476:13:12:72:177:594:122:g_d0_f69:122:g_d0_f69:  6 months of diagnosis 
66:2395:111499:12:0:72:77:582:122:g_d0_f69:122:g_d0_f62:  
66:2396:111499:0:12:277:309:594:122:g_d0_f69:122:g_d0_f69:-0.015 
66:2397:111505:12:0:275:310:582:122:g_d0_f69:122:g_d0_f69:(0.002) 
66:2398:111512:0:12:352:384:594:122:g_d0_f69:122:g_d0_f69:-0.015 
66:2399:111518:12:25:351:386:582:122:g_d0_f69:122:g_d0_f69:(0.003) 
66:2400:111525:25:0:367:370:557:122:g_d0_f69:122:g_d0_f69: 
66:2401:111525:0:12:424:455:594:122:g_d0_f69:122:g_d0_f69:-0.020 
66:2402:111531:12:0:422:457:582:122:g_d0_f69:122:g_d0_f69:(0.002) 
66:2403:111538:0:12:495:527:594:122:g_d0_f69:122:g_d0_f69:-0.020 
66:2404:111544:12:25:493:528:582:122:g_d0_f69:122:g_d0_f69:(0.003) 
66:2405:111551:25:12:509:512:557:122:g_d0_f69:122:g_d0_f69: 
66:2406:111551:12:13:72:177:545:122:g_d0_f69:122:g_d0_f69:  9 months of diagnosis 
66:2407:111574:13:0:72:77:532:122:g_d0_f69:122:g_d0_f62:  
66:2408:111574:0:13:277:309:545:122:g_d0_f69:122:g_d0_f69:-0.011 
66:2409:111580:13:0:280:306:532:122:g_d0_f69:122:g_d0_f69:(0.00 
66:2410:111585:0:13:352:384:545:122:g_d0_f69:122:g_d0_f69:-0.010 
66:2411:111591:13:25:351:386:532:122:g_d0_f69:122:g_d0_f69:(0.003) 
66:2412:111598:25:0:367:370:507:122:g_d0_f69:122:g_d0_f69: 
66:2413:111598:0:13:424:455:545:122:g_d0_f69:122:g_d0_f69:-0.021 
66:2414:111604:13:0:422:457:532:122:g_d0_f69:122:g_d0_f69:(0.003) 
66:2415:111611:0:13:495:527:545:122:g_d0_f69:122:g_d0_f69:-0.022 
66:2416:111617:13:25:493:528:532:122:g_d0_f69:122:g_d0_f69:(0.003) 
66:2417:111624:25:12:509:512:507:122:g_d0_f69:122:g_d0_f69: 
66:2418:111624:12:13:72:311:495:122:g_d0_f69:122:g_d0_f69:  1 year of diagnosis -0.0005 
66:2419:111652:13:0:275:310:482:122:g_d0_f69:122:g_d0_f69:(0.003) 
66:2420:111659:0:13:350:387:495:122:g_d0_f69:122:g_d0_f69:-0.0001 
66:2421:111666:13:25:351:386:482:122:g_d0_f69:122:g_d0_f69:(0.003) 
66:2422:111673:25:0:367:370:457:122:g_d0_f69:122:g_d0_f69: 
66:2423:111673:0:13:424:455:495:122:g_d0_f69:122:g_d0_f69:-0.026 
66:2424:111679:13:0:422:457:482:122:g_d0_f69:122:g_d0_f69:(0.002) 
66:2425:111686:0:13:495:527:495:122:g_d0_f69:122:g_d0_f69:-0.025 
66:2426:111692:13:25:493:528:482:122:g_d0_f69:122:g_d0_f69:(0.002) 
66:2427:111699:25:12:509:512:457:122:g_d0_f69:122:g_d0_f69: 
66:2428:111699:12:12:72:518:445:122:g_d0_f69:122:g_d0_f69:Number of Observations (weeks) 96 72 96 72 
66:2429:111737:12:10:72:518:433:81:g_d0_f69:81:g_d0_f69:Notes: Each cell is based on a separate regression. Estimates are the coefficients on an indicator for the period that the ASP 
66:2430:111864:10:10:72:521:423:81:g_d0_f69:81:g_d0_f69:payment scheme was in effect. Regressions control for other mean patient characteristics (see Table 1). Columns (1) and (2) 
66:2431:111988:10:10:72:523:413:81:g_d0_f69:81:g_d0_f69:include relative-month trends that are allowed to differ on either side of the payment change and columns (3) and (4) include 
66:2432:112114:10:11:72:503:403:81:g_d0_f69:81:g_d0_f69:calendar month fixed effects. Newey-West standard errors allowing for autocorrelation up to 52-week lags are given in 
66:2433:112232:11:13:72:121:392:81:g_d0_f69:81:g_d0_f69:parentheses.  
66:2434:112246:13:25:72:75:379:144:g_d0_f69:144:g_d0_f69: 
66:2435:112246:25:315:72:219:354:122:g_d0_f69:122:g_d0_f69:  
67:2436:112246:315:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
67:2437:112246:0:15:72:535:710:122:g_d0_f71:122:g_d0_f71:Appendix Table 7. Change in Treatment and Survival: States with Above vs. Below Pre-reform Rates of 
67:2438:112346:15:20:72:396:695:122:g_d0_f71:122:g_d0_f71:Paclitaxel Use Among Patients Receiving Any Chemotherapy Treatment 
67:2439:112413:20:12:72:356:675:122:g_d0_f71:122:g_d0_f71: Above Median Rates of 
67:2440:112435:12:0:268:335:663:122:g_d0_f71:122:g_d0_f71:Paclitaxel Use 
67:2441:112449:0:12:408:515:675:122:g_d0_f71:122:g_d0_f71:Below Median Rates of 
67:2442:112471:12:24:428:495:663:122:g_d0_f71:122:g_d0_f71:Paclitaxel Use 
67:2443:112485:24:12:72:255:639:122:g_d0_f71:122:g_d0_f71: Mean 
67:2444:112490:12:13:227:263:627:122:g_d0_f71:122:g_d0_f71:Pre-Jan 
67:2445:112497:13:0:227:252:614:122:g_d0_f71:122:g_d0_f71:2005 
67:2446:112501:0:12:285:321:639:122:g_d0_f71:122:g_d0_f71:Feb/04  
67:2447:112508:12:0:281:325:627:122:g_d0_f72:122:g_d0_f71:–Nov/05  
67:2448:112516:0:12:338:375:639:122:g_d0_f71:122:g_d0_f71:Apr/04  
67:2449:112523:12:0:334:376:627:122:g_d0_f72:122:g_d0_f71:–Sept/05 
67:2450:112531:0:12:394:422:639:122:g_d0_f71:122:g_d0_f71:Mean 
67:2451:112536:12:13:390:426:627:122:g_d0_f71:122:g_d0_f71:Pre-Jan 
67:2452:112544:13:0:396:421:614:122:g_d0_f71:122:g_d0_f71:2005 
67:2453:112548:0:12:445:481:639:122:g_d0_f71:122:g_d0_f71:Feb/04  
67:2454:112555:12:0:441:485:627:122:g_d0_f72:122:g_d0_f71:–Nov/05  
67:2455:112563:0:12:498:535:639:122:g_d0_f71:122:g_d0_f71:Apr/04  
67:2456:112570:12:31:494:536:627:122:g_d0_f72:122:g_d0_f71:–Sept/05 
67:2457:112578:31:23:70:352:596:122:g_d0_f72:122:g_d0_f71:Share  of  Patients  Receiving  Chemotherapy  Treatment  within... 
67:2458:112644:23:12:70:315:573:122:g_d0_f71:122:g_d0_f71: 1 month of diagnosis  0.177 0.018 
67:2459:112675:12:0:284:319:561:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2460:112682:0:12:341:369:573:122:g_d0_f71:122:g_d0_f71:0.024 
67:2461:112687:12:0:337:373:561:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2462:112694:0:12:394:475:573:122:g_d0_f71:122:g_d0_f71:0.154 0.014 
67:2463:112704:12:0:444:479:561:122:g_d0_f71:122:g_d0_f71:(0.005) 
67:2464:112711:0:12:501:529:573:122:g_d0_f71:122:g_d0_f71:0.005 
67:2465:112716:12:33:497:533:561:122:g_d0_f71:122:g_d0_f71:(0.002) 
67:2466:112723:33:13:70:219:528:122:g_d0_f71:122:g_d0_f71: 1 month, excluding carboplatin   
67:2467:112755:13:0:70:75:515:122:g_d0_f71:122:g_d0_f71:  
67:2468:112755:0:13:234:315:528:122:g_d0_f71:122:g_d0_f71:0.076 0.016 
67:2469:112767:13:0:284:319:515:122:g_d0_f71:122:g_d0_f71:(0.002) 
67:2470:112775:0:13:341:369:528:122:g_d0_f71:122:g_d0_f71:0.017 
67:2471:112780:13:0:337:373:515:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2472:112787:0:13:394:475:528:122:g_d0_f71:122:g_d0_f71:0.071 0.015 
67:2473:112797:13:0:444:479:515:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2474:112804:0:13:501:529:528:122:g_d0_f71:122:g_d0_f71:0.008 
67:2475:112809:13:33:497:533:515:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2476:112816:33:12:70:186:482:122:g_d0_f71:122:g_d0_f72: 1  month,  in  a  Physician’s  
67:2477:112847:12:13:70:104:470:122:g_d0_f71:122:g_d0_f71:Office  
67:2478:112854:13:0:70:75:457:122:g_d0_f71:122:g_d0_f71:  
67:2479:112854:0:12:234:315:482:122:g_d0_f71:122:g_d0_f71:0.142 0.018 
67:2480:112866:12:0:284:319:470:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2481:112874:0:12:341:369:482:122:g_d0_f71:122:g_d0_f71:0.024 
67:2482:112879:12:0:337:373:470:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2483:112886:0:12:394:475:482:122:g_d0_f71:122:g_d0_f71:0.117 0.019 
67:2484:112896:12:0:444:479:470:122:g_d0_f71:122:g_d0_f71:(0.004) 
67:2485:112903:0:12:501:529:482:122:g_d0_f71:122:g_d0_f71:0.014 
67:2486:112908:12:38:497:533:470:122:g_d0_f71:122:g_d0_f71:(0.002) 
67:2487:112915:38:13:70:210:432:122:g_d0_f71:122:g_d0_f71: 1 month, in outpatient hospital 
67:2488:112947:13:0:70:97:419:122:g_d0_f71:122:g_d0_f71:clinic 
67:2489:112953:0:13:234:317:432:122:g_d0_f71:122:g_d0_f71:0.026 -0.001 
67:2490:112966:13:0:284:319:419:122:g_d0_f71:122:g_d0_f71:(0.001) 
67:2491:112974:0:13:341:369:432:122:g_d0_f71:122:g_d0_f71:0.001 
67:2492:112979:13:0:337:373:419:122:g_d0_f71:122:g_d0_f71:(0.002) 
67:2493:112986:0:13:394:478:432:122:g_d0_f71:122:g_d0_f71:0.029 0.0001 
67:2494:112997:13:0:444:479:419:122:g_d0_f71:122:g_d0_f71:(0.002) 
67:2495:113004:0:13:498:532:432:122:g_d0_f71:122:g_d0_f71:0.0004 
67:2496:113010:13:28:497:533:419:122:g_d0_f71:122:g_d0_f71:(0.001) 
67:2497:113017:28:25:70:172:391:122:g_d0_f72:122:g_d0_f71:Share  Dying  Within... 
67:2498:113040:25:12:70:317:366:122:g_d0_f71:122:g_d0_f71:  3 months of diagnosis  0.341 -0.005 
67:2499:113075:12:0:284:319:354:122:g_d0_f71:122:g_d0_f71:(0.006) 
67:2500:113082:0:12:339:371:366:122:g_d0_f71:122:g_d0_f71:-0.014 
67:2501:113088:12:0:337:373:354:122:g_d0_f71:122:g_d0_f71:(0.004) 
67:2502:113095:0:12:394:480:366:122:g_d0_f71:122:g_d0_f71:0.337 -0.001  
67:2503:113107:12:13:444:479:354:122:g_d0_f71:122:g_d0_f71:(0.004) 
67:2504:113114:13:0:459:464:341:122:g_d0_f71:122:g_d0_f71:  
67:2505:113114:0:12:499:533:366:122:g_d0_f71:122:g_d0_f71:-0.002  
67:2506:113121:12:13:497:533:354:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2507:113128:13:13:513:516:341:122:g_d0_f71:122:g_d0_f71: 
67:2508:113128:13:13:70:175:328:122:g_d0_f71:122:g_d0_f71:  6 months of diagnosis 
67:2509:113151:13:0:70:75:315:122:g_d0_f71:122:g_d0_f71:  
67:2510:113151:0:13:234:320:328:122:g_d0_f71:122:g_d0_f71:0.473 -0.021  
67:2511:113163:13:0:284:319:315:122:g_d0_f71:122:g_d0_f71:(0.005) 
67:2512:113170:0:13:339:373:328:122:g_d0_f71:122:g_d0_f71:-0.028  
67:2513:113177:13:0:337:373:315:122:g_d0_f71:122:g_d0_f71:(0.007) 
67:2514:113184:0:13:394:477:328:122:g_d0_f71:122:g_d0_f71:0.464 -0.005 
67:2515:113195:13:13:444:479:315:122:g_d0_f71:122:g_d0_f71:(0.008) 
67:2516:113202:13:0:459:464:302:122:g_d0_f71:122:g_d0_f71:  
67:2517:113202:0:13:499:531:328:122:g_d0_f71:122:g_d0_f71:-0.006 
67:2518:113208:13:36:497:533:315:122:g_d0_f71:122:g_d0_f71:(0.006) 
67:2519:113215:36:13:70:175:279:122:g_d0_f71:122:g_d0_f71:  9 months of diagnosis 
67:2520:113238:13:0:70:75:266:122:g_d0_f71:122:g_d0_f71:  
67:2521:113238:0:13:234:320:279:122:g_d0_f71:122:g_d0_f71:0.533 -0.019  
67:2522:113250:13:0:284:319:266:122:g_d0_f71:122:g_d0_f71:(0.004) 
67:2523:113257:0:13:339:373:279:122:g_d0_f71:122:g_d0_f71:-0.026  
67:2524:113264:13:0:337:373:266:122:g_d0_f71:122:g_d0_f71:(0.004) 
67:2525:113271:0:13:394:475:279:122:g_d0_f71:122:g_d0_f71:0.521 0.002 
67:2526:113281:13:12:444:479:266:122:g_d0_f71:122:g_d0_f71:(0.007) 
67:2527:113288:12:0:459:464:254:122:g_d0_f71:122:g_d0_f71:  
67:2528:113288:0:13:501:529:279:122:g_d0_f71:122:g_d0_f71:0.003 
67:2529:113293:13:12:497:533:266:122:g_d0_f71:122:g_d0_f71:(0.006) 
67:2530:113300:12:24:513:516:254:122:g_d0_f71:122:g_d0_f71: 
67:2531:113300:24:12:70:320:230:122:g_d0_f71:122:g_d0_f71:  1 year of diagnosis 0. 625 -0.008  
67:2532:113334:12:0:284:319:218:122:g_d0_f71:122:g_d0_f71:(0.003) 
67:2533:113341:0:12:339:373:230:122:g_d0_f71:122:g_d0_f71:-0.013  
67:2534:113348:12:0:337:373:218:122:g_d0_f71:122:g_d0_f71:(0.004) 
67:2535:113355:0:12:394:478:230:122:g_d0_f71:122:g_d0_f71:0.612 0.012  
67:2536:113366:12:13:444:479:218:122:g_d0_f71:122:g_d0_f71:(0.007) 
67:2537:113373:13:0:459:464:205:122:g_d0_f71:122:g_d0_f71:  
67:2538:113373:0:12:501:529:230:122:g_d0_f71:122:g_d0_f71:0.006 
67:2539:113378:12:32:497:533:218:122:g_d0_f71:122:g_d0_f71:(0.004) 
67:2540:113385:32:17:70:522:186:122:g_d0_f71:122:g_d0_f71:Number of Obs (weeks 48 96 72 48 96 72 
67:2541:113416:17:10:72:538:169:81:g_d0_f71:81:g_d0_f71:Notes: Means in column 1 and 3 are for the dependent variable for patients in states with above versus below the median rates of 
67:2542:113545:10:11:72:514:159:81:g_d0_f71:81:g_d0_f71:relative paclitaxel use in the pre-reform period. Estimates in columns 2 and 4 are from separate time-series regressions for 
67:2543:113670:11:10:72:518:148:81:g_d0_f71:81:g_d0_f71:patients from each group and are the coefficients on an indicator for the period that the ASP payment scheme was in effect. 
67:2544:113794:10:11:72:516:138:81:g_d0_f71:81:g_d0_f71:Regressions control for mean patient characteristics and relative-week trends that are allowed to differ on either side of the 
67:2545:113921:11:12:72:507:127:81:g_d0_f71:99:g_d0_f71:payment change. Newey-West standard errors allowing for autocorrelation up to 52-week lags are given in parentheses.  
67:2546:114039:12:24:72:74:115:99:g_d0_f71:99:g_d0_f71: 
67:2547:114039:24:14:72:75:91:122:g_d0_f71:122:g_d0_f71: 
67:2548:114039:14:38:72:75:77:122:g_d0_f71:122:g_d0_f71: 
68:2549:114039:38:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
68:2550:114039:0:20:72:488:710:122:g_d0_f73:122:g_d0_f73:Appendix Table 8. Change in Treatment and Survival: Above vs. Below Median Age Patients 
68:2551:114127:20:30:72:525:690:122:g_d0_f73:122:g_d0_f73: Above Median Age Patients Below Median Age Patients 
68:2552:114177:30:13:72:255:660:122:g_d0_f73:122:g_d0_f73: Mean 
68:2553:114182:13:12:227:264:647:122:g_d0_f73:122:g_d0_f73:Pre-Jan 
68:2554:114190:12:0:227:252:635:122:g_d0_f73:122:g_d0_f73:2005 
68:2555:114194:0:13:285:321:660:122:g_d0_f73:122:g_d0_f73:Feb/04  
68:2556:114201:13:0:281:325:647:122:g_d0_f74:122:g_d0_f73:–Nov/05  
68:2557:114209:0:13:338:375:660:122:g_d0_f73:122:g_d0_f73:Apr/04  
68:2558:114216:13:0:334:376:647:122:g_d0_f74:122:g_d0_f73:–Sept/05 
68:2559:114224:0:13:394:422:660:122:g_d0_f73:122:g_d0_f73:Mean 
68:2560:114229:13:12:390:426:647:122:g_d0_f73:122:g_d0_f73:Pre-Jan 
68:2561:114237:12:0:396:421:635:122:g_d0_f73:122:g_d0_f73:2005 
68:2562:114241:0:13:445:481:660:122:g_d0_f73:122:g_d0_f73:Feb/04  
68:2563:114248:13:0:441:485:647:122:g_d0_f74:122:g_d0_f73:–Nov/05  
68:2564:114256:0:13:498:535:660:122:g_d0_f73:122:g_d0_f73:Apr/04  
68:2565:114263:13:30:494:536:647:122:g_d0_f74:122:g_d0_f73:–Sept/05 
68:2566:114271:30:23:70:352:617:122:g_d0_f74:122:g_d0_f73:Share  of  Patients  Receiving  Chemotherapy  Treatment  within... 
68:2567:114337:23:13:70:315:594:122:g_d0_f73:122:g_d0_f73: 1 month of diagnosis  0.119 0.014 
68:2568:114368:13:0:284:319:581:122:g_d0_f73:122:g_d0_f73:(0.002) 
68:2569:114375:0:13:341:369:594:122:g_d0_f73:122:g_d0_f73:0.014 
68:2570:114380:13:0:337:373:581:122:g_d0_f73:122:g_d0_f73:(0.003) 
68:2571:114387:0:13:394:475:594:122:g_d0_f73:122:g_d0_f73:0.210 0.024 
68:2572:114397:13:0:443:479:581:122:g_d0_f73:122:g_d0_f73:(0.003) 
68:2573:114404:0:13:500:528:594:122:g_d0_f73:122:g_d0_f73:0.020 
68:2574:114409:13:33:500:529:581:122:g_d0_f73:122:g_d0_f73:(.003) 
68:2575:114415:33:12:70:219:548:122:g_d0_f73:122:g_d0_f73: 1 month, excluding carboplatin   
68:2576:114447:12:0:70:75:536:122:g_d0_f73:122:g_d0_f73:  
68:2577:114447:0:12:234:315:548:122:g_d0_f73:122:g_d0_f73:0.054 0.013 
68:2578:114459:12:0:284:319:536:122:g_d0_f73:122:g_d0_f73:(0.002) 
68:2579:114467:0:12:341:369:548:122:g_d0_f73:122:g_d0_f73:0.011 
68:2580:114472:12:0:337:373:536:122:g_d0_f73:122:g_d0_f73:(0.002) 
68:2581:114479:0:12:394:475:548:122:g_d0_f73:122:g_d0_f73:0.014 0.016 
68:2582:114489:12:0:443:479:536:122:g_d0_f73:122:g_d0_f73:(0.002) 
68:2583:114496:0:12:500:528:548:122:g_d0_f73:122:g_d0_f73:0.013 
68:2584:114501:12:33:497:532:536:122:g_d0_f73:122:g_d0_f73:(0.001) 
68:2585:114508:33:13:70:186:503:122:g_d0_f73:122:g_d0_f74: 1  month,  in  a  Physician’s  
68:2586:114539:13:12:70:104:490:122:g_d0_f73:122:g_d0_f73:Office  
68:2587:114546:12:0:70:75:478:122:g_d0_f73:122:g_d0_f73:  
68:2588:114546:0:13:234:315:503:122:g_d0_f73:122:g_d0_f73:0.094 0.014 
68:2589:114558:13:0:284:319:490:122:g_d0_f73:122:g_d0_f73:(0.002) 
68:2590:114566:0:13:341:369:503:122:g_d0_f73:122:g_d0_f73:0.016 
68:2591:114571:13:0:337:373:490:122:g_d0_f73:122:g_d0_f73:(0.002) 
68:2592:114578:0:13:394:475:503:122:g_d0_f73:122:g_d0_f73:0.164 0.024 
68:2593:114588:13:0:443:479:490:122:g_d0_f73:122:g_d0_f73:(0.004) 
68:2594:114595:0:13:500:528:503:122:g_d0_f73:122:g_d0_f73:0.023 
68:2595:114600:13:38:497:532:490:122:g_d0_f73:122:g_d0_f73:(0.004) 
68:2596:114607:38:12:70:317:452:122:g_d0_f73:122:g_d0_f73: 1 month, in outpatient hospital  0.018 -0.001 
68:2597:114652:12:0:284:319:440:122:g_d0_f73:122:g_d0_f73:(0.001) 
68:2598:114660:0:12:339:371:452:122:g_d0_f73:122:g_d0_f73:-0.001 
68:2599:114666:12:0:337:373:440:122:g_d0_f73:122:g_d0_f73:(0.001) 
68:2600:114673:0:12:394:475:452:122:g_d0_f73:122:g_d0_f73:0.036 0.003 
68:2601:114683:12:0:443:479:440:122:g_d0_f73:122:g_d0_f73:(0.001) 
68:2602:114690:0:12:500:528:452:122:g_d0_f73:122:g_d0_f73:0.004 
68:2603:114695:12:27:497:532:440:122:g_d0_f73:122:g_d0_f73:(0.002) 
68:2604:114702:27:18:70:522:413:122:g_d0_f73:122:g_d0_f73:Observations (weeks) 48 96 72 48 96 72 
68:2605:114736:18:10:72:509:395:81:g_d0_f73:81:g_d0_f73:Notes: Means in column 1 and 4 are for the dependent variable for patients above versus below the median age patient at 
68:2606:114856:10:12:72:462:385:81:g_d0_f73:81:g_d0_f73:diagnosis in the period prior to the reform. see notes to Tables 2-4. See notes to Tables 2-4 for more details. 
68:2607:114968:12:25:72:75:373:122:g_d0_f62:122:g_d0_f62: 
68:2608:114968:25:24:72:75:348:122:g_d0_f62:122:g_d0_f62: 
68:2609:114968:24:25:72:75:324:122:g_d0_f62:122:g_d0_f62: 
68:2610:114968:25:260:72:219:299:122:g_d0_f73:122:g_d0_f73:  
69:2611:114968:260:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
69:2612:114968:0:15:72:526:710:122:g_d0_f75:122:g_d0_f75:Appendix Table 9. Change in Treatment and Survival: Counties with a High vs. Low Concentration of 
69:2613:115066:15:20:72:299:695:122:g_d0_f75:122:g_d0_f75:Providers Administering Chemotherapy Treatment 
69:2614:115113:20:12:72:366:675:122:g_d0_f75:122:g_d0_f75: Counties with High Provider 
69:2615:115141:12:0:269:334:663:122:g_d0_f75:122:g_d0_f75:Concentration 
69:2616:115154:0:12:397:525:675:122:g_d0_f75:122:g_d0_f75:Counties with Low Provider 
69:2617:115181:12:24:429:494:663:122:g_d0_f75:122:g_d0_f75:Concentration 
69:2618:115194:24:12:72:321:639:122:g_d0_f75:122:g_d0_f75: Mean  Feb/04  
69:2619:115206:12:0:281:325:627:122:g_d0_f76:122:g_d0_f75:–Nov/05  
69:2620:115214:0:12:338:375:639:122:g_d0_f75:122:g_d0_f75:Apr/04  
69:2621:115221:12:0:334:376:627:122:g_d0_f76:122:g_d0_f75:–Sept/05 
69:2622:115229:0:12:394:481:639:122:g_d0_f75:122:g_d0_f75:Mean  Feb/04  
69:2623:115241:12:0:441:485:627:122:g_d0_f76:122:g_d0_f75:–Nov/05  
69:2624:115249:0:12:498:535:639:122:g_d0_f75:122:g_d0_f75:Apr/04  
69:2625:115256:12:22:494:536:627:122:g_d0_f76:122:g_d0_f75:–Sept/05 
69:2626:115264:22:23:70:352:605:122:g_d0_f76:122:g_d0_f75:Share  of  Patients  Receiving  Chemotherapy  Treatment  within... 
69:2627:115330:23:12:70:320:582:122:g_d0_f75:122:g_d0_f75: 1 month of diagnosis  0.169 -0.0004 
69:2628:115363:12:0:284:319:570:122:g_d0_f75:122:g_d0_f75:(0.005) 
69:2629:115370:0:12:341:369:582:122:g_d0_f75:122:g_d0_f75:0.001 
69:2630:115375:12:0:337:373:570:122:g_d0_f75:122:g_d0_f75:(0.007) 
69:2631:115382:0:12:394:475:582:122:g_d0_f75:122:g_d0_f75:0.165 0.020 
69:2632:115392:12:0:444:479:570:122:g_d0_f75:122:g_d0_f75:(0.002) 
69:2633:115399:0:12:501:529:582:122:g_d0_f75:122:g_d0_f75:0.019 
69:2634:115404:12:24:497:533:570:122:g_d0_f75:122:g_d0_f75:(0.003) 
69:2635:115411:24:12:70:315:546:122:g_d0_f75:122:g_d0_f75: 1 month, excluding carboplatin   0.076 0.004 
69:2636:115455:12:0:284:319:534:122:g_d0_f75:122:g_d0_f75:(0.003) 
69:2637:115463:0:12:341:369:546:122:g_d0_f75:122:g_d0_f75:0.002 
69:2638:115468:12:0:337:373:534:122:g_d0_f75:122:g_d0_f75:(0.005) 
69:2639:115475:0:12:394:475:546:122:g_d0_f75:122:g_d0_f75:0.073 0.016 
69:2640:115485:12:0:444:479:534:122:g_d0_f75:122:g_d0_f75:(0.001) 
69:2641:115492:0:12:501:529:546:122:g_d0_f75:122:g_d0_f75:0.014 
69:2642:115497:12:24:497:533:534:122:g_d0_f75:122:g_d0_f75:(0.002) 
69:2643:115504:24:12:70:186:510:122:g_d0_f75:122:g_d0_f76: 1  month,  in  a  Physician’s  
69:2644:115535:12:0:70:104:498:122:g_d0_f75:122:g_d0_f75:Office  
69:2645:115542:0:12:234:315:510:122:g_d0_f75:122:g_d0_f75:0.122 0.008 
69:2646:115554:12:0:284:319:498:122:g_d0_f75:122:g_d0_f75:(0.005) 
69:2647:115562:0:12:341:369:510:122:g_d0_f75:122:g_d0_f75:0.010 
69:2648:115567:12:0:337:373:498:122:g_d0_f75:122:g_d0_f75:(0.007) 
69:2649:115574:0:12:394:475:510:122:g_d0_f75:122:g_d0_f75:0.132 0.019 
69:2650:115584:12:0:444:479:498:122:g_d0_f75:122:g_d0_f75:(0.003) 
69:2651:115591:0:12:501:529:510:122:g_d0_f75:122:g_d0_f75:0.019 
69:2652:115596:12:24:497:533:498:122:g_d0_f75:122:g_d0_f75:(0.003) 
69:2653:115603:24:12:70:210:474:122:g_d0_f75:122:g_d0_f75: 1 month, in outpatient hospital 
69:2654:115635:12:0:70:97:462:122:g_d0_f75:122:g_d0_f75:clinic 
69:2655:115641:0:12:234:317:474:122:g_d0_f75:122:g_d0_f75:0.045 -0.010 
69:2656:115654:12:0:284:319:462:122:g_d0_f75:122:g_d0_f75:(0.002) 
69:2657:115662:0:12:339:371:474:122:g_d0_f75:122:g_d0_f75:-0.009 
69:2658:115668:12:0:337:373:462:122:g_d0_f75:122:g_d0_f75:(0.002) 
69:2659:115675:0:12:394:475:474:122:g_d0_f75:122:g_d0_f75:0.024 0.003 
69:2660:115685:12:0:444:479:462:122:g_d0_f75:122:g_d0_f75:(0.001) 
69:2661:115692:0:12:501:529:474:122:g_d0_f75:122:g_d0_f75:0.004 
69:2662:115697:12:27:497:533:462:122:g_d0_f75:122:g_d0_f75:(0.001) 
69:2663:115704:27:26:70:332:435:122:g_d0_f76:122:g_d0_f75:Percent  Change  in  Chemotherapy  Service  Counts  within... 
69:2664:115765:26:12:70:315:409:122:g_d0_f75:122:g_d0_f75: 1 month of diagnosis  0.973 0.203 
69:2665:115798:12:0:284:319:397:122:g_d0_f75:122:g_d0_f75:(0.045) 
69:2666:115806:0:12:341:369:409:122:g_d0_f75:122:g_d0_f75:0.185 
69:2667:115811:12:0:337:373:397:122:g_d0_f75:122:g_d0_f75:(0.045) 
69:2668:115818:0:12:397:475:409:122:g_d0_f75:122:g_d0_f75:1.01 0.389 
69:2669:115827:12:0:444:479:397:122:g_d0_f75:122:g_d0_f75:(0.031) 
69:2670:115834:0:12:503:527:409:122:g_d0_f75:122:g_d0_f75:0390 
69:2671:115838:12:26:497:533:397:122:g_d0_f75:122:g_d0_f75:(0.030) 
69:2672:115845:26:12:70:315:371:122:g_d0_f75:122:g_d0_f75: 1 month, excluding carboplatin   0.320 0.089 
69:2673:115887:12:0:284:319:359:122:g_d0_f75:122:g_d0_f75:(0.038) 
69:2674:115894:0:12:341:369:371:122:g_d0_f75:122:g_d0_f75:0.085 
69:2675:115899:12:0:337:373:359:122:g_d0_f75:122:g_d0_f75:(0.026) 
69:2676:115906:0:12:394:475:371:122:g_d0_f75:122:g_d0_f75:0.301 0.232 
69:2677:115916:12:0:444:479:359:122:g_d0_f75:122:g_d0_f75:(0.021) 
69:2678:115923:0:12:501:529:371:122:g_d0_f75:122:g_d0_f75:0.240 
69:2679:115928:12:26:497:533:359:122:g_d0_f75:122:g_d0_f75:(0.014) 
69:2680:115935:26:12:70:186:333:122:g_d0_f75:122:g_d0_f76: 1  month,  in  a  Physician’s  
69:2681:115966:12:0:70:104:321:122:g_d0_f75:122:g_d0_f75:Office  
69:2682:115973:0:12:234:315:333:122:g_d0_f75:122:g_d0_f75:0.821 0.242 
69:2683:115983:12:0:284:319:321:122:g_d0_f75:122:g_d0_f75:(0.045) 
69:2684:115990:0:12:341:369:333:122:g_d0_f75:122:g_d0_f75:0.231 
69:2685:115995:12:0:337:373:321:122:g_d0_f75:122:g_d0_f75:(0.044) 
69:2686:116002:0:12:394:475:333:122:g_d0_f75:122:g_d0_f75:0.933 0.389 
69:2687:116012:12:0:444:479:321:122:g_d0_f75:122:g_d0_f75:(0.034) 
69:2688:116019:0:12:501:529:333:122:g_d0_f75:122:g_d0_f75:0.392 
69:2689:116024:12:26:497:533:321:122:g_d0_f75:122:g_d0_f75:(0.033) 
69:2690:116031:26:12:70:210:295:122:g_d0_f75:122:g_d0_f75: 1 month, in outpatient hospital 
69:2691:116063:12:0:70:97:283:122:g_d0_f75:122:g_d0_f75:clinic 
69:2692:116069:0:12:234:317:295:122:g_d0_f75:122:g_d0_f75:0.152 -0.043 
69:2693:116080:12:0:284:319:283:122:g_d0_f75:122:g_d0_f75:(0.024) 
69:2694:116087:0:12:339:371:295:122:g_d0_f75:122:g_d0_f75:-0.049 
69:2695:116093:12:0:337:373:283:122:g_d0_f75:122:g_d0_f75:(0.017) 
69:2696:116100:0:12:394:475:295:122:g_d0_f75:122:g_d0_f75:0.075 0.029 
69:2697:116110:12:0:444:479:283:122:g_d0_f75:122:g_d0_f75:(0.005) 
69:2698:116117:0:12:501:529:295:122:g_d0_f75:122:g_d0_f75:0.028 
69:2699:116122:12:25:497:533:283:122:g_d0_f75:122:g_d0_f75:(0.008) 
69:2700:116129:25:18:70:522:258:122:g_d0_f75:122:g_d0_f75:Observations (weeks) 48 96 72 48 96 72 
69:2701:116161:18:10:72:542:240:81:g_d0_f75:81:g_d0_f75:Notes: Means in column 1 and 3 are for the dependent variable for patients in counties with low vs. high concentration. The mean 
69:2702:116290:10:10:72:530:230:81:g_d0_f75:81:g_d0_f75:for service counts is without logs. High concentration is defined as an HHI greater than 0.25. Estimates in columns 2 and 4 are 
69:2703:116418:10:11:72:535:220:81:g_d0_f75:81:g_d0_f75:from separate time-series regressions for patients from each group and are the coefficients on an indicator for the period that the 
69:2704:116550:11:10:72:512:209:81:g_d0_f75:81:g_d0_f75:ASP payment scheme was in effect. Regressions control for mean patient characteristics and relative-week trends that are 
69:2705:116671:10:11:72:533:199:81:g_d0_f75:81:g_d0_f75:allowed to differ on either side of the payment change. Newey-West standard errors allowing for autocorrelation up to 52-week 
69:2706:116797:11:10:72:178:188:81:g_d0_f75:81:g_d0_f75:lags are given in parentheses 
69:2707:116827:10:24:72:74:178:81:g_d0_f75:81:g_d0_f75: 
69:2708:116827:24:12:72:75:154:122:g_d0_f75:122:g_d0_f75: 
69:2709:116827:12:103:72:219:142:122:g_d0_f75:122:g_d0_f75:  
70:2710:116827:103:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
70:2711:116827:0:13:72:542:710:122:g_d0_f77:122:g_d0_f77:Appendix Table 10. Change in Treatment and Survival: Counties with Above vs. Below Median Numbers 
70:2712:116925:13:18:72:361:697:122:g_d0_f77:122:g_d0_f77:of Patients Per Provider Administering Chemotherapy Treatment 
70:2713:116987:18:13:72:363:679:122:g_d0_f77:122:g_d0_f77: Above Median Patients Per 
70:2714:117013:13:0:281:322:666:122:g_d0_f77:122:g_d0_f77:Provider 
70:2715:117021:0:13:400:523:679:122:g_d0_f77:122:g_d0_f77:Below Median Patients Per 
70:2716:117047:13:23:441:482:666:122:g_d0_f77:122:g_d0_f77:Provider 
70:2717:117055:23:12:72:255:643:122:g_d0_f77:122:g_d0_f77: Mean 
70:2718:117060:12:13:227:264:631:122:g_d0_f77:122:g_d0_f77:Pre-Jan 
70:2719:117068:13:0:227:252:618:122:g_d0_f77:122:g_d0_f77:2005 
70:2720:117072:0:12:285:321:643:122:g_d0_f77:122:g_d0_f77:Feb/04  
70:2721:117079:12:0:281:325:631:122:g_d0_f78:122:g_d0_f77:–Nov/05  
70:2722:117087:0:12:338:375:643:122:g_d0_f77:122:g_d0_f77:Apr/04  
70:2723:117094:12:0:334:376:631:122:g_d0_f78:122:g_d0_f77:–Sept/05 
70:2724:117102:0:12:394:422:643:122:g_d0_f77:122:g_d0_f77:Mean 
70:2725:117107:12:13:390:426:631:122:g_d0_f77:122:g_d0_f77:Pre-Jan 
70:2726:117115:13:0:396:421:618:122:g_d0_f77:122:g_d0_f77:2005 
70:2727:117119:0:12:445:481:643:122:g_d0_f77:122:g_d0_f77:Feb/04  
70:2728:117126:12:0:441:485:631:122:g_d0_f78:122:g_d0_f77:–Nov/05  
70:2729:117134:0:12:498:535:643:122:g_d0_f77:122:g_d0_f77:Apr/04  
70:2730:117141:12:31:494:536:631:122:g_d0_f78:122:g_d0_f77:–Sept/05 
70:2731:117149:31:23:70:352:600:122:g_d0_f78:122:g_d0_f77:Share  of  Patients  Receiving  Chemotherapy  Treatment  within... 
70:2732:117215:23:13:70:315:577:122:g_d0_f77:122:g_d0_f77: 1 month of diagnosis  0.173 0.013 
70:2733:117246:13:0:284:319:564:122:g_d0_f77:122:g_d0_f77:(0.004) 
70:2734:117253:0:13:341:369:577:122:g_d0_f77:122:g_d0_f77:0.013 
70:2735:117258:13:0:337:373:564:122:g_d0_f77:122:g_d0_f77:(0.003) 
70:2736:117265:0:13:394:475:577:122:g_d0_f77:122:g_d0_f77:0.159 0.019 
70:2737:117275:13:0:444:479:564:122:g_d0_f77:122:g_d0_f77:(0.001) 
70:2738:117282:0:13:501:529:577:122:g_d0_f77:122:g_d0_f77:0.017 
70:2739:117287:13:32:497:533:564:122:g_d0_f77:122:g_d0_f77:(0.003) 
70:2740:117294:32:13:70:219:532:122:g_d0_f77:122:g_d0_f77: 1 month, excluding carboplatin   
70:2741:117326:13:0:70:75:519:122:g_d0_f77:122:g_d0_f77:  
70:2742:117326:0:13:234:315:532:122:g_d0_f77:122:g_d0_f77:0.076 0.015 
70:2743:117338:13:0:284:319:519:122:g_d0_f77:122:g_d0_f77:(0.002) 
70:2744:117346:0:13:341:369:532:122:g_d0_f77:122:g_d0_f77:0.014 
70:2745:117351:13:0:337:373:519:122:g_d0_f77:122:g_d0_f77:(0.003) 
70:2746:117358:0:13:394:475:532:122:g_d0_f77:122:g_d0_f77:0.071 0.014 
70:2747:117368:13:0:444:479:519:122:g_d0_f77:122:g_d0_f77:(0.003) 
70:2748:117375:0:13:501:529:532:122:g_d0_f77:122:g_d0_f77:0.010 
70:2749:117380:13:33:497:533:519:122:g_d0_f77:122:g_d0_f77:(0.003) 
70:2750:117387:33:12:70:186:486:122:g_d0_f77:122:g_d0_f78: 1  month,  in  a  Physician’s  
70:2751:117418:12:13:70:104:474:122:g_d0_f77:122:g_d0_f77:Office  
70:2752:117425:13:0:70:75:461:122:g_d0_f77:122:g_d0_f77:  
70:2753:117425:0:12:234:315:486:122:g_d0_f77:122:g_d0_f77:0.138 0.017 
70:2754:117437:12:0:284:319:474:122:g_d0_f77:122:g_d0_f77:(0.002) 
70:2755:117445:0:12:341:369:486:122:g_d0_f77:122:g_d0_f77:0.018 
70:2756:117450:12:0:337:373:474:122:g_d0_f77:122:g_d0_f77:(0.004) 
70:2757:117457:0:12:394:475:486:122:g_d0_f77:122:g_d0_f77:0.122 0.019 
70:2758:117467:12:0:444:479:474:122:g_d0_f77:122:g_d0_f77:(0.003) 
70:2759:117474:0:12:501:529:486:122:g_d0_f77:122:g_d0_f77:0.019 
70:2760:117479:12:38:497:533:474:122:g_d0_f77:122:g_d0_f77:(0.003) 
70:2761:117486:38:13:70:210:436:122:g_d0_f77:122:g_d0_f77: 1 month, in outpatient hospital 
70:2762:117518:13:0:70:97:423:122:g_d0_f77:122:g_d0_f77:clinic 
70:2763:117524:0:13:234:320:436:122:g_d0_f77:122:g_d0_f77:0.025 -0.0004 
70:2764:117538:13:0:284:319:423:122:g_d0_f77:122:g_d0_f77:(0.001) 
70:2765:117546:0:13:337:373:436:122:g_d0_f77:122:g_d0_f77:-0.0004 
70:2766:117553:13:0:337:373:423:122:g_d0_f77:122:g_d0_f77:(0.001) 
70:2767:117560:0:13:394:480:436:122:g_d0_f77:122:g_d0_f77:0.030 -0.0001 
70:2768:117572:13:0:444:479:423:122:g_d0_f77:122:g_d0_f77:(0.001) 
70:2769:117579:0:13:501:529:436:122:g_d0_f77:122:g_d0_f77:0.001 
70:2770:117584:13:27:497:533:423:122:g_d0_f77:122:g_d0_f77:(0.002) 
70:2771:117591:27:22:70:332:396:122:g_d0_f78:122:g_d0_f77:Percent  Change  in  Chemotherapy  Service  Counts  within... 
70:2772:117652:22:13:70:315:374:122:g_d0_f77:122:g_d0_f77: 1 month of diagnosis  1.06 0.336 
70:2773:117682:13:24:284:319:361:122:g_d0_f77:122:g_d0_f77:(0.048) 
70:2774:117689:24:0:300:303:337:122:g_d0_f77:122:g_d0_f77: 
70:2775:117689:0:13:341:369:374:122:g_d0_f77:122:g_d0_f77:0.328 
70:2776:117694:13:0:337:373:361:122:g_d0_f77:122:g_d0_f77:(0.061) 
70:2777:117701:0:13:394:475:374:122:g_d0_f77:122:g_d0_f77:0.942 0.400 
70:2778:117711:13:24:443:479:361:122:g_d0_f77:122:g_d0_f77:(0.035) 
70:2779:117718:24:0:459:462:337:122:g_d0_f77:122:g_d0_f77: 
70:2780:117718:0:13:502:527:374:122:g_d0_f77:122:g_d0_f77:0383 
70:2781:117722:13:38:497:532:361:122:g_d0_f77:122:g_d0_f77:(0.036) 
70:2782:117729:38:24:70:219:323:122:g_d0_f77:122:g_d0_f77: 1 month, excluding carboplatin   
70:2783:117761:24:0:70:75:299:122:g_d0_f77:122:g_d0_f77:  
70:2784:117761:0:12:234:315:323:122:g_d0_f77:122:g_d0_f77:0.322 0.185 
70:2785:117771:12:25:284:319:311:122:g_d0_f77:122:g_d0_f77:(0.030) 
70:2786:117778:25:0:300:303:286:122:g_d0_f77:122:g_d0_f77: 
70:2787:117778:0:12:341:369:323:122:g_d0_f77:122:g_d0_f77:0.203 
70:2788:117783:12:0:337:373:311:122:g_d0_f77:122:g_d0_f77:(0.029) 
70:2789:117790:0:12:394:475:323:122:g_d0_f77:122:g_d0_f77:0.286 0.258 
70:2790:117800:12:25:443:479:311:122:g_d0_f77:122:g_d0_f77:(0.022) 
70:2791:117807:25:0:459:462:286:122:g_d0_f77:122:g_d0_f77: 
70:2792:117807:0:12:500:528:323:122:g_d0_f77:122:g_d0_f77:0.245 
70:2793:117812:12:38:497:532:311:122:g_d0_f77:122:g_d0_f77:(0.017) 
70:2794:117819:38:15:70:186:273:122:g_d0_f77:122:g_d0_f78: 1  month,  in  a  Physician’s  
70:2795:117850:15:24:70:104:258:122:g_d0_f77:122:g_d0_f77:Office  
70:2796:117857:24:0:70:75:234:122:g_d0_f77:122:g_d0_f77:  
70:2797:117857:0:13:234:315:273:122:g_d0_f77:122:g_d0_f77:0.987 0.339 
70:2798:117867:13:24:284:319:260:122:g_d0_f77:122:g_d0_f77:(0.043) 
70:2799:117874:24:0:300:303:236:122:g_d0_f77:122:g_d0_f77: 
70:2800:117874:0:13:341:369:273:122:g_d0_f77:122:g_d0_f77:0.337 
70:2801:117879:13:0:337:373:260:122:g_d0_f77:122:g_d0_f77:(0.062) 
70:2802:117886:0:13:394:475:273:122:g_d0_f77:122:g_d0_f77:0.844 0.411 
70:2803:117896:13:0:443:479:260:122:g_d0_f77:122:g_d0_f77:(0.036) 
70:2804:117903:0:13:500:528:273:122:g_d0_f77:122:g_d0_f77:0.395 
70:2805:117908:13:12:497:532:260:122:g_d0_f77:122:g_d0_f77:(0.037) 
70:2806:117915:12:40:513:516:248:122:g_d0_f77:122:g_d0_f77: 
70:2807:117915:40:14:70:210:208:122:g_d0_f77:122:g_d0_f77: 1 month, in outpatient hospital 
70:2808:117947:14:0:70:97:194:122:g_d0_f77:122:g_d0_f77:clinic 
70:2809:117953:0:12:234:315:208:122:g_d0_f77:122:g_d0_f77:0.077 0.019 
70:2810:117963:12:25:284:319:196:122:g_d0_f77:122:g_d0_f77:(0.008) 
70:2811:117970:25:0:300:303:171:122:g_d0_f77:122:g_d0_f77: 
70:2812:117970:0:12:341:369:208:122:g_d0_f77:122:g_d0_f77:0.012 
70:2813:117975:12:25:337:373:196:122:g_d0_f77:122:g_d0_f77:(0.007) 
70:2814:117982:25:0:353:356:171:122:g_d0_f77:122:g_d0_f77: 
70:2815:117982:0:12:394:475:208:122:g_d0_f77:122:g_d0_f77:0.097 0.013 
70:2816:117992:12:13:443:479:196:122:g_d0_f77:122:g_d0_f77:(0.004) 
70:2817:117999:13:0:459:462:183:122:g_d0_f77:122:g_d0_f77: 
70:2818:117999:0:22:500:528:208:122:g_d0_f77:122:g_d0_f77:0.015 
70:2819:118004:22:29:497:532:186:122:g_d0_f77:122:g_d0_f77:(0.007) 
70:2820:118011:29:25:70:172:157:122:g_d0_f78:122:g_d0_f77:Share  Dying  Within... 
70:2821:118034:25:13:70:317:132:122:g_d0_f77:122:g_d0_f77:  3 months of diagnosis  0.353 -0.009 
70:2822:118069:13:0:284:319:119:122:g_d0_f77:122:g_d0_f77:(0.006) 
70:2823:118076:0:13:339:371:132:122:g_d0_f77:122:g_d0_f77:-0.019 
70:2824:118082:13:0:337:373:119:122:g_d0_f77:122:g_d0_f77:(0.004) 
70:2825:118089:0:13:394:480:132:122:g_d0_f77:122:g_d0_f77:0.335 -0.002  
70:2826:118101:13:13:444:479:119:122:g_d0_f77:122:g_d0_f77:(0.005) 
70:2827:118108:13:0:459:464:106:122:g_d0_f77:122:g_d0_f77:  
70:2828:118108:0:13:501:532:132:122:g_d0_f77:122:g_d0_f77:0.008  
70:2829:118114:13:13:497:533:119:122:g_d0_f77:122:g_d0_f77:(0.005) 
70:2830:118121:13:67:513:516:106:122:g_d0_f77:122:g_d0_f77: 
71:2831:118121:67:0:72:74:39:122:g_d0_f27:122:g_d0_f27: 
71:2832:118121:0:13:70:175:708:122:g_d0_f79:122:g_d0_f79:  6 months of diagnosis 
71:2833:118144:13:15:70:75:695:122:g_d0_f79:122:g_d0_f79:  
71:2834:118144:15:0:111:194:680:122:g_d0_f79:122:g_d0_f79:  
71:2835:118144:0:13:234:320:708:122:g_d0_f79:122:g_d0_f79:0.474 -0.015  
71:2836:118156:13:0:284:319:695:122:g_d0_f79:122:g_d0_f79:(0.006) 
71:2837:118163:0:13:339:373:708:122:g_d0_f79:122:g_d0_f79:-0.022  
71:2838:118170:13:0:337:373:695:122:g_d0_f79:122:g_d0_f79:(0.006) 
71:2839:118177:0:13:394:477:708:122:g_d0_f79:122:g_d0_f79:0.463 -0.009 
71:2840:118188:13:12:444:479:695:122:g_d0_f79:122:g_d0_f79:(0.004) 
71:2841:118195:12:0:459:464:683:122:g_d0_f79:122:g_d0_f79:  
71:2842:118195:0:13:499:531:708:122:g_d0_f79:122:g_d0_f79:-0.003 
71:2843:118201:13:12:497:533:695:122:g_d0_f79:122:g_d0_f79:(0.004) 
71:2844:118208:12:24:513:516:683:122:g_d0_f79:122:g_d0_f79: 
71:2845:118208:24:12:70:175:659:122:g_d0_f79:122:g_d0_f79:  9 months of diagnosis 
71:2846:118231:12:0:70:75:647:122:g_d0_f79:122:g_d0_f79:  
71:2847:118231:0:12:234:320:659:122:g_d0_f79:122:g_d0_f79:0.532 -0.008  
71:2848:118243:12:0:284:319:647:122:g_d0_f79:122:g_d0_f79:(0.006) 
71:2849:118250:0:12:339:371:659:122:g_d0_f79:122:g_d0_f79:-0.028 
71:2850:118256:12:0:337:373:647:122:g_d0_f79:122:g_d0_f79:(0.003) 
71:2851:118263:0:12:394:477:659:122:g_d0_f79:122:g_d0_f79:0.522 -0.004 
71:2852:118274:12:13:444:479:647:122:g_d0_f79:122:g_d0_f79:(0.003) 
71:2853:118281:13:0:459:464:634:122:g_d0_f79:122:g_d0_f79:  
71:2854:118281:0:12:501:529:659:122:g_d0_f79:122:g_d0_f79:0.001 
71:2855:118286:12:13:497:533:647:122:g_d0_f79:122:g_d0_f79:(0.005) 
71:2856:118293:13:23:513:516:634:122:g_d0_f79:122:g_d0_f79: 
71:2857:118293:23:13:70:320:611:122:g_d0_f79:122:g_d0_f79:  1 year of diagnosis 0. 635 -0.008  
71:2858:118327:13:0:284:319:598:122:g_d0_f79:122:g_d0_f79:(0.008) 
71:2859:118334:0:13:341:369:611:122:g_d0_f79:122:g_d0_f79:0.024 
71:2860:118339:13:0:337:373:598:122:g_d0_f79:122:g_d0_f79:(0.003) 
71:2861:118346:0:13:394:478:611:122:g_d0_f79:122:g_d0_f79:0.616 0.008  
71:2862:118357:13:13:444:479:598:122:g_d0_f79:122:g_d0_f79:(0.004) 
71:2863:118364:13:0:459:464:585:122:g_d0_f79:122:g_d0_f79:  
71:2864:118364:0:13:501:532:611:122:g_d0_f79:122:g_d0_f79:0.012  
71:2865:118370:13:13:497:533:598:122:g_d0_f79:122:g_d0_f79:(0.004) 
71:2866:118377:13:18:513:516:585:122:g_d0_f79:122:g_d0_f79: 
71:2867:118377:18:18:70:522:567:122:g_d0_f79:122:g_d0_f79:Number of Obs (weeks) 48 96 72 48 96 72 
71:2868:118410:18:10:72:532:549:81:g_d0_f79:81:g_d0_f79:Notes: Means in column 1 and 3 are for the dependent variable for patients in counties with above vs. below median number of 
71:2869:118535:10:10:72:541:539:81:g_d0_f79:81:g_d0_f79:patients per provider. Estimates in columns 2 and 4 are from separate time-series regressions for patients from each group and are 
71:2870:118666:10:11:72:532:529:81:g_d0_f79:81:g_d0_f79:the coefficients on an indicator for the period that the ASP payment scheme was in effect. Regressions control for mean patient 
71:2871:118794:11:10:72:527:518:81:g_d0_f79:81:g_d0_f79:characteristics and relative-week trends that are allowed to differ on either side of the payment change. Newey-West standard 
71:2872:118920:10:12:72:358:508:81:g_d0_f79:81:g_d0_f79:errors allowing for autocorrelation up to 52-week lags are given in parentheses 
71:2873:119000:12:25:72:75:496:122:g_d0_f62:122:g_d0_f62: 
71:2874:119000:25:24:72:75:471:122:g_d0_f62:122:g_d0_f62: 
71:2875:119000:24:25:72:75:447:122:g_d0_f62:122:g_d0_f62: 
71:2876:119000:25:19:72:75:422:122:g_d0_f29:122:g_d0_f29: 
71:2877:119000:19:0:72:74:403:122:g_d0_f27:122:g_d0_f27: 
